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Role of Gigaxonin in the Regulation of Intermediate Filaments: a Study Using Giant 
Axonal Neuropathy Patient-Derived Induced Pluripotent Stem Cell-Motor Neurons 
Bethany Johnson-Kerner 
Patients with giant axonal neuropathy (GAN) exhibit loss of motor and sensory function 
and typically live for less than 30 years. GAN is caused by autosomal recessive mutations 
leading to low levels of gigaxonin, a ubiquitously-expressed cytoplasmic protein whose cellular 
roles are poorly understood. GAN pathology is characterized by aggregates of intermediate 
filaments (IFs) in multiple tissues.  
Disorganization of the neuronal intermediate filament (nIF) network is a feature of 
several neurodegenerative disorders, including amyotrophic lateral sclerosis, Parkinson’s disease 
and axonal Charcot-Marie-Tooth disease. In GAN such changes are often striking: peripheral 
nerve biopsies show enlarged axons with accumulations of neurofilaments; so called “giant 
axons.” Interestingly, IFs also accumulate in other cell types in patients. These include desmin in 
muscle fibers, GFAP (glial fibrillary acidic protein) in astrocytes, and vimentin in multiple cell 
types including primary cultures of biopsied fibroblasts. These findings suggest that gigaxonin 
may be a master regulator of IFs, and understanding its function(s) could shed light on GAN as 
well as the numerous other diseases in which IFs accumulate. However, an interaction between 
gigaxonin and IFs has not been detected and how IF accumulation is triggered in the absence of 
functional gigaxonin has not been determined. 
To address these questions I undertook a proteomic screen to identify the normal binding 
partners of gigaxonin. Prominent among them were several classes of IFs, including the 
 
 
neurofilament subunits whose accumulation leads to the axonal swellings for which GAN is 
named. Strikingly, human motor neurons (MNs) differentiated from GAN iPSCs recapitulate this 
key phenotype. Accumulation of nIFs can be rescued by reintroduction of gigaxonin, by viral 
delivery or genetic correction. GAN iPS-MNs do not display survival vulnerability in the 
presence of trophic factors, but do display increased cell death in the presence of oxidative stress. 
Preliminary experiments suggest that in iPS-MNs nIFs are degraded by contributions from both 
the proteasome and lysosome. Gigaxonin interacts with the autophagy protein p62 which has 
been implicated in the clearance of ubiquitin aggregates by the lysosome, and this interaction is 
greatly enhanced in conditions of oxidative stress. My data provide the first direct link between 
gigaxonin loss and IF aggregation, and suggest that gigaxonin may be a substrate adaptor for the 
degradation of IFs by autophagy, pointing to future approaches for reversing the phenotype in 
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Chapter 1. General Introduction 
 Previously, it was not feasible to study diseases of the human nervous system through the 
using of living human tissue. Nerve cells in the spinal cord and brain are inaccessible to routine 
biopsy without causing severe harm to the subject. In lieu of human tissue, mouse models have 
been the principal way to study diseases of the nervous system. While we have gained much 
insight from these animal models, they also come with many limitations. Namely, the disease has 
to be caused by known genetic mutations, the mouse genome has to have a homolog to the 
human gene, and the phenotype has to recapitulate key aspects of pathology.  While this 
approach has worked for some diseases, many diseases do not have useful mouse models. The 
way in which we can study human diseases of the nervous system changed with the introduction 
of induced pluripotent stem cell (iPS) technology. For the first time we can generate stable 
pluripotent cell lines directly from patients with mutations and modifiers causing disease in 
patients. These induced pluripotent stem cells (iPSCs) can be differentiated into the very neurons 
inaccessible to biopsy. Moreover large quantities of neurons can be generated for biochemistry 
and drug discovery on human cells.  Here I demonstrate this approach for the study of giant 
axonal neuropathy (GAN), a very rare pediatric neuropathy. 
 Little is understood about the sensorimotor neuropathy GAN. Efforts to better understand 
this disease have been hindered by mouse models that do not recapitulate the human disease. The 
mild and delayed phenotype of the mice suggests that gigaxonin, the protein mutated in GAN, 
may have human-specific functions. I therefore sought to develop a human model of GAN.  
Overall, I will discuss our current understanding of GAN. First, I review the clinical 





multiple cell types, including neurons (neuronal intermediate filaments, or nIFs). Because of 
these findings, I then review basic principles of IF classification, structure and function, focusing 
on aspects of degradation of IFs. I then describe existing cellular and mouse models of GAN as 
well as the proposed functions of gigaxonin. I conclude by reviewing the uses of ES and iPS-
derived neurons for disease modeling. From this survey, it is clear that further work needs to be 
done to a) develop a human model of GAN and b) identify the binding partners of gigaxonin as a 






Part I. Giant axonal neuropathy in humans  
Clinical findings in GAN 
Giant axonal neuropathy (GAN) is a rare autosomal recessive disease caused by 
mutations in the GAN gene encoding gigaxonin. GAN was first described by Asbury and Berg in 
1972, with a case report of a 6-year-old girl with kinky hair, progressive clumsiness, muscle 
weakness and atrophy, areflexia and sensory loss (Asbury et al., 1972; Berg et al., 1972). Sural 
nerve biopsy revealed large axonal spheroids densely packed with neurofilaments in both 
myelinated and unmyelinated fibers. In 2000 Bomont et al. identified the disease causing gene 
GAN, which encodes a ubiquitously expressed protein named gigaxonin located on chromosome 
16q24.1 (Bomont et al., 2000; Flanigan et al., 1998).  Although the true incidence of GAN is 
difficult to determine, since the first report in 1972 approximately 80 cases have been published, 
and nearly 50 unique mutations in GAN reported. Although disease onset has been observed 
from soon after birth to up to ten years of age, the majority of GAN cases have an age of onset of 
approximately 3 years, with sensorimotor involvement of both the peripheral and central nervous 
system. Currently there are no therapies for GAN, and most patients are confined to a 
wheelchair, paraplegic or deceased by their second or third decade (Gordon, 2004).  
The predominant features of the disease include motor impairment and muscle weakness 
(Tazir et al., 2002). This typically manifests as progressive distal “clumsiness” and muscle 
weakness. Patients usually have a “waddling gait” at first which progresses to eventual loss of 
ambulation (Yang et al., 2007). The first GAN patient described by Asbury et al. (1972) began to 
have difficulty walking at age 3, and within 6 months “weakness and unsteadiness of gait had 
progressed to the point at which the child’s feet began to turn out and she was falling 





fine-skilled voluntary movements and an up-going Babinski reflex are typical signs of upper MN 
lesions, whereas muscle atrophy and loss of reflexes are considered signs of lower MN lesions. 
While distal muscle weakness is striking in GAN patients, proximal muscle groups are also 
affected, as evidenced by wasting of the pectoralis muscles, winging of the scapula, and 
exhibition of Gower’s sign on attempting to rise from the floor (Asbury et al., 1972).  
The peripheral neuropathy also presents with evidence of sensory involvement. Patients 
usually have absent tendon reflexes. GAN patients also have mild distal impairment of light 
touch, followed by loss of pain and temperature sensation (Akagi et al., 2011; Asbury et al., 
1972). This indicates that fast fibers in the dorsal column-medial lemniscus system are affected 
first by the disease, and slow fibers of the anterolateral system (which carry pain and temperature 
information) are affected later, at least in some patients. Patients also have abnormal vibration 
sense and proprioception. Position sense is moderately impaired at the toes and finger tips, and 
patients usually have difficulty performing the heel-shin test and have a positive Romberg test 
(Asbury et al., 1972).    
In addition, the cranial nerves can also be affected in GAN. Patients often display signs 
of dysfunction in the 3
rd
 (oculomotor) and 7
th
 (facial) cranial nerves. As a result, patients can 
have coarse saccades, nystagmus, ptosis, slight atrophy of the tongue, mild weakness of the 
facial muscles and dysarthria (Gordon, 2004; Kuhlenbaumer et al., 2002). Patients can also have 
visual problems with optic atrophy (Houlden et al., 2007), although some patients have normal 
vision (Kretzschmar et al., 1987). Patients can have normal or reduced hearing (Tazir et al., 
2002). There is also heterogeneity in terms of cognitive abilities and epilepsy. Some patients 
have no intellectual impairment whereas others are very impaired (Boltshauser et al., 1977). It is 





GAN patients are from consanguineous unions, which have been shown to be an independent 
risk factor for MR and epilepsy (Bener and Hussain, 2006).  
A characteristic physical appearance is a hallmark of the disease. The forehead of GAN 
patients tends to be high, the complexion pale and eyelashes long. Most patients, but not all, have 
tightly curled, kinky hair (Akagi et al., 2011). While this is suggestive of involvement of keratin 
intermediate filaments in the pathogenesis of the disease, evidence of this has not been found to 
date. Three GAN patients were found to have longitudinal grooves in the hair as identified by 
SEM (Treiber-Held et al., 1994), but this was not seen in a fourth patient, although that patient 
did have extensive loss of the regular hair cuticle (Mohri et al., 1998). There is one report of “pili 
torti” (twisted hairs, often found in Menkes disease) (Larbrisseau et al., 1979) but they are not 
found in all patients with kinky hair (Gambarelli et al., 1977). 
In addition to changes in the hair there can also be skin and skeletal abnormalities. There 
are reports of ichthyosis (scaly skin) and keratosis pilaris (excess keratin surrounding the hair 
follicle, resulting in red bumps) (Ionasescu et al., 1983; Mohri et al., 1998). Many patients have 
some form of scoliosis (Berg et al., 1972; Mohri et al., 1998) or short stature (Koch et al., 1977), 
and some patients have dental malocclusion (Nalini et al., 2008). Additionally, endocrine 
disturbances can occur in GAN, such as precocious puberty (Takebe et al., 1981) or diabetes 
(Hoffman et al., 1995). One patient was reported to have renal tubular acidosis (Ionasescu et al., 
1983).   
While diagnosis is usually based on the clinical presentation and nerve biopsy, other 
studies have been informative in our attempts to understand the disease. Electroencephalograms, 





auditory brainstem evoked response indicates an increase in brainstem conduction time 
(Majnemer et al., 1986).   Nerve conduction studies are consistent with an axonal neuropathy; 
conduction velocity of motor nerves is either normal or slightly decreased and sensory action 
potentials are usually absent. Electromyography is often consistent with a neurogenic disturbance 
but can be more suggestive of a myopathic disorder (Tazir et al., 2009). If there is involvement 
of the CNS the EEG may show slowing as well as focal spikes and sharp waves. This is 
especially true if seizures have occurred, but EEG traces may be abnormal even if there is not 
such history. In the latter case, the abnormal EEG associated with changes in 
electronystagmography (a diagnostic test to record involuntary eye movements) and the auditory 
evoked responses suggests lesions in the connections between the brainstem and cerebellum. 
Brain MRI and/or CT-scan typically demonstrates diffuse white matter changes (Houlden et al., 
2007; Mohri et al., 1998) but can be normal (Tazir et al., 2009). Muscle biopsies show evidence 
of a neurodegenerative disorder, with the presence of small, atrophic muscle fibers (Nafe et al., 
2001).   
Pathological findings in GAN  
Disorganization of the neurofilament network is a feature of several neurodegenerative 
disorders, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease and axonal 
Charcot-Marie-Tooth disease (Lariviere and Julien, 2004; Liem and Messing, 2009). In GAN 
such changes are usually striking; peripheral nerve biopsies show enlarged axons with 
accumulations of neurofilaments (Figure 1.1) (Gordon, 2004). Interestingly, intermediate 
filaments also accumulate in other cell types in GAN patients; this includes desmin in muscle 
fibers, GFAP in astrocytes, and vimentin in multiple cell types, including primary fibroblast 





EM studies of the giant axons show hyperplasia of NFs (Figure 1.1B). In these swellings 
NFs retain their general morphology and diameter (80-100 Å) (Gambarelli et al., 1977) but lose 
their normally visible side arms from increased packing and organization (Mohri et al., 1998). 
The NFs are arranged in alternating directions and often display incomplete whorl-like patterns 
(Peiffer et al., 1977). Fewer microtubules and axonal organelles are present in these swellings, 
and the swellings tend to push remaining axonal organelles and structures to the periphery 
(Kumar et al., 1990; Peiffer et al., 1977). In additions to changes in NFs, Kumar et al. (1990) 
reported increased glial filaments in most astrocytes. These filaments often merged to form the 
dense core typical or Rosenthal fibers (Kumar et al., 1990).  Desmin and vimentin also have an 
abnormal distribution in patient biopsies (Figure 1.1C, D). Desmin tends to form diffuse 
collections while vimentin forms very tight aggregates that are normally found adjacent to the 
nucleus (Mohri et al., 1998).  
Abnormal aggregates of cytoskeletal proteins are neuropathological signatures of many 
neurodegenerative diseases. Whether this accumulation in neurons is primary or secondary to 
GAN is not well understood. One study found that onset of symptoms proceeded the appearance 
of giant axons (Gambarelli et al., 1977), but the sequence of phenotype and pathological onset 
has not been examined in most patients. The NF swellings found in GAN patients have a 
characteristic segmental appearance, and appear as “beads on a string” in teased nerve biopsies 
(Figure 1.2A). These swellings measure 30-120 μm (Gambarelli et al., 1977) and occur in both 
myelinated and unmyelinated fibers. One GAN patient had a decrease in the number of 
myelinated fibers: 573 fibers/0.1mm
2
 in the patient as compared with 881 fibers/0.1mm
2
 in the 
control (Gambarelli et al., 1977). This decrease affected fibers of both 1-2 and 10-13 μm in 





only 2% of the whole population. The axonal swellings can appear anywhere along the axon, and 
may have loss or preservation of the myelin sheath (Figure 1.2B). Overall, a 63% reduction in 
myelination of peripheral nerve fibers was reported (Gambarelli et al., 1977). Only one published 
report examined the myenteric plexus. Gambarelli et al. (1977) observed axonal swellings here, 
suggesting autonomic involvement in the disease.  
To date there are four published autopsy studies on GAN patients. The samples studied 
came from a 25-year-old male, an 18-year-old female (incidentally the first GAN patient 
described by Asbury et al. (1972)), an 18-year-old male and an 11-year-old female (Kretzschmar 
et al., 1987; Kumar et al., 1990; Peiffer et al., 1977; Thomas et al., 1987). Notable findings in all 
these studies include abundant axon swellings and spheroids in the spinal cord, brain stem and 
cerebral cortex (Figure 1.2C-G). Peiffer et al. (1977) described severe alterations throughout the 
spinal cord, accentuated in the posterior tracts (Figure 1.2F). The spinocerebellar tracts were 
demyelinated and had spongiose appearance. Spheroids were very large, reaching the size of 
“two or three times that of an anterior horn cell.” Smaller axonal swellings were distributed in 
the anterior and posterior nerve roots. Within the anterior and posterior horns, the spheroids were 
only seldom located immediately adjacent to nerve cell perikarya. Spheroids were also scattered 
throughout the pyramidal tracts, especially in the pons. The corticospinal tracts of the pons 
showed “spongiform alternation of small regions near the midline.” In the cortex spheroids were 
greater in number but smaller in size (Figure 1.2C). The composition of these aggregates is 
poorly characterized and is discussed in the next section. Astrocytosis was absent in this patient 
but present in the patient reported by Thomas et al. (1987). Rosenthal fibers were abundant in the 
ventricle walls and while matter of the spinal cord (Figure 1.2D, E). Normal oligodendrocytes 





In addition to these pathological findings, the autopsy reports also show signs of axonal 
and nerve cell body loss. Thomas et al. (1987) report that the pyramidal tracts were shrunken and 
gray and the spinal cord was of reduced caliber. In the medulla, these tracts were almost devoid 
of nerve fibers. This degeneration of the long tracts most likely contributes to the profound 
weakness seen in patient. In addition, anterior horn nerve cells were slightly distended with 
central chromatolysis (Figure 1.2G) (Peiffer et al., 1977). Anterior horn cell loss was reported in 
the cervical and lumbar regions of the spinal cord (Kumar et al., 1990; Thomas et al., 
1987).Various stages of astrocytic degeneration were indicated by nuclear pyknosis and 
degeneration of cytoplasmic organelles (Kumar et al., 1990).  
The presence of giant axons and nIF inclusion is not specific to GAN; other conditions 
may be considered in the differential diagnosis (Table 1.3). Infantile neuraxonal dystrophy has 
more evidence of cerebral involvement and more scattered lesions in the peripheral nerves. Other 
neuropathies should also be excluded, such as toxic neuropathies (from acrylamide or toxic 
hexacarbons), hereditary sensorimotor neuropathy usually of dominant inheritance (Charcot-
Marie-Tooth disease), and those secondary of vitamin B12 deficiency, diabetes mellitus and 
amyloid polyneuropathies (Cairns et al., 2004; Hartley et al., 1997; Yiu and Ryan, 2012). When 
the CNS is involved, other types causes of spinocerebellar degeneration should be ruled out, 
including Alexander’s disease, Fazio-Londe disease with cranial nerve involvement and Menke’s 
syndrome (Gordon, 2004).  
Biochemical findings in GAN 
Few studies have performed a careful biochemical analysis of GAN patient samples. 
Although several studies have looked at the distributation of vimentin in patient fibroblasts, only 





levels in two GAN and two control fibroblast lines and did not find a significant difference (63.3 
± 4.7 μg and 60.0 ± 3.2 μg of vimentin per mg total cell protein respectively, p > 0.30). The rate 
of vimentin synthesis was also estimated by calculating the amount of 
3
H-leucine incorporated 
into vimentin in a two-hour pulse as a proportion of the incorporation into the total cytoskeleton. 
Mean values for percentage incorporation were very similar for GAN and control fibroblasts 
(13.0% and 12.7% respectively) (Pena, 1982). Last, the phosphorylation of vimentin was 
examined by measuring the specific activity of 
32
P in vimentin after a four-hour incubation of 
fibroblasts with 
32
PO4. Again, there was no difference between GAN and control. Pena (1982) 
concludes that “the basic genetic defect in GAN does not involve the IFs subunit proteins, but 
other molecules involved in the control of assembly and structural organization of IFs.”   
No neuropathological studies have examined the composition of the spheroids seen in the 
CNS (Figure 1.2C-G). One study examined the NF protein identity and content of the sural nerve 
of a GAN patient (Ionasescu et al., 1983). NF-enriched fractions of fragments of sural nerve 
belonging to a 14-year-old male patient and an age- and sex-matched control were separated by 
gel electrophoresis. Molecular weights were compared on a ladder consisting of purified NFs 
from bovine brain and levels were compared by densitometric scanning. NFs found in the normal 
nerve were also present in the diseased nerve. NF-M and NF-H were present at comparable 
levels or between the patient and control, but NF-L levels were twice as high in the GAN patient.  
Other than that they contain NFs, little else is known about the specific composition of 
the giant axons. According to one report, the swellings stained pale green in Klüver Barrera, 
bluish in Mallory’s trichrome, pink in haematoxylin-eosin and yellow in van Gieson 
preparations. They are PAS-negative but argyrophilic. No stains have been reported on GAN 





intensely for NF-H, but did not stain for NF-M or NF-L. The spheroids described by Peiffer et al. 







Figure 1.1. IF changes in GAN. GAN patients have IF abnormalities in a variety of tissue types. 
(A) Loss of axons and thinning of the myelin sheath in the sural nerve biopsies of GAN patients. 
Many remaining axons (arrowheads) are enlarged compared to control (E). The accumulated 
NFs in GAN patients (B) lack regular orientation and identifiable side arms, indicated by the 
arrow in (F). The inter-NF spacing is reduced by approximately half in GAN patients (from 57 
nm to 27 nm). GAN patients also have abnormal accumulation of desmin in muscle (compare C 
and G) and oval aggregates of vimentin in fibroblasts (compare D and H). Images from Asbury 
et al. (1972) and Mohri et al. (1998). 
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Figure 1.2. Human GAN pathology. Axon swellings and spheroids are observed throughout the 
PNS and CNS in GAN patients. (A) Teased sural nerve biopsy showing segmental swelling of 
axons. (B) Longitudinal 2 μm section of sural nerve from a six-year-old female patient with 
GAN. Again, the segmental character of the axonal enlargement is apparent. Swellings can begin 
at a node of Ranvier or anywhere along the axon. Myelin can be lost or preserved (as in B) at the 
swelling. (C) Axon swellings in the frontal cortex shown by Bodian stain from an autopsy of a 
25-year-old male patient with GAN. (D) Ventricle wall with many subependymal Rosenthal 
fibers, Mallory trichrome stain. (E) Rosenthal fibers in the white matter of the spinal cord, 
electron micrograph, 4800:1. (F) Spheroids in the posterior tracts, Klüver stain. (G) Spheroids in 
the anterior horn as well as nerve cell with central chromatopysis, hematoxylin-eosin stain. 






















CMT4C + +  SH3TC2  Demyelinating 
neuropathy 
AR 
CMT2E/1F + +  NEFL   AA 
n-hexane 
toxicity 










INAD   + PLA2G6 Nystagmus and 
hearing loss 
General weakness AR 
DHMN    ATP7A Patients have 
kinky/brittle hair 
General weakness X-linked recessive; 
allelic with Menkes 
disease 
MLD    ARSA  General weakness AR 








Table 1.3. Differential diagnoses of GAN. Compiled from Yiu and Ryan (2012), Cairns et al. 
(2004) and Hartley et al. (1997). The differential diagnoses presented in this table are focused on 
neuropathies of pre-natal and infantile onset. GAN, giant axonal neuropathy; CMT, Charcot-
Marie-Tooth; SH3TC2, SH3 domain and tetratricopeptide repeats-containing protein 2; INAD, 
infantile neuraxonal dystrophy; DHMN, distal hereditary motor neuropathy; ATP7A, Copper-
transporting ATPase 1; MLD, metachromatic leukodystrophy; ARSA, arylsulfatase A; SMA, 





Genetics of GAN 
GAN is inherited in an autosomal recessive fashion. The GAN1 locus was localized by 
homozygosity mapping to chromosome 16q24.1 (Ben Hamida et al., 1997; Flanigan et al., 1998). 
It was referred to as GAN1 due to possible heterogeneity. Since the discovery of the causative 
gene, several reports of patient mutations have been published. In order to identify possible 
mutation “hot spots,” J. Palmer Greene and myself compiled all published mutations in 
gigaxonin (Figure 1.4). We identified over 50 unique mutations in approximately 80 cases of 
GAN. Strikingly, there appears to be no clustering of mutations. Most patients have point 
mutations, and these can be found throughout the BTB, BACK and six Kelch repeats of 
gigaxonin. Kelch repeats have eight key conserved residues: four hydrophobic residues followed 
by a double glycine, separated from two aromatic residues that are spaced by six amino acids 
(Kuhlenbaumer et al., 2002). Our compilation showed that disease-causing mutations can be 
found both within and outside of these conserved residues. This suggests that gigaxonin may be 
very sensitive to any changes in the primary amino acid sequence. One study that looked at 
protein levels in eight GAN patients found that all the mutations resulted in a severe reduction in 
the levels of functional gigaxonin protein (Cleveland et al., 2009). Interestingly, there was no 
correlation between protein level and phenotypic disease severity. Taken together, these findings 
suggest that the varied mutations result in destabilization and degradation of gigaxonin protein.  
It is worth noting that there are a few cases where mutations were not found in the GAN 
gene. In one consanguineous Algerian family, three patients had a clinical presentation of a mild 
motor and sensory neuropathy with pes cavus (a highly arched foot, often seen in neuromuscular 
disease), moderate to severe scoliosis, and hypoacousia without any sign of CNS involvement. 





absent myelin and filled with neurofilaments. However, no mutations in the GAN gene could be 
detected (Tazir et al., 2002). Although the clinical picture is milder than classic GAN cases, a 
diagnosis of GAN was based on clinical similarity and the neuropathology. Identification of the 
causative mutations – if outside the GAN1 locus - may shed light on pathways important for 
disease pathogenesis.  
 More recently, mutations in Bcl-2 associated athanogene-3 (BAG3) were found to be a 
cause of a sensorimotor neuropathy with clinical and pathological similarities to GAN (Jaffer et 
al., 2012). Mutations in BAG3 had previously been known to be a rare cause of myofibrillar 
myopathy, a disease characterized by rapid progressive proximal and axial myopathy, 
cardiomyopathy and respiratory problems. The BAG family are chaperone regulators with a 
common conserved region that mediates binding to the ATPase domain of Hsp70 (Takayama et 
al., 1999). BAG3 is constitutively expressed in human monocytes, kidney, lung, liver and 
placenta (Bruno et al., 2008) and can be induced in most cell types by the stress-induced 
transcription factor Heat Shock Transcription Factor 1 (Rosati et al., 2011). BAG3 binds Hsp22, 
which in turn stimulates autophagy of misfolded proteins and stops further protein translation 
(Carra et al., 2009).   
Neuropathy was documented in some cases of BAG3-associated myofibrillar myopathy 
and in some cases giant axons were observed on nerve biopsies; however, neuropathy was not 
thought to be a dominant feature of the disease. Recently four patients (ages 12-16) with BAG3 
mutations had clinical signs of a sensorimotor neuropathy; for three of these patients neuropathy 
was the presenting sign, rather than cardiac problems. Sural nerve biopsies of two patients 





well as the importance of understanding the formation of giant axons for a variety of clinical 
disorders.  
Shortly after GAN was characterized in humans, several reports recognized the presence 
of a similar disease in dogs (Duncan et al., 1981; Griffiths and Duncan, 1979; Julien et al., 1981). 
Rather than an engineered animal model, the disease seems to have appeared spontaneously. 
Because the causative gene was not identified at the time, diagnosis was based on symptoms and 
pathology. One case described an 18-month-old male Alsatian dog with progressive paraparesis 
(partial paralysis of the lower extremities) and ataxia of two months duration. Similar to human 
GAN patients, reflexes were absent, limbs hypotonic, and sensation reduced. Additionally, motor 
nerve conduction velocities, evoked compound muscle action potentials and sensory potential 
were also reduced (Griffiths and Duncan, 1979). Swollen axons containing excessive and 
disorganized neurofilaments were present in the spinal cord, also in agreement with the human 
pathology (Griffiths and Duncan, 1979). These finding were later confirmed in three more dogs 
(Duncan et al., 1981). Unfortunately there are no reports of sequencing of the Gan gene in these 
animals, so we cannot conclude that the phenotypically similar disease was due to mutations in 









Figure 1.4. Reported gigaxonin mutations. Gigaxonin is a BTB/Kelch protein with an N-
terminal BTB domain, central BACK domain, and 6 Kelch repeats. The schematic represents the 
compilation of all previously published gigaxonin mutations, which include point mutations, 
frameshift mutations, 6- and 44- amino acid deletions, as well as truncated forms. Included are 
83 individual patients and 50 unique mutations. *Indicates a patient that is a compound 
heterozygote. Data compilation performed by myself and J. Palmer Greene.   




















Part II. Intermediate filaments in normal neuronal function and disease  
Classification and expression 
 The dynamic behavior and structure of eukaryotic cells is made possible by three distinct 
yet interconnected filament systems: microfilaments (MFs) consisting of actin, microtubules 
(MTs) made from α/β-tubulin heterodimers, and intermediate filaments (IFs) (Herrmann and 
Aebi, 2000). In contrast to MFs and MTs, which are assembled from globular proteins that have 
nucleotide-binding and hydrolyzing activity, IFs are made of filamentous proteins that have no 
known enzymatic activity. These proteins have a conserved substructure that is necessary for 
their self-assembly into IFs of ~10 nm in diameter. However, they also show considerable 
diversity, especially with respect to the primary sequences of their N- and C-terminal domains. 
Humans have at least 67 genes that encode IF proteins, making this gene family one of the 
largest in the human genome (Chang and Goldman, 2004). 
The cytoplasmic IF proteins are grouped into four sequence homology classes (types I-
IV) with the nuclear lamins forming class V (Table 1.5). This classification is based on primary 
structure, gene structure, assembly properties and developmentally regulated tissue-specific 
expression patterns (Strelkov et al., 2003). IF classes I and II - the keratins - form 
heteropolymers in epithelial cells. By contrast, the class III IFs - which include vimentin, desmin, 
glial fibrillary acidic protein (GFAP) and peripherin – tend to form homopolymer filaments. 
Vimentin is expressed in mesenchymal and some ectodermal cells early in development, and 
often forms a scaffold network before the expression and integration of differentiation-specific 
IF proteins, such as desmin in muscle and the neurofilament proteins in neurons. The latter are 





NF-H) as well as nestin, syncolin and α-internexin. The only nuclear IFs are found in class V and 
consist of lamin A and its splice variant lamin C, together with lamin B1 and B2 (Chang and 
Goldman, 2004). Phakinin and Filensin are more recently described IF proteins that contribute to 












Intermediate filament Expression location Expression timing in neurons 
Type I Acidic keratins Epithelia N/A 
Type II Basic keratins Epithelia N/A 
Type III Vimentin Mesenchymal cells Appears transiently in emerging neurites 
 Desmin Muscle cells N/A 
 Glial fibrillary acidic 
protein 
Glia, astrocytes, stellate liver cells Splice variants detected in the Alzheimer’s affected 
hippocampal neurons (Hol et al., 2003) 
 Peripherin Neurons Expressed early during neuronal migration and axonal 
growth; upregulated in regenerating adult neurons 
 Synemin Muscle cells; neurons of the midbrain 
and pons (Mizuno et al., 2007) 
Expressed in neuronal progenitors and neurons (de 
Souza Martins et al., 2011) 
 Paranemin Neuroepithelial stem cells, muscle cells N/A 
Type IV NF-L Neurons Appears as neurites differentiate along with NF-M 
 NF-M Neurons        Appears as neurites differentiate along with NF-L 
 NF-H Neurons       Expressed in mature neurons 
 Nestin Neuroepithelial stem cells, muscle cells Expressed in neural stem cells 
 α-internexin Neurons    Expressed early during neuronal migration and axonal 
growth; also expressed in regenerating adult neurons 
 Syncolin Muscle cells N/A 
Type V Lamin A/C Most differentiated cells† Expressed in mature neurons but not neural progenitors 
(Takamori et al., 2007) 
 Lamin B1/2 All cell types† Lamin B2>A/C>B1 expression in mature neurons 
(Takamori et al., 2007) 
N/A Phakinin Lens N/D 
 Filensin Lens N/D 






Table 1.5. Classification of intermediate filaments and their expression patterns. 
Intermediate filaments have been classified into five distinct types on the basis of their sequence 
identity and tissue distribution (adapted from Chang and Goldman (2004) and Herrmann and 
Aebi (2000) unless otherwise cited). Expression data from Grant and Pant (2000) unless 







Basic structure  
 All cytoplasmic IFs have a common secondary structure, which consists of a central α-
helical rod domain of about 310-amino acids flanked by non-α-helical domains of various sizes 
(Figure 1.6) (Chang and Goldman, 2004). The rod domain is highly conserved and contains a 
hydrophobic heptad repeat essential for assembly into the classic 10 nm filament (Figure 1.7). 
Two segments of the rod domain, the 1A subdomain (in the N-terminal region) and the 2B 
subdomain (in the C-terminus) are the most conserved regions among IFs (Chang and Goldman, 
2004).  
Flanking this central rod domain are globular head and tail domains. The non-α-helical 
domains share little homology among different IFs, but are similar within a given type (Parry and 
Steinert, 1999). While the rod domain is essential for filament packing, the functions of the non-
α-helical end domains are not well understood. Transfection experiments have demonstrated that 
N-terminal head domains are essential for IF assembly, whereas the C-terminal tail domains may 
be involved in the organization of IF networks (Herrmann et al., 2003). Additionally, post-
translational modification of the globular head domain may influence the dynamics of 
neurofilament assembly (Barry et al., 2007). These domains may also be important for tissue-
specific functions of different IF proteins (Chang and Goldman, 2004).  
Mature vertebrate neurons contain a combination of peripherin, α-internexin and the NF 
triplet proteins (Szaro and Strong, 2009). The propensity of these proteins to form homo- and 
heteropolymers and their stoichiometry within the filament vary with species and neuronal 
subtype and directly affect their structural and functional characteristics (Szaro and Strong, 








Figure 1.6. Schematic of IF structure. Adapted from Young (2011).  IF proteins consist of head 
(blue region) and tail (red) domains separated by a coiled-coil rod domain (green). The tail 
domain of some IFs can be quite elongated (in for example nestin) and can give unique functions 
to these proteins. In NF-M and NF-H the tail domains protrude from the sides of the NFs and can 
affect NF spacing (Young, 2011). In this diagram the N-terminus is at left and the C-terminus at 




















Assembly and integration within the cytoskeletal network and dynamics 
In vivo, IFs are predominantly heteropolymers (Herrmann and Aebi, 2000). Neurons 
express members of class III and IV, as well as the lamins (class V) which are also expressed in 
many other cell types. Class III and IV members are able to form both homopolymers and 
heteropolymers, both within one group and between the two groups (Herrmann and Aebi, 2000). 
Typically, a homotypic NF-L core filament is decorated with NF-L/NF-M and NF-L/NF-H 
heterodimers. Two newly identified IF proteins, synemin and paranemin (originally classified as 
IF-associated proteins) form heteropolymers with vimentin and desmin (Bilak et al., 1998). The 
advantage of forming heteropolymers is unclear, but integration of heterologous subunits into the 
homotypic IF might increase its mechanical stability (Herrmann and Aebi, 2000). For example, 
homopolymeric NF-L filaments were much less stable under mechanical stress (as measured by 
atomic force microscopy) than intact neurofilaments from bovine spinal cord in their endogenous 
heterodimer formation (Brown et al., 1998).    
Although it is not clear how IFs assemble in vivo, in vitro assembly of homopolymers 
occurs in four steps (Figure 1.7). First, dimers form by association of the central rod domains of 
two polypeptide chains, through hydrophobic interactions between amino acids at specific 
repeats in the polypeptide. Dimers then attach N- to C-terminus, forming dimers of dimers, also 
referred to as tetramers. These tetramers (which have been detected in vivo) associate laterally to 
form protofilaments (also known as unit-length filaments, or ULFs) measuring approximately 16 
nm in diameter and 60 nm in length. This process takes less than one second. Within one minute 
these ULFs anneal end-to-end to form loosely packed, immature IFs, measuring several hundred 





depending on the IF type) yielding mature IFs (Herrmann et al., 1999). How heterotypic IFs 








Figure 1.7. Individual steps of IF assembly. Based on Minin and Moldaver (2008). IF assembly 
includes several steps. First, dimers are formed when central domains of two polypeptide chains 
are wound around each other, forming a helix. Dimers adhere N- to C-terminus, forming 
staggered dimers of dimers, which join end to end to produce a protofilament. Protofilaments 
join together and undergo internal compaction to produce a mature intermediate filament (Chang 




























The surface of mature IFs is highly charged due to the presence of many acidic residues 
at regular positions along the central rod’s heptad repeats. These charged clusters constitute 
potential binding sites for a variety of IF binding partners (Herrmann and Aebi, 1999). IF-
associated proteins fall into three main categories: IF connections to junctions, microtubules and 
microfilaments (Figure 1.8). Plakins (desmoplakin, BPAG1 and plectin, among others) have a 
long central α-helical domain able to mediate IF homodimeric coiled-coil formation (Herrmann 
and Aebi, 2000). Plakins also have an amino-terminal domain that may contain actin-binding 
domains (ABDs) and/or microtubule-binding domains (MBDs), which may facilitate 
coordination between the three cytoskeletal systems (Ruhrberg and Watt, 1997; Wiche, 1998). 
Desmoplakin connects several IF systems to desmosomal adhering junctions in a polar fashion 
(Gallicano et al., 1998).   
 For many years it was thought that IFs were stable cytoskeletal elements contributing 
primarily to the maintenance of the structural and mechanical integrity of cells. However, recent 
studies focusing on interaction between IFs and microtubules (MTs) highlight the dynamic 
nature of the IF networks. Some of the first evidence for this came from studies using 
microtubule inhibitors: when cells were treated with colchicines, vimentin aggregates were 
reorganized into perinuclear aggregates coincident with the depolymerization of MTs (Goldman, 
1971). It is now known that IF subunit exchange is largely dependent on the presence of MTs 
(Yoon et al., 2001; Yoon et al., 1998). In the absence of MTs the rate of fluorescence recovery of 
GFP-vimentin IFs decreases by ~60%. Moreover, nocodazole treatment increases the time 
required for GFP-keratin fluorescence recovery after photobleaching (FRAP).    
 In axons, short filaments (also called squiggles) of GFP-labeled NF-M and NF-H move at 





same filaments move only ~30% of the time due to long pause intervals (Roy et al., 2000). By 
contrast, peripherin filaments move >70% of the time, but the motility of individual peripherin 
particles varies based on their location within a neuron. Peripherin particles within the growth 
cone and cell body reverse direction 50% of the time; whereas in the neurite that drops to 8% 
(Helfand et al., 2003). Immunofluorescence and ultrastructural evidence suggests that there is a 
close association between IF structures and MTs, and NF squiggles have been observed to move 
along microtubules suggesting that to some extent IF transport is MT-dependent (Helfand et al., 
2003; Shah et al., 2000).  
IF movement along MTs is bidirectional, with most (65-70%) being directed towards the 
cell surface (Roy et al., 2000; Wang et al., 2000). This movement is likely mediated by the plus-
end-directed motor kinesin (Gyoeva and Gelfand, 1991; Prahlad et al., 1998). The association of 
IFs with kinesin and MTs is required for both their transport and integration into the assembled 
IF network. Retrograde IF movement is mediated by dynein associated with dynactin (Helfand et 
al., 2002; LaMonte et al., 2002).  
IFs are also transported along the actin network. Treatment of epithelial cells with the 
actin inhibitor cytochalasin D disrupts the organization of keratin networks (Green et al., 1987). 
Furthermore, more than half of the total actin-associated motor, myosin Va, associates with IFs 
in neurons. Deletion of the gene encoding myosin Va results in an altered distribution of IFs 
within axons (Rao et al., 2002). In light of these results, it is apparent that interaction with the 
MF and MT networks is essential for regulation of the cytoplasmic organization of IFs.  







Figure 1.8. IF interactions with the cytoskeletal network. Schematic showing the interaction 
between microfilaments (MF, also known as actin), microtubules (MT) and intermediate 
filaments (IF); adapted from Herrmann and Aebi (2000). Plectin interacts with MFs through its 
N-terminal actin-binding domain (ABD), with MTs through its microtubule binding domain 
(MBD) and with IFs through its C-terminal domain. It is thought that nestin’s long α-helical tail 
domain can also bind MTs and MFs, thereby linking IFs to other cytoskeletal components. 
Kinesins also are able to connect IFs to MTs to facilitate dynamic interactions (Herrmann and 










Additionally, post-translational modification modulates the functional dynamics of IFs. 
Phosphorylation of type III and IV IFs is known to regulate their organization and function 
(Sihag et al., 2007). IF proteins are phosphorylated on their head and tail domains and the 
dynamics of their phosphorylation/dephosphorylation plays a major role in regulating the 
structural organization and function of IFs in a cell- and tissue-specific manner. Specifically, 
phosphorylation plays a major role in regulating the assembly/disassembly of filaments. IF 
proteins are substrates for numerous kinases, including the mitosis-specific p34cdc2 kinase as 
well as various stimulus-specific kinases, including isoforms of protein kinase C (PKC), PKA, 
Ca
2+
/calmodulin-dependent kinase II (CAMK), RhoA-binding kinase-α (ROKα), Jun amino-
terminal kinase (JNK), p21-activated kinase (PAK) and p38 kinase (Chang and Goldman, 2004). 
For example, the phosphorylation of NF-L subunit by protein kinase A or protein kinase C can 
inhibit reassembly or even induce disassembly (Hisanaga et al., 1990).  
HSPs and IFs 
 An important class of IF binding partners is the heat shock proteins (HSPs). Heat shock 
proteins form a large protein family comprising proteins important in the cellular stress response. 
Heat shock proteins are important for many cellular processes including suppression of protein 
aggregation, cellular growth, transcription, differentiation, and involvement in cytoskeletal 
dynamics (Perng et al., 1999). The association of HSPs with IFs has been observed in a wide 
range of cell lines and IF types and with both IF monomers and whole IFs. The interactions 
occur both in stress and normal conditions, and the association is known to maintain the 
individuality of IFs, to modulate IF interactions in their networks and to stabilize the assembly of 





The first report of chaperones interacting with IFs came from studies on the ocular lens. 
Here, immunoprecipitation (IP) of soluble vimentin resulted in co-precipitation of α-crystallins, 
which are molecular chaperones and are homologous to HSPs (Nicholl and Quinlan, 1994). α-
crystallins inhibit the in vitro assembly of GFAP and vimentin in an ATP-independent manner. 
Furthermore, α-crystallins can increase the soluble pool of GFP when added to preformed 
filaments (Nicholl and Quinlan, 1994). HSP27 is associated with GFAP and vimentin in 
unstressed astrocytoma cells and keratin in MCF7 cells and vimentin associates with HSP90 in 
human neuroblastoma SK-N-SH cells, indicating that this association is not limited to a 
particular IF or cell type (Perng et al., 1999; Zhang et al., 2006). HSPs are able to associate with 
both soluble and insoluble IF fractions and it was observed that IFs form a gel in the absence of 
HSPs. It has been proposed that a major function of the association between IFs and HSPs may 
be to help integrate IFs into the cellular network. This may be accomplished by protecting 
filaments against the non-covalent interactions that result when they come into close proximity 
(Perng et al., 1999).     
Timing of IF expression 
IFs are expressed differentially during embryonic development and in terminally 
differentiated neurons. NF triplet proteins are phenotypic markers of differentiating neurons but 
prior to their synthesis neuronal precursors express (either independently or in addition to NF 
proteins) other IF proteins such as nestin, vimentin, α-internexin and peripherin (Grant and Pant, 
2000). Synthesis of IF proteins during neurogenesis is initially detected in neuronal cell bodies in 
the earliest stages of differentiation. Subsequently, NFs begin to appear in neurites and axons, 





within the axon, perhaps to accommodate local demands more rapidly. However, most (99%) of 
NF protein synthesis is localized in cell bodies (Grant and Pant, 2000).  
Although there are regional and temporal variations in expression within the developing 
nervous system, there are common trends with respect to the timing of expression of different IF 
proteins. The earliest IF protein expressed during neurogenesis is nestin in the neuroepithelia of 
the developing neural tube (Grant and Pant, 2000). Nestin is therefore used as a phenotypic 
marker of neural stem cells (Lendahl et al., 1990), although its expression is not restricted to the 
nervous system. As neuroblasts replicate within the neuroepithelium they also express vimentin, 
an IF protein more typical of mesenchyme that can also appear transiently in emerging neurites 
(Tapscott et al., 1981). However, neurons become vimentin-negative within a day following 
neuronal differentiation (Grant and Pant, 2000). 
 Peripherin or α-internexin are expressed during this same early period of neuronal 
migration and axon growth (Grant and Pant, 2000). The expression of peripherin correlates with 
the outgrowth of specific CNS and PNS neuronal populations, and it is transient in many cases as 
NF subunits are synthesized to form the stable cytoskeleton (Troy et al., 1990). However, 
peripherin is present in the mature nervous system, including in some PNS neurons (such dorsal 
root ganglion neurons) as well as motor neurons of the brain and spinal cord of the rat (Goldstein 
et al., 1991; Troy et al., 1990). Peripherin and NF-L are able to form filaments in transfected 
cells; by contrast, peripherin cannot assemble with NF-M or NF-H in isolation (Beaulieu et al., 
1999b). The early expression of α-internexin also correlates with the early stages of axonal 
outgrowth although it does persist in adult neurons and may copolymerize with NF-subunits 
(Kaplan et al., 1990). In general, the NF proteins follow a sequential order of expression in 





differentiate. At later stages, NF-H is expressed in the brain and spinal cord neurons as the 
cytoskeleton is stabilized (Willard and Simon, 1983).     
During axonal regeneration the sequential expression of IF proteins is generally 
recapitulated (Szaro and Strong, 2009). In regenerating adult DRG neurons the initial neurite 
outgrowths are enriched in peripherin but again gives way to NF-subunit expression (Wong and 
Oblinger, 1990). mRNAs for all NF subunits proteins are detected in intact as well as proximal 
and distal stumps of severed rat sciatic nerve. After nerve injury there is significant upregulation 
of NF-L and NF-M mRNAs, with RNA and protein synthesis greater in proximal than in distal 
stumps of the axon (Sotelo-Silveira et al., 2000). Thus nerve injury, demyelination and axonal 
regeneration are associated with local, sequential expression of IF and NF triplet mRNAs and 
protein synthesis, possibly in an effort to reassemble and sustain the axonal cytoskeleton during 
nerve regeneration (Grant and Pant, 2000). 
Hierarchical levels of control of IF protein expression in neurons 
Several control points – both transcriptional and post-transcriptional - exist for the 
expression of IFs in neurons. Transcriptional control plays an important role in expression, 
especially with regard to onset and neuronal specificity in development. Efforts to define the 
regulatory sites on the 5’-flanking regions of the NF promoters have been only partially 
successful (Grant and Pant, 2000). Thus far, some promising regulators have been found, but 
have lacked neuronal specificity. For example, a search for nuclear factors interacting with the 
promoter of human NF-M by gel mobility shift assays and DNaseI footprinting uncovered sites 
for NF-1 and AP-1 DNA binding proteins, but these lacked specificity for neurons (Elder et al., 





suggested that the proximal 5’ region (0.3 kb) constitutes a weak promoter and that it lacks 
information to confer neural specificity. Specificity could be achieved by combination with a 
larger (7.3 or 4.6 kb) region downstream of the transcription start point (Beaudet et al., 1992). 
The authors conclude that “the intragenic NF-L region contains cis-acting elements conferring 
cell-type-specific regulation on the basal activity of the NF-L promoter.” Finally, some progress 
has been made in understanding the transcription factors responsible for regulating NF 
expression. The POU family of transcription factors play an important role in neuronal 
development in a variety of species, and POU DNA binding domains (Pit-1, among others) are 
found in NF gene promoters (Grant and Pant, 2000). Overexpression of the POU transcription 
factor Brn-3a enhances the expression of the three NF genes at both the mRNA and protein 
levels, whereas Brn-3b overexpression has no effect (Smith et al., 1997). This differential effect 
is due to a single amino acid change in the POU homeodomain of Brn-3b as compared with Brn-
3a. These experiments suggest that Brn-3a, which is expressed in early development, is sufficient 
to induce the coordinated expression of all NF genes (Grant and Pant, 2000).  
 Recently, evidence has accumulated that post-transcriptional regulation is equally 
important for control of IF expression in neurons (Szaro and Strong, 2009). The 3’-untranslated 
regions (3’-UTRs) of NF subunit mRNAs are very well conserved, even more so than the 
promoters, suggesting that this region of the gene may have important conserved functions. The 
targets of post-transcriptional trans-regulatory factors are generally within UTRs. These factors 
include ribonucleoproteins and microRNAs (miRNAs), which together regulate mRNA 
transport, localization, translation and degradation. Thus the 3’-UTR has been focused on as a 
place to begin to look for cis-regulatory modules that bind trans-factors responsible for directing 





 One example of a conserved function of NF 3’-UTR is determination of intracellular 
localization. For example, the squid has three NF proteins (NF60, NF70 and NF220), which 
originate through alternative splicing of a single transcript. Each NF mRNA has a different 3’-
UTR (Szaro and Strong, 2009). In the stellate sympathetic ganglion, NF70 mRNA is 
concentrated in the axon hillock, whereas NF220 mRNA is more evenly distributed throughout 
the cell body (Way et al., 1992). In addition to controlling the localization, the 3’-UTR has been 
shown to influence the gene expression levels. When the 3’-UTR is deleted from mouse NF-L, 
the NF-L transgene undergoes a 3-fold aberrant upregulation between E15 and E18, and loses its 
susceptibility to axotomy-induced down-regulation. In striking contrast, the distribution pattern 
of NF-L is unchanged (Schwartz et al., 1995). Collectively, these results suggest that the 
expression of NF proteins in development is controlled at multiple levels.  
Cellular roles of IFs  
 Due to their relative stability and because they are temporally the last of the IFs to be 
expressed during axonal growth, IFs were once considered to play a rather passive role within 
cells (Szaro and Strong, 2009). They are now known to be dynamic structures that influence both 
the morphology and physiology of many cells, including neurons.  
All types of IF proteins are engaged in structural support in vivo (Kim and Coulombe, 
2007). In most vertebrate cells, IFs form extensive networks within the cytoplasm. These 
networks form a cage-like structure around the nucleus and extend radially to the cell surface 
(Chang and Goldman, 2004). This mechanical support is essential; this was exemplified by 
keratin-5- and keratin-14-null mice which display a severe skin blistering disease. This is 





caused by mutations in either of these keratin genes. Mutations in these keratins markedly 
weaken the mechanical resilience of the filament assemblies in vitro and affect de novo IF 
network formation. In addition to providing mechanical strength, IFs also serve as scaffolding to 
anchor and transport intracellular contents. They are important for the targeting of proteins to 
specific locations in polarized cells, in the transport and distribution of organelles, and in the 
regulation of cell-cell and cell-matrix adhesion (Kim and Coulombe, 2007).  
In addition to providing structure and support for neurons, nIFs also are essential for 
dynamic axogenesis. It is well established that actin and MTs play roles in axonal outgrowth and 
stability, and there is increasing evidence that nIF proteins are important for axonal elongation 
(Lariviere and Julien, 2004). Support from this came from the injection of anti-NF-M antibodies 
into Xenopus laevis embryos at the two-cell stage followed by the analysis of dissociated spinal 
cord cultures (Lin and Szaro, 1995; Walker et al., 2001). By the second day of axon outgrowth, 
the injected anti-NF-M antibodies resulted in shorter axons, both in intact embryos and in 
culture. Additionally, the neurites from anti-NF-M containing antibodies grew slower than 
normal ones. NFs also modulate the radial growth of large myelinated axons, a very important 
function as the caliber of axons is a determinant of conduction velocity (Lariviere and Julien, 
2004). The lack of NF structures due to an NF-L mutation in a quail line (Yamasaki et al., 1991) 
or to targeted disruption in mice (Zhu et al., 1997) causes severe hypotrophy of myelinated 
axons.       
IFs also fill important non-mechanical roles, and are essential for mounting a response to 
injury and stressors. For example, after sciatic nerve injury, translation of vimentin and importin-
β (a protein that moves other proteins into the nucleus) mRNA is locally activated in the wound-





newly synthesized vimentin forms a bridge between activated ERK and importin-β, resulting in 
the formation of a structure for retrograde transport. In this case, vimentin is thought to preserve 
the activated state of ERKs in long-range kinase signaling (Kim and Coulombe, 2007).  
IF proteins also play a role in controlling cell death. This is exemplified by the fact that 
IF proteins are able to attenuate the response to specific proapoptotic signals. In one report, the 
interaction of K18 with the death domain protein TRADD (tumor necrosis factor receptor type 1 
associated DEATH domain protein) prevents it from being recruited to activated TNFR1 (tumor 
necrosis factor receptor 1), resulting in apoptotic signal attenuation in epithelial cells (Inada et 
al., 2001). Additionally, nestin promotes the survival of neuronal progenitor cells exposed to 
oxidative stress and apoptosis, through its ability to scaffold and regulate the activity of cyclin-
dependent kinase 5 (cdk5) and its regulator p53 (Sahlgren et al., 2006). Last, interactions 
between select kinases and IFs appear instrumental in signaling toward apoptosis (Kim and 
Coulombe, 2007).  
In addition to participating in apoptotic signaling cascades and protection against 
mechanical stressors, some have argued that IFs may play an even more direct role in the stress 
response. Several features suggest that IFs should be considered directly as stress proteins 
(Toivola et al., 2010). First, despite their already high abundance under normal conditions 
(vimentin makes up 2-3% of total fibroblast protein), IF RNA and/or protein levels are increased 
several-fold in response to a variety of stressors. Second, IF mutations in humans cause 
numerous diseases (Table 1.9), some of which are phenocopied by HSP mutations. For example, 
the neuropathy Charcot-Marie-Tooth (CMT) type 2 can be caused by either mutations in either 
NF-L or in the small heat shock protein HSPB1 (also known as HSP27) (Almeida-Souza et al., 





susceptible to various types of stressors, similar to HSPs. Third, IF organization is often altered 
upon stress, and IFs and HSPs aggregate together as inclusions in several human diseases. 
Finally, IFs are major substrates for stress kinases and ablation of IF phosphorylation by 
mutation renders cells highly susceptible to apoptosis. These commonalities between IFs and 
HSPs point to IFs as important cellular stress proteins in addition to their classical roles in 






Nervous system disease-specific alterations in IFs 
 IFs are involved in more than 80 human diseases (Rogel et al., 2010). The majority of 
these diseases are rare (affecting fewer than 200,000 patients in the United States) or difficult to 
treat, but collectively they affect most tissues, and not all of them are rare; Keratin 8/18 
mutations result in a three-fold increase risk of developing nonalcoholic fatty liver disease 
(NAFLD) which affects an estimated 17-33% of Americans (Ku et al., 2005; Osterreicher and 
Brenner, 2007).   
A summary of diseases caused by mutations in IF proteins is presented in Table 1.9. The 
majority of these disorders are caused by mutations in the keratins and lamins. In general, skin 
diseases are caused by dominant-negative mutations, primarily affecting the central rod domain. 
Mutations elsewhere in the gene usually cause less severe disease or lead to disease 
susceptibility, as seen in mutations in keratins 8 and 18 (Omary et al., 2004). Mutations in the 
LMNA gene, which encodes the developmentally regulated lamin A and C isoforms, have been 
implicated in 10 diseases (Omary et al., 2004). These disorders tend to be late in onset and affect 
select tissues very specifically, such as dilated cardiomyopathy with conduction defects. Desmin 
myopathy was identified as the first non-keratin IF disease in 1998 (Munoz-Marmol et al., 1998). 
Gain-of-function mutations in  αβ-crystallin can also cause desmin-related myopathy, whereas 
loss-of-function mutations cause congenital cataract (Omary et al., 2004). Mutations in nIF 
proteins are related to several neurologic diseases: mutations in GFAP cause Alexander disease 
in children; mutations in NF-L cause axonal forms of CMT; and mutations in NF-H and 
peripherin are potential causes of sporadic amyotrophic lateral sclerosis (ALS). Several IF 





remains possible that mutations in the genes encoding some of these proteins will also be found 
to be disease-related (Omary et al., 2004).  
Several chronic human degenerative diseases show intracellular IF inclusions (Kunze and 
Rustow, 1993). These include desmin in cytoplasmic inclusions in myopathies and keratins in 
Mallory bodies in alcoholic liver disease. In the nervous system, NFs are present in the Lewy 
bodies in Parkinson’s disease, NF tangles in Alzheimer’s disease, and Pick’s bodies in Pick’s 
disease. Bunina bodies – small, granular eosinophilic inclusions found in ALS – were recently 
shown to often co-stain for peripherin (Mizuno et al., 2011). In addition, GFAP and vimentin 
form aggregates in the form of Rosenthal fibers in several conditions including astrocytoma and 
Alexander disease. Most of these inclusions also contain ubiquitin, but the mechanism(s) of 








Table 1.9. Disease-specific alterations of intermediate filaments. 
IF Disorder Main clinical features Gene products 
Keratin Chronic pancreatitis 
Cirrhosis and hepatitis 
Epidermolysis bullosa simplex 
Epidermolytic hyperkeratosis 
Ichthyosis bullosa of Siemens 
Inflammatory bowel disease 
Loose-anagen syndrome 
Meesman corneal dystrophy 
Monilethrix 





Malabsorption, pain, weight loss 
Variceal bleeting, ascites, confusion 
Fluid-filled bullous skin lesions 
Hyperkeratosis, skin fragility 
Bullous icthyosis, erythema 
Ulcerative colitis, Chrohn’s disease 
Sparse, short hair that falls out easily 
Fine punctuate opacities in cornea 
Alopecia, beaded and fragile hair 
Thick, white mucosa in mouth 
Severe nail dystrophy 
Hyperkeratosis of palm and sole 
In-grown hairs 
Multiple cystic tumors  
Keratin 8 
Keratins 8, 18 
Keratins 5, 14† 




Keratins 3, 12† 
Hair Keratins 1, 6† 
Keratins 4, 13† 
Keratins 6a/b, 16, 17† 
Keratins 1, 9, 16† 
Keratin 6hf 
Keratin 17† 
Lamin Atrial fibrillation, early onset 
Charcot-Marie-Tooth, type 2B1 
Dilated cardiomyopathy, type 1A 







Atrioventricular conduction defect 
Symmetrical muscle weakness 
Dilated cardiomyopathy 
Redistribution of adipose tissue 
Premature aging, alopecia 
Liver, skin, heart defects 
Lipodystrophy, joint contractures 
Joint contractures, muscle weakness 
Lamins A and C† 
Lamins A and C† 
Lamins A and C† 
Lamins A and C† 
Lamins A and C† 
Lamins A and C† 
Lamins A and C† 





Table 1.9. (Continued.) 
 Limb-girdle type 1B 
Werner’s syndrome, atypical 
Progressive proximal weakness 
Premature aging, senescence 
Lamins A and C† 
Lamins A and C† 
Other Alexander disease Progressive spasticity, dementia GFAP† 
 Amyotrophic lateral sclerosis 
(sporadic) 
Rapid loss of motor function NF-H, Peripherin† 
 Cataracts, juvenile-onset Ocular cataracts Phakinin, filensin†* 
 Charcot-Marie-Tooth, types 2E 
and 1F 
Sensorimotor neuropathy NF-L† 
 Dilated cardiomyopathy, type II Pure cardiomyopathy Desmin† 
 Desmin-related myopathy 
Parkinson disease 
Neuronal IF Inclusion disease 
(NIFID) 
Muscle weakness, arrhythmias 
Tremor, rigidity, slow movements 




†Causative association identified 
*Also caused by mutations in αβ-crystallin 
 
Table 1.9. Disease-specific alterations of intermediate filaments. Adapted from the Human 
Intermediate Filament database and Omary et al. (2004). Diseases affecting the neuromuscular 





Part III. Protein turnover: UPS and autophagy  
Overview of intracellular degradation pathways 
 Autophagy and the ubiquitin-proteasome system (UPS) are the two major intracellular 
degradation pathways. Autophagy is responsible mainly for the degradation of long-lived 
proteins, complexes and organelles; the UPS rapidly eliminates short-lived and single proteins in 
a process thought to be more selective than bulk autophagy (Kraft et al., 2010). It was once 
thought that these two degradation pathways functioned independently. However, there is 
increasing evidence that the two are linked by crosstalk (Zheng et al., 2009). Before discussing 
their relevance to the degradation of IFs I will begin with a general overview of the two 
pathways.  
 There are three major types of autophagy: macroautophagy, microautophgy, and 
chaperone-mediated autophagy (CMA) (Figure 1.10). Microautophagy is the simplest of these; 
lysosomes directly engulf cytoplasm by invagination, protrusion, and/or septation of the 
lysosomal limiting membrane (Tai and Schuman, 2008). The contents of the lysosome are then 
degraded by acidic hydrolases. In macroautophagy, targets are first sequestered in an 
autophagosome. Autophagosomes then fuse with lysosomes to form autolysosomes (also called 
autophagolysosomes) and their contents are then degraded. The formation of autophagosomes is 
initiated by class III phosphoinositide 3-kinase and autophagy-related gene 6 (Atg6, also known 
as Beclin-1). In contrast, CMA is selective for specific cytosolic proteins that contain a 
pentapeptide motif recognized by the chaperone heat shock cognate 70 (Hsc70), which transfers 
protein substrates to the lysosomal membrane, where, through binding to the receptor lysosome-





degraded (Rubinsztein et al., 2005). Unlike macro and microautophagy, CMA is very selective in 
what it degrades and substrates are translocated into the lysosome one at a time, rather than 
sequestered in bulk.   
























Figure 1.10. Lysosomal pathways. Adapted from Tai and Schuman (2008). Lysosomes contain 
acid hydrolases that break down polypeptides. Plasma membrane proteins are endocytosed, 
sorted to the late endosome and then the lysosome. Many types of signals can regulate 
endocytosis and sorting, including monoubiquitination. The acid hydrolases in the lumen of 
lysosomes (pH 4-5) and late endosomes (pH 5-6) are highly active in acidic environments but 
lose their activities in the cytosol (pH ~7.2). Intracellular proteins can enter lysosomes though 
three main autophagic mechanisms. In microautophagy, large amounts of cytosolic materials or 
even organelles are surrounded by a double-membrane structure (autophagosome) that fuses with 
lysosomes. In microautophagy, a small amount of cytoplasm is internalized through lysosomal 
invagination. In chaperone-mediated autophagy, proteins that have been unfolded by the 
chaperone translocate into the lysosome through interactions with lysosome-associated 






Proteins are targeted for degradation by the proteasome by covalent modification of a 
lysine residue that requires the coordinated reactions of four enzymes (Figure 1.11). First, a 
ubiquitin-activating enzyme (E1) hydrolyzes ATP and adenylylates a ubiquitin molecule. This is 
then transferred to the E1 active site in concert with the adenylylation of a second ubiquitin. This 
adenylylated ubiquitin is then transferred to a second enzyme, the ubiquitin-conjugating enzyme 
(E2). In the next step, a member of a highly diverse class (more than 1,000) of enzymes known 
as ubiquitin ligases (E3) recognizes a specific protein to be ubiquitinated and catalyzes the 
transfer of ubiquitin from E2 to this target protein. It is the E3 that confers substrate specificity in 
this system. A target protein must be labeled with at least four ubiquitin monomers (in the form 
of a polyubiquitin chain, created by the action of E4 elongation enzymes) before it is recognized 
by the proteasome lid. Found in the cytosol and nucleus of cells, the 26S proteasome then 
catalyzes the rapid degradation of ubiquitinated proteins. 
 Ubiquitin is a small, 76-amino acid protein with 7 lysine residues. Ubiquitin can be 
conjugated to itself via specific lysine (K6, K11, K27, K29, K33, K48 or K63) residues which 
results in diverse types of chain linkages. K48 chains lead to degradation by the proteasome; 
monoubiquitination and K63 chains have other functions, including lysosomal degradation. A 
protein’s ubiquitination pattern can be dynamically edited by E3s, E4s and DUBs 
(deubiquitinating enzymes). When K48-polyubiquitinated, the protein can reach the proteasome 
by diffusion or with the assistance of chaperones and shuttling factors. After substrate-
proteasome association, DUBs and ATP-dependent unfoldase activities help the substrate to 
enter the proteolytic lumen of the proteasome (Tai and Schuman, 2008).  
E1 activity is nonspecific with regard to the proteins it targets, and only two isoforms of 





identified. E3 ligases are the most variable and abundant with over 500 E3 ligases identified to 
date. A given E2 can associate with multiple E3s, resulting in a broad variety of functional E2/E3 
activities and a relatively high degree of target substrate specificity (Lehman, 2009). Most E3 
ligases are classified as to whether they contain HECT (homologous to E6AP COOH-terminus) 
or RING (really interesting new gene) domains. Both HECT and RING proteins usually possess 
E3 ligase functions; for example the HECT-type ligase UBE3A and the RING-type ligase Cbl. 
RING-type E3s, however, often associate with scaffolding proteins to form multimeric 
functional complexes. These complexes can associate with substrate-specific scaffolding proteins 































Figure 1.11. The ubiquitin-proteasome system. Adapted from Tai and Schuman (2008). 
Ubiquitination is a post-translational modification that forms an isopeptide bind between a lysine 
residue on the protein and the C-terminus of ubiquitin. The ubiquitin system consists of four 
different classes of enzymes: E1-E4. First, ubiquitin is covalently conjugated to the E1 
(ubiquitin-activating enzyme) in an ATP-dependent reaction, and then it is transferred to the E2 
(ubiquitin-conjugating enzyme). The E3 (ubiquitin-protein ligase) transfers the ubiquitin from 
the E2 to the substrate protein. After the first ubiquitin has been attached (monoubiquitination), 
the E3 can elongate the ubiquitin chain by creating ubiquitin-ubiquitin isopeptide bonds. The E4 
enzymes (chain elongation factors) are a subclass of E3-like enzymes that only catalyze chain 
extension. Only K48 chains lead to degradation by the proteasome. A protein’s ubiquitination 
can be modified by E3s, E4s and DUBs (deubiquitinating enzymes) before being degraded by 






Role of autophagy and the UPS in IF degradation 
Autophagy is a part of normal cell growth and development. It also has a role in the cell’s 
response to stressors including nutrient starvation, infection, repair of damaged proteins and 
programmed cell death. Similarly, proteasomal degradation is essential for many cellular 
processes, including the cell cycle, regulation of gene expression, and responses to oxidative 
stress. Importantly, these pathways have been implicated in IF degradation.  
Our understanding of how IF degradation occurs is still evolving. Progress in this area is 
hindered by the long half-life of IF proteins and their relative insolubility. Radiolabeling of 
newly synthesized NF proteins after intravitreal injection of [
3
H]proline suggests two phases of 
NF disappearance in retinal ganglion cell (RGC) axons, one with a protein half-life of ~20 days 
and a second phase with a slower half-life of ~55 days (Nixon and Logvinenko, 1986). 
Additionally, a 6-9% peak of radiolabeled proteins that lasted several months was observed. To 
further address this question, mice were generated with doxycycline control of human 
neurofilament light (hNF-L) transgene (Tet-off promoter system) (Millecamps et al., 2007). The 
hNF-L mRNA disappeared rapidly within one week of doxycycline administration in the 
drinking water. By contrast, the hNF-L proteins persisted for much longer, and the half-life was 
calculated to be approximately three weeks, consistent with previous studies.  
Despite this, there is some evidence that ubiquitination and proteasome degradation play 
a role in IF degradation. One of the better characterized systems for studying this is shear stress-
induced degradation of keratin in lung epithelial cells in the laboratory of Karen Ridge. Jaitovich 
et al. (2008) found that ubiquitin was covalently associated with GFP-keratin 





epithelial cell line) and pretreatment with the proteasomal inhibitor MG132 prevented 
degradation of the keratin IF network. Under unstressed conditions GFP-keratin was not 
associated with ubiquitin. In neurons, indirect support for nIFs being degraded by the proteasome 
comes from work on the ubiquitin ligase TRIM2. Deficiency of TRIM2 results in accumulation 
of NF-L in the axons of null mice and NF-L filled axonal swellings in the cerebellum, retina, 
spinal cord and cerebral cortex. The axonopathy is followed by progressive neurodegeneration 
accompanied by juvenile-onset tremor and ataxia (Balastik et al., 2008). By overexpressing 
tagged forms of NF-L, ubiquitin and TRIM2 (including full-length and truncated forms) Balastik 
et al. (2009) showed that TRIM2 coexpression leads to a significant increase in NF-L 
ubiquitination in the presence of MG132. The ubiquitination of endogenous NF-L was not 
examined. Although these experiments suggest that nIFs are ubiquitinated and subsequently 
degraded by the proteasome, further studies are needed to examine the turnover of endogenous 
nIFs to determine the precise mechanism(s) by which they are degraded.     
Neurofilaments are degraded during axon degeneration, including Wallerian degeneration 
and pruning during development. However, the molecular pathways that regulate this process 
remain unclear (Wang et al., 2012). As soon as a few minutes after axotomy, the axonal 
segments immediately proximal and distal to the injury site rapidly degenerate by several 
hundred micrometers in either direction. This process begins within minutes after axotomy and 
lasts between 5-60 minutes and is followed by the formation of dystrophic bulb structures at the 
terminals of both transected ends. This short, early-onset degenerative event is termed acute 
axonal degeneration (AAD) and is initiated by channel-mediated influx of extracellular Ca
2+
. 
The primary mechanism by which Ca
2+
 leads to cytoskeletal breakdown in AAD is by Ca
2+
-





axonal neurofilaments and microtubule-associated components. However, other degradative 
processes such as autophagy are also triggered by the initial Ca
2+
 influx after axotomy (Wang et 
al., 2012), and the respective contributions of the UPS and autophagy are not well understood.  
Alterations of protein degradation in neurological diseases  
A diversity of human diseases is associated with severe alternations of IFs (see Table 
1.9). One common pathological feature of many IF-related diseases is the accumulation of 
intracytoplasmic inclusion bodies or aggresomes consisting of modified IF proteins. It is unclear 
whether these structures are protective, harmful or neutral to the disease process, but their 
composition may lend insight into the process by which they form and therefore the pathways of 
IF degradation. Aggresomes - such as those formed in liver disorders – consist of IFs, 
chaperones (such as HSP70 and HSP90) and degradation machinery (including p62 and 
ubiquitin). The IFs present in aggresomes are often post-translationally modified; for example 
keratin phosphorylation appears to act as a degradation marker for the UPS (Rogel et al., 2010).  
 The collaboration between the UPS and autophagy is essential to protein quality control, 
and ultimately, cell survival. Mutations in components essential for protein degradation can on 
their own result in neurological disease, as summarized in Table 1.12. Many of these diseases are 
associated with mutations in E3 ligases – responsible for a) the addition of ubiquitin onto targets 
as well as b) specificity - or proteins that aid in the activity of the E3 ligase. Highlighting the 
importance of the E3 ligase, four out of seven forms of Parkinson disease are related to E3 ligase 
activity (Park, 2012).  
Several of diseases listed in Table 1.12 present in children, including juvenile forms of 





indispensable nature of protein degradation  (Lehman, 2009). The E3 ligase UBE3A has been 
implicated in several of these diseases, including Angelman, Rett syndrome and autism. 
Angelman syndrome is caused by loss of function of UBE3A, but the proteins that UBE3A 
targets for degradation remain to be identified, obscuring the link between UBE3A and the 
disease mechanism. Most cases of Rett syndrome are caused by sporadic mutations of methyl-
CpG-binding protein-2 (MECP2) on the X chromosome. MECP2 binds methylated DNA and 
acts as a transcriptional repressor and its mutations can lead to disruption of methylation 
imprinting of UBE3A, resulting in decreased UBE3A activity in the brains of MECP2-deficient 
mice and Rett patients (Lehman, 2009). Gigaxonin, the protein mutated in GAN, as been 
proposed to act as an E3 ligase substrate adaptor (Furukawa and Xiong, 2005).   
 Although no specific mutations in autophagy components have yet been linked to human 
disease, autophagy is implicated in the pathogenesis of many major neurodegenerative diseases. 
More specifically, in Alzheimer’s, Parkinson’s, Huntington’s and ALS, impairment in different 
stages of autophagy leads to the build-up of pathogenic proteins and organelles (Nixon and 
Yang, 2012). It is widely believed that autophagy exerts mainly pro-survival effects on normal 
cells and its enhanced activity has been linked to increased longevity in animal models. 
Autophagy protects cells under stress from nutrient deprivation, loss of energy and protein 
aggregation, thereby delaying apoptosis (Nixon and Yang, 2012). Autophagy in neurons is 
constitutive and although neurons are able to perform autophagy at high rates, neurons are 
especially vulnerable to any impairment of autophagy (Boland et al., 2008). Indeed many human 
primary lysosomal diseases (for example lysosomal storage disorders), preferentially affect the 
brain. The reliance of neurons on autophagy comes as little surprise given that neurons must 





dividing cells dilute waste through cell division. Additionally, neurons must maintain large 
volumes of membrane and cytoplasm along axons and dendrites and must continually traffic 
autophagy-related components long distances back to the cell body where waste clearance by 






Table 1.12. Mutations in protein degradation components linked to neurological disease. 
Disorder Mutation  Function of mutated protein (if known) 
Parkinson disease 
     Autosomal dominant (late onset) 
     Autosomal dominant (late onset) 
     Autosomal recessive (juvenile onset) 
     Autosomal recessive (early onset) 
     Autosomal recessive (early onset) 
Spinocerebellar ataxias 
     SCA1 
     SCA2 
     SCA3 
Prion diseases 
























CHIP ubiquitin ligase substrate 
DUB 
Subunit of SCF E3 ubiquitin ligase 
Promotes parkin ubiquitin ligase activity 
Promotes parkin ubiquitin ligase activity 
 
UBE3A E3 ligase 
Associates with c-Cbl E3 ligase 
DUB 
Block of normal proteasome function  
Endosome membrane fusion and trafficking 
E3 ligase 
Decreased UBE3A E3 ligase due to MECP2 mutations 
Copy number alternations of UBEA3 (& other UPS genes) 
Possible E3 ligase substrate adaptor 








Table 1.12. Mutations in protein degradation components linked to neurological disease. 
Adapted from Lehman (2009). Dysregulation of protein degradation may contribute directly to 
many neurodegenerative diseases. SCA, spinocerebellar ataxia; GAN, giant axonal neuropathy; 
IBMPFD, inclusion body myopathy with early-onset Paget disease and frontotemporal dementia; 
LRRK2/PARK8, leucine-riche repeat kinase 2; UCH-L1/PARK5, ubiquitin carboxy-terminal 
hydrolases L1; SCF, Skp/cullin/F-box; PINK1/PARK6, PTEN-induced putative kinase 1; 
UBE3A, ubiquitin-protein ligase E3A; MECP2, methyl CpG binding protein 2; GAN, gigaxonin; 
CHIP, C-terminus of HSC70-interacting protein; DUB, deubiquitinating enzymes; c-Cbl, casitas 








Part IV. Existing cellular and mouse models of giant axonal neuropathy 
Fibroblast cellular models of GAN  
 Soon after the identification of GAN, patient fibroblasts were adopted as an in vitro 
cellular model to study the disease. In one of the first reports (Pena, 1982), it was noted that 
>90% of the fibroblasts examined contained large filamentous aggregates (Figure 1.1D). These 
were identified as vimentin aggregates. In contrast to the striking vimentin morphology, there 
was no change in the overall levels of vimentin protein or its phosphorylation state (Pena, 1982). 
Later studies found that the vimentin aggregate phenotype is conditional rather than constitutive: 
in normal serum conditions (>2% fetal bovine serum or FBS) most GAN cells had normal IF 
organization, but IF bundles formed when the cells were transferred to low (0.1%) serum 
(Bomont and Koenig, 2003; Klymkowsky and Plummer, 1985). One study found that 
trypsinization – but not serum concentration – influenced the formation of IF bundles, leading 
them to suggest that a “putative ‘organizing’ molecule might act as a component of a linkage 
system between extracellular plasma membrane components and cytoskeletal elements” (Manetti 
et al., 1987).   
 It is clear that the microfilaments are not affected in GAN fibroblasts. However, there is 
some disagreement on the state of the MT network. Two reports have found MTs are organized 
in GAN fibroblasts (Bomont and Koenig, 2003; Klymkowsky and Plummer, 1985); whereas one 
found them to be disorganized and tangled (Bousquet et al., 1996). This led Bousquet et al. 
(1996) to propose that the aggregation of IFs in GAN “may be due to a defective interaction 
between microtubules and IFs.” This was supported by experiments with nocodazole: when 





contrast, control cells never displayed such aggregates upon nocodazole treatment (Bousquet et 
al., 1996). Bomont and Koenig (2003) did note that the IF bundles are found in close proximity 
to the microtubule organizing centers (MTOCs) and they confirmed that MT depolymerization 
induces vimentin aggregation in GAN fibroblasts.     
 In the absence of an understanding of the functions of gigaxonin, two screens were 
performed as an unbiased approach to identify genes and proteins disrupted in GAN. Leung et al. 
(2007) compared the expression profiles of two GAN and two control fibroblast lines grown in 
low serum medium by Affymetrix microarray. Gene products involved in lipid metabolism 
displayed the most dramatic changes. Oil Red O staining revealed that the GAN fibroblasts 
contained significantly more lipid droplets (52 and 21% in GAN versus 6 and 9% in control) 
(Leung et al., 2007). However, this is the only report to link lipid metabolism to the pathogenesis 
of GAN. 
 More recently, a proteomic study analyzed differences between fibroblasts from four 
GAN patients and four controls (Mussche et al., 2012). Dysregulated proteins included 
ribosomal protein L29, ribosomal protein L37, galectin-1, glia-derived nexin and aminopeptidase 
N. Several of these play a role in cytoskeletal function. However, somewhat surprisingly, the 
levels of 76 structural cytoskeletal proteins were unaltered. This is in contrast with from findings 
from the sural nerve, in which levels of NF-L were increased ~2-fold in GAN (Ionasescu et al., 
1983). This led Mussche et al. (2012) to speculate that gigaxonin may degrade a protein that 
regulates the cytoskeletal structure and turnover, rather than the cytoskeleton itself. Despite these 
different findings, the disease mechanism remains unclear. Moreover, although the human 
fibroblast model recapitulates some of the neuropathology features, extrapolation has been 





Mouse models of GAN 
The mouse is currently the premier mammalian model system for genetic research. 
Transgenic mouse models are a powerful reagent for modeling genetic disorders where the 
causative gene has been identified. Since the identification of GAN, two main strategies have 
been used to create a knockout mouse: deletion of either the promoter-exon 1 or exons 3-5.  Both 
strategies result in an absence of gigaxonin RNA or protein, but the phenotype appears to be 
mild overall and to vary based on the genetic background of the animal (Table 1.13).  
Ding et al. (2006) published the first GAN knockout mouse (Gan
Δex3-5
) and reported that 
homozygotes developed strong motor deficits as early as 6 months of age (Ding et al., 2006). 
However, the only motor function that was quantified was the gait functional index (calculated 
by dividing the average stride length by the average distance between feet). By this measure, 
Gan null mutants had a ~2-fold reduction in the gait functional index, due to decreased average 
stride length and increased average distance between feet. Ding et al. (2006) also noted “bizarre 
limb positioning,” spasticity, seizure, weakness, muscle wasting and progressive weight loss, but 
none of these were quantified. A Kaplan-Meier analysis was not performed, although the authors 
note that “very few Gan null mutants died prior to the age of 12 months.” An unquantified hair 
phenotype was observed: “some had no whiskers and others displayed abnormal or fragile hairs” 
(Ding et al., 2006). 
   Some tissue pathology in their Gan null mice was quantified. At 9-12 months Ding et al. 
(2006) reported 18-27% axon loss involving both myelinated and unmyelinated nerve fibers 
(Figure 1.14H, I). Ultrastructural studies revealed enlarged axons distended with NFs (Figure 
1.14B, C, E, F), but the degree of enlargement was not quantified and the characteristic “giant 





conclude that “the phenotypes and the pathological features of the Gan null mice validate this 
null mouse as a model of human GAN.”  
While recapitulating some of the features of the human disease, this model was 
incompletely characterized and it was additionally critiqued for the heterogeneous genetic 





 models were made on the 129/SvJ (100%) and C57/BL6 (98.4%) 
background (Ganay et al., 2011). Ganay et al. (2011) were not able to reproduce the findings 
reported in the Ding et al. (2006) paper; moreover, as described below, they found that the mild 
phenotype appeared as sensory or motor depending on the genetic background of the mice.  
On the 129/SvJ genetic background, Gan
Δex3-5
 null mice have mild but persistent motor 
deficits starting at 15 months of age. At 72 weeks of age, Gan null mice have a ~10% reduction 
in forelimb grip strength. No significant changes were detected using a Rotarod test, sensitivity 
to temperature, gait, weight or viability. In contrast, on the C57BL/6 background Gan null mice 
have sensory deficits but no motor changes. Gan null mice were significantly less sensitive to 
heat, although gait, weight and survival remained unchanged. Additionally, Ganay et al. (2011) 
re-tested the mice strain used by Ding et al. (2006) and did not find the early and severe motor 
deficits previously reported. The mice did not have any motor deficits over a 52 week period, as 
quantified by normal grip strength and Rotarod. Difficulty in walking, fragile hair or absence of 
whiskers were occasionally observed in control mice and at a similar and normal frequency in 
both Gan
Δex3-5
 models from Ganay et al. (2011) and Ding et al. (2006).  
Ganay et al. (2011) did not observe any neurodegeneration, but found dysregulation of 





in the lumbar spinal cord did not differ between WT and KO mice. Axonal content in the lumbar 
and sciatic regions also was not significantly reduced. No giant axons were observed in any 
tissues. Ultrastructurally, Gan null mice on both genetic backgrounds displayed striking changes 
at 48 weeks of age. In the 129/SvJ mice, Gan null axoplasms had a 2.9-6.3-fold decrease in the 
number of microtubules (depending on the nerve type examined). NFs lost their orientation in 
the KO mice, as quantified by measuring the circularity (CIRC) of the sections of individual NFs 
(if 1 represents an NF perfectly parallel to the axon, the CIRC in WT mice was 0.62 ± 0.003 and 
0.52 ± 0.006 in KO sciatic nerve). In addition, the diameter of the properly oriented NFs 
significantly increased in Gan null axoplasms, from 8.77 ± 0.08 nm for controls to 12.76 ± 0.22 
nm in KO sciatic nerve (Ganay et al., 2011). 
Ganay et al. (2011) also quantified the level of expression of the NF proteins in addition 
to characterizing their orientation. The brain, spinal cord and sciatic nerve tissue in all three 
Gan
Δex3-5
 models was examined (on both the 129/SvJ and C57BL/6 backgrounds, as well as the 
mice from the Yang lab on a mixed background). For all three NF subunits the maximum 
increase was found in the brain (as opposed to the spinal cord), and NF-L was found to be the 
highest elevated over WT (4.3-to 6.7-fold at 48 weeks of age). NF-M and NF-H were generally 
elevated in the three mouse models, although there were some exceptions. In the lumbar spinal 
cord and sciatic nerve the NFs appear to be elevated approximately 1.5-fold (Ganay et al., 2011).        
Dequen et al. (2008) created a knockout mouse by targeted deletion of exon 1, but they 
too found that the knockout mouse had no overt neurological phenotype. Their strategy was to 
remove a 1 kb sequence containing part of the promoter with the translation initiation site in the 
first exon. Despite an absence of full-length gigaxonin, the Gan
Δex1
 mice did not exhibit motor 





decrease in the cross-sectional area of hindlimb muscle fibers in Gan
Δex1 
compared with wild 
type mice. A 10% reduction in the colocalization of α-bungarotoxin and SV2/NF-M markers was 
noted, indicating muscle denervation in the hindlimb muscle fibers. Both of these outcomes were 
found at 6 but not 3 months of age and denervation did not increase when measured at 12 months 
(Dequen et al., 2008).  
The authors also examined the dorsal and ventral root axons by stereomicroscopy. 
Neither the number of sensory axons nor the axon caliber was altered in Gan
Δex1 
dorsal root 
compared to wild type. However, the number of motor axons was significantly diminished by 
~25% in the Gan
Δex1 L5 ventral root. A “subset” of Gan null axons had larger calibers than wild 
type mice but no giant axons were detected. To follow up on the axonal degeneration observed in 
the L5 ventral root the motor neurons in the lumbar spinal cord were counted. There was no 
significant reduction in motor neuron number over a 12 month period (Dequen et al., 2008).  




mice have elevated levels of certain IF proteins 
(Figure 1.14J, K). Beginning at 3 months of age, Gan
Δex1 
mice have elevated levels of NF-L, NF-
M, NF-H, α-internexin and vimentin in the brain, cerebellum and spinal cord. The alteration in 
NF-M levels was less dramatic than for NF-L and NF-H. Protein levels were quantified by dot 
blot at 3, 6, 12 and 24 months of age (Figure 1.14K). In general, the protein increase does not 
appear to be progressive; elevated levels remain fairly constant throughout the time course. No 
variation in neurofilament mRNA levels was detected by qualitative RT-PCR on total RNA from 
brain and spinal cord; quantified results were not reported. In contrast to the elevated levels of IF 
proteins, levels of tau1, α- β- and γ-tubulin and actin were not elevated in GanΔex1 mice. GFAP 
was the single IF protein that appeared comparable between null and wild type mice (Dequen et 





Measurement of total protein levels was accompanied by immunohistochemical analysis. 
In the brain, immunostaining for NF-L was stronger in the cortex but not the three other regions 
(hippocampus, thalamus and cerebellum) examined. NF-H and α-internexin-positive aggregates 
were observed in the cortex and thalamus. The magnification of the published images is not 
sufficient to determine whether these aggregates are axonal or perikaryal, but the authors note 
that these two IF proteins “formed accumulations reminiscent of intracellular IF inclusion 
bodies” (Dequen et al., 2008). A similar analysis was also performed on sections of cervical, 
thoracic and lumbar spinal cord. No changes were detected in the corticospinal tracts. In the 
ventral horn the intensity of NF-L appeared stronger in fibers around motor neurons in Gan
Δex1 
spinal cord as compared with wild type. In dorsal root ganglia, NF-L and peripherin formed 
abnormal accumulations in cell bodies (Dequen et al., 2008).   
Dequen et al. (2008) followed up on their finding of NF-H inclusions with 
immunohistochemistry using SMI31 and 32 antibodies for the detection of hyperphosphorylated 
and hypophosphorylated NF-H, respectively. The inclusions were composed only of non-
phosphorylated NF-H. Double immunofluorescence revealed that the NF-H and a-internexin 
accumulations in neuronal cells did not always colocalize. The aggregates did colocalize with 
NeuN and were neuron-specific and intracytoplasmic; no other co-labeling studies were shown 
(Dequen et al., 2008).   
Overall therefore, although the mouse models do not recapitulate the early and severe 
sensorimotor phenotypes of patients, they do exhibit cytoskeletal dysregulation as early as 3 
months of age.  The observation that mild and variable phenotype of the mouse models does not 





gigaxonin engages in species-specific interactions and functions that might be more faithfully 
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vimentin from 3 
months onwards 
10% decrease in 
muscle 
innervation and 
27% axonal loss 
in L5 ventral roots 


































Elevated levels of 
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24 and 48 weeks 
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Elevated levels of 
NF-L,  and to a 
lesser extent NF-
M and NF-H at 
24 and 48 weeks 
Cytoskeletal 
disorganization at 
48 weeks of age 
No No (Ganay et 
al., 2011) 
Exon 3-5 C57/BL6 No Less 
sensitive 
to heat 
Elevated levels of 
NF-L,  and to a 
lesser extent NF-
M and NF-H at 
24 and 48 weeks 
Cytoskeletal 
disorganization at 
48 weeks of age 
No 
 
No (Ganay et 
al., 2011) 






Table 1.13. Summary of existing Gan
-/-
 mouse models. The four Gan null mice made to date 
recapitulate some aspects of the human disease, but the predominant finding - biochemical 
dysregulation of nIFs - has a late onset and is not progressive. All of the studies report elevated 
levels of NF-L, and to a lesser extent NF-M and NF-H. They also report cytoskeletal 
disorganization. No studies report a consistent reduction of motor abilities across multiple tests 




















 mouse pathology. (A-I) Pathological lesions found in Gan
Δxe3-5
 null animals 
reproduced from Ding et al. (2006). (A-F) Ultrastructural analysis (EM) on WT (A, D) and null 
axons (B, C, E and F). Cross-section (A-C) and longitudinal (D-F) section of WT (A, D) and null 
(B, C, E and F) samples show swollen axons (B), densely accumulated NFs (E), thin myelin 
sheaths (indicated by arrows in B, C and F), disorganized cytoarchitecture and accumulated 
membranous structures (C, from brain and F, from sciatic nerve) in the null animals. (G-I) Semi-
thin sections of sciatic nerves from WT (G) and null mice (H, I) at 28 weeks. Axons appear 
larger with signs of degeneration in the null samples. Scale bar 500 nm (A-D), 750 nm (E, F) and 
12 μm for (G-I). (J, K) Increased levels of IFs in specific regions of the GanΔxe1 null nervous 
system reproduced from Dequen et al. (2008). (J) Western blots were performed at 3 months of 
age. (K) Dot blot analysis of IF content in the CNS in extracts from the brain, cerebellum and 
spinal cord of Gan mice and of WT littermate at 3, 4, 12, and 24 months of age (n = 3; t test; 






Part V. Proposed functions of gigaxonin  
Structure and homology of gigaxonin 
 Gigaxonin is a 597- amino acid protein. When the human GAN gene was identified in 
2000 it was determined to be a BTB (Bric-a-brac, Tramtrack and Broad complex)-Kelch protein 
family member based on homology (Bomont et al., 2000; Stogios et al., 2005). Within this 
family, gigaxonin shows highest similarity (22-27% identity from residues 9 to 554) with human 
mayven and ENC-1, and mouse Keap1 proteins (Figure 1.15) (Bomont et al., 2000). The crystal 
structure of the BTB domain of gigaxonin was determined by X-ray diffraction and deposited in 
the Protein Data Bank in 2007 (PDB ID: 2PPI; structure is unpublished). To date the Kelch 
domain of gigaxonin has not been crystallized.  
The members of the BTB-Kelch family share both a common domain organization and 
~25% sequence identity (Zhang et al., 2005). The biochemical functions of this family of 
proteins are, in general, not well known. Humans have a significant expansion of the number of 
BTB-Kelch proteins as compared with invertebrates; humans have ~50 BTB-Kelch proteins 
while Drosophila have ~10 (Prag and Adams, 2003). With few exceptions, all of the 51 human 
BTB-Kelch proteins also contain the BTB and carboxy-terminal kelch (BACK) domain. These 
“BBK” (BTB-BACK-Kelch) proteins are composed of a long-form BTB domain, the 130 
residue BACK domain, and a carboxy-terminal region containing four to seven kelch motifs 
(Bomont et al., 2000). Gigaxonin is BBK protein and contains six kelch motifs. BTB domains 
from BBK proteins have been shown to mediate dimerization through conserved residues 






BTB-Kelch proteins act as E3 ligase substrate adaptors 
Nine of the 49 human BBK proteins have been identified as components of Cul3-based 
SCF-like complexes (Stogios et al., 2005). In some cases the BTB domain is necessary and 
sufficient for interaction with Cul3 (Wilton et al., 2008). It has been proposed that BBK proteins 
are structurally analogous to the two-chain Skp1/Fbox or ElonginC/SOCS box complexes 
(Stogios et al., 2005). Stogois et al. posit that “the central BACK domain would serve to position 
the carboxy-terminal β-propeller Kelch repeats for substrate recognition.” They also generated a 
structural model of a BBK protein dimerized by its BTB domain in complex with Cul3, Rbx1, 
E2 and ubiquitin. BTB proteins from several families have been shown to interact with Cul3 
(Chen et al., 2009; Maerki et al., 2009; Pintard et al., 2003; Sambuughin et al., 2012) and Stoigos 
et al. argue that based on this it is “reasonable to postulate that these BTB domains drive the 
dimerization of Cul3 complexes” (Stogios et al., 2005). 
Several studies focused on one family member with homology to gigaxonin, Keap1, have 
demonstrated that it functions as a substrate adaptor protein to form a Cul3-dependent E3 
ubiquitin-ligase complex. Keap1 targets its substrate, the Nrf2 (nuclear factor-like 2) 
transcription factor for ubiquitination and subsequent degradation by the 26 S proteasome 
(Figure 1.16A) (Zhang et al., 2005). Nrf2 controls a genetic program that protects cells from 
oxidative damage and maintains cellular redox homeostasis (Zhang et al., 2004). Inhibition  of 
Keap1-dependent ubiquitination of Nrf2 increases steady-state levels of Nrf2 and enables 
activation of cytoprotective Nrf2-dependent genes (Figure 1.16B) (Zhang et al., 2005). Keap1 
assembles into a functional E3 ubiquitin ligase complex with Cul3 and Rbx1 that targets multiple 
lysine residues in the N-terminal domain of Nrf2 for ubiquitin conjugation both in vivo and in 





quinine-induced oxidative stress. This correlates with decreased association of Keap1 with Cul3, 
rather than with Nrf2. Keap1 is the major upstream regulator of Nrf2 and controls both the 
subcellular localization and steady-state levels of Nrf2 (Zhang et al., 2004).   
In overexpression studies, gigaxonin was found to associate with Cul3 and Rbx1 to form 
a functional ubiquitin ligase complex (Zhang et al., 2005) and has been shown to interact with 
Cul3 bait in a proteomic analysis of the cullin-RING ubiquitin ligase network (Bennett et al., 
2010). Moreover, it was shown by immunoprecipitation of overexpressed components in 293T 
cells that Cul3, but not other cullins, binds directly to multiple BTB domains – including that of 
gigaxonin - through a conserved amino-terminal domain (Furukawa et al., 2003).  
Allen et al. (2005) reported that the BTB domain of gigaxonin binds to the ubiquitin-
activating enzyme E1. E1 was identified as a binding partner in a yeast two-hybrid screen 
(described in the next section) and confirmed by co-IP of purified His-tagged BTB and GST-
tagged E1. No interaction between gigaxonin and an E3 ligase was shown, and the existence of 
other interactions related to the ubiquitin-proteasome system was not discussed. The association 
of gigaxonin with E1 in mammalian cells was verified by co-IP from PC12 cells and blotting for 
endogenous proteins. This interaction was disrupted by mutated form of gigaxonin (V82F) with a 






Figure 1.15. Gigaxonin sequence and homology with other BTB/Kelch proteins. Reproduced 
from Bomont et al. (2000). Shown is the alignment between human gigaxonin, mayven and 
ENC-1 proteins as well as mouse Keap1 protein. Identical residues are highlighted on a black 








Figure 1.16. Regulation of Nrf2 by Keap1. Keap1 is a key regulator of the Nrf2 (nuclear factor-
like 2)-signaling pathway and serves as a molecular switch to turn the Nrf2-mediated antioxidant 
response on and off. (A) Under normal conditions, Keap1 associates with the E3 ligase Cul3 
through its BTB domain and Nrf2 through its Kelch domain for the ubiquitination and 
subsequent degradation of Nrf2. (B) Oxidative stress causes a conformational change in the 
Keap1-E3 ligase complex by acting on specific cysteine residues in Keap1, allowing Nrf2 to 
translate into the nucleus and subsequent activation of Nrf2 target genes through the antioxidant 


















Reported binding partners of gigaxonin 
 To date three binding partners of gigaxonin have been identified – MAP1B, TBCB and 
MAP8. All were identified by a yeast two-hybrid screen performed by the laboratory of Yamin 
Yang (Allen et al., 2005; Ding et al., 2006; Ding et al., 2002; Wang et al., 2005). For the yeast 
two-hybrid screen, full-length gigaxonin was fused to a GAL4 DNA-binding domain and used as 
the bait to screen a human brain cDNA library (Ding et al., 2002).   The total number of hits was 
not reported, but the three substrates listed above were characterized in three individual papers. 
Importantly, these studies rely heavily on overexpression studies and no binding partners of 
gigaxonin have been truly validated.   
In 2002 Ding et al. reported the first identified binding partner of gigaxonin, microtubule-
associated protein 1B (MAP1B). MAP1B is predominantly expressed in young neurons and is 
involved in many cellular processes including morphogenesis, differentiation and maintenance of 
cytoskeletal integrity (Mansfield et al., 1991). To confirm this interaction, HA-GIG and FLAG-
MAP1B-LC were cotransfected into COS-7 cells. Double staining revealed identical staining 
patterns for gigaxonin and MAP1B-LC. Additionally, FLAG IP pulled down HA-GIG, 
suggesting a physical association, direct or indirect, between these two proteins. Interaction 
between endogenous proteins was not shown since, according to a statement made in the paper, 
COS-7 cells lack endogenous gigaxonin expression (Ding et al., 2002). 
To determine if this interaction may be relevant to neurons, cultured mouse DRG neurons 
were subjected to double immunofluorescence using anti-mouse MAP1B-LC and anti-rabbit 
gigaxonin (Ding et al., 2002). The authors report strong co-labeling of gigaxonin with MAP1B-





others suggest that most anti-gigaxonin antibodies are very non-specific, even generally labeling 
the cytoplasm in knockout tissues. To obtain in vivo evidence for interaction double immuno-EM 
labeling of mouse sciatic nerve samples using two different sizes of gold-conjugated particles 
was performed. ~43 ± 7% of gigaxonin labeling colocalizes with MAP1B, and ~41 ± 6% of the 
MAP1B-associated gold particles were within 15 nm of gigaxonin labeling. In contrast, no 
significant colocalization was detected in negative control samples in which only secondary 
antibodies were applied (Ding et al., 2002). However, a correction of this data was published 
after it was detected that the images had been inappropriately digitally manipulated. The images 
reproduced from the original data leave the colocalization more ambiguous and an updated 
quantification is not provided.   
   To define the domains responsible for the association of the two proteins, Ding et al. 
(2002) used HA-tagged domains of both the BTB and Kelch domains of gigaxonin. The Kelch 
domain colocalized with MAP1B-LC in cotransfected cells (the BTB result is not shown). The 
N- and C-terminal domains of MAP1B-LC were expressed and the Kelch domain colocalized 
with the C-terminal domain of MAP1B-LC (Ding et al., 2002). The authors did not follow up on 
these experiments with IP analysis.  
 Ding et al. (2002) conclude by assessing the functional significance of the interaction 
between gigaxonin and MAP1B-LC. To do so, cells were transfected with either MAP1B-LC 
alone or MAP1B-LC with gigaxonin. The transfected cells were treated with the MT 
depolymerizing agent colchicine. In untransfected cells, all MTs depolymerized within 15 
minutes of colchicine treatment. MAP1B alone had only a modest effect on MT stabilization, but 
the pair significantly increased MT stability; in 20% of MAP1B-LC/GIG double transfected cells 





condition expressing a mutant form of gigaxonin (R293X) was also included, and the authors 
argue that by IF analysis the mutant loses its association with MAP1B-LC (Ding et al., 2002). 
However, the authors acknowledge that WB and IF analysis suggests that this mutant form of 
gigaxonin is very unstable, so this experiment is difficult to interpret. Ding et al. (2002) conclude 
that “these findings reveal an important correlation between gigaxonin-MAP1B interaction and 
microtubule stability.”    
 In a follow-up paper, the Yang lab provides evidence that gigaxonin controls the 
degradation of MAP1B-LC, which is critical to neuronal survival (Allen et al., 2005). The 
authors first show that MAP1B is degraded by the proteasome; in the presence of HA-Ubiquitin 
and FLAG-MAP1B, a typical ubiquitin ladder was formed in the presence of proteasome 
inhibitors (not specified) when FLAG was blotted for. In the presence of FLAG-Ubiquitin 
endogenous MAP1B-LC was also ubiquitinated (FLAG IP followed by blotting for MAP1B-
LC). To examine if protein degradation of MAP1B-LC is controlled by gigaxonin FLAG-GIG 
was overexpressed in PC12 cells. Gigaxonin expression significantly reduced endogenous 
MAP1B-LC levels by ~25% after 48 hours and ~60% after 96 hours. This reduction was 
inhibited by the presence of proteasome inhibitors, suggesting that MAP1B-LC degradation by 
gigaxonin is through the proteasome. The authors do not include specifics on how this 
experiment was done (for example when the proteasome inhibitor was added) and do not look at 
other proteins to determine if the effect of gigaxonin on MAP1B-LC is specific.  
 To analyze the effect of gigaxonin on MAP1B-LC in vivo, protein levels from WT or 
Gan
Δxe3-5
 mice (Ding et al., 2006) produced within the lab and described above were examined. 
The absence of gigaxonin led to a ~2-fold increase in MAP1B-LC levels in brain and spinal cord 





(Allen et al., 2005). qPCR confirmed that this increase is not due to transcriptional upregulation. 
MAP1B-LC accumulation was found in the hippocampus and DRG of knockout mice.  
During this immunohistochemical analysis, the authors noted that the “number of viable 
neurons in the hippocampus and DRG of gigaxonin-null mice seemed reduced, and the surviving 
neurons appeared disorganized and morphologically abnormal” (Allen et al., 2005). To follow up 
with this cortical neurons isolated from the mice were cultured. After 4-6 days in vitro both WT 
and KO mice formed abundant neurites. However, neurons of the KO mice became 
progressively shorter and sparser after ~7-12 days, whereas WT neurites grew denser and longer 
in the coming weeks. A 90% reduction in cell density by day 15 was observed in the null 
cultures (as scored by DAPI and Tubulin
+
 cells per field). While this seems a striking phenotype, 
no cell death is reported in vivo in the subsequent paper (Ding et al., 2006) where the mouse 
model is fully characterized. Using transient transfection the authors show that overexpression of 
MAP1B-LC in WT cortical neurons leads to neurite fragmentation (70% 5-7 days after 
transfection; fragmentation not quantified in control cultures). Finally, Map1b-specific short 
interfering RNAs (siRNA) were expressed in KO cultures. 9-15 days after transfection the 
Map1b siRNA-expressing neurons have substantially improved survival rate (as reported by the 
authors; the scoring system is not explained). In contrast, the scrambled siRNA-expressing 
neurons are not rescued from neurodegeneration and cell death. The authors conclude that 
MAP1B-LC contributes directly to the pathogenesis of neuronal death in GAN (Allen et al., 
2005).      
It is difficult to align these in vitro finding with those of the four mouse models of GAN. 
In a comparison of the mouse models of GAN, MAP1B-LC is only elevated 1.5-fold in the 
Gan
Δxe3-5





models at 48 weeks in the brain and spinal cord. Moreover, the lab itself notes that “because of 
[MAP1B-LC’s] restricted expression pattern, disruption of the gigaxonin-MAP1B-LC 
interaction could not account for the generalized cytoskeletal abnormality” (Wang et al., 2005).  
In a subsequent paper, the Yang lab shows evidence that gigaxonin controls the 
degradation of the α-tubulin chaperone protein tubulin folding cofactor B (TBCB) (Wang et al., 
2005). Unlike MAP1B, TBCB is a ubiquitously expressed tubulin chaperone. The yeast two-
hybrid result was confirmed with pull down assays using transfected COS7 cells which revealed 
that the interaction is through the kelch domain of gigaxonin. FLAG-GIG was also able to 
coimmunoprecipitate endogenous TBCB from COS7 cells. They find that mutations in the Kelch 
domain of gigaxonin – but not the BTB domain – disrupt the interaction with TBCB.  
In vivo Wang et al. (2005) find that TBCB protein is significantly elevated in their 
Gan
Δxe3-5  animals. There was also a slight increase in α- and β-tubulin; actin was not increased, 
but none of the Western blots shown are quantified. The level of TBCB transcript is not elevated, 
leading to the conclusion that the increased levels of TBCB protein is due to protein 
accumulation. By contrast, TBCB is not reported to be elevated in patient fibroblasts (Cleveland 
et al., 2009). When Wang et al. (2005) overexpress both partners in COS7 cells, increased levels 
of HA-GIG corresponds to decreased levels of FLAG-TBCB. HA-GIG had no effect on the 
levels of TBCA, another tubulin chaperone protein. Addition of MG132 blocked the HA-GIG-
dependent degradation of TBCB. Furthermore, in cells cotransfected with MYC-Ubiquitin and 
FLAG-TBCB, TBCB formed a high-molecular mass complex consistent with the conjugation of 
polyubiquitin tags in the presence of gigaxonin; this was enhanced by the addition of MG132 
and blocked by mutations in the BTB and Kelch domain of gigaxonin (in three of four different 





gigaxonin in cultured wild-type or knockout neurons. They find that when FLAG-TBCB was 
transfected for 3 days, in WT neurons it colocalized with ubiquitin staining but not in KO 
neurons. This finding is not quantified, and is particularly strange because in the images shown it 
appears that there is cytoplasmic ubiquitin signal in the WT neurons, but no ubiquitin the KO 
neurons. Surely this – a total loss of ubiquitin - is not what would be expected from the loss of 
gigaxonin.                
 In the Gan
Δxe3-5 
mice Wang et al. report a significant reduction in microtubules (Wang et 
al., 2005) as observed by EM and α-tubulin immunostaining. This noted reduction was not 
quantified, although the authors do note that there was an average decrease of ~51% of MT 
density. A similar finding was reported by Ganay et al. (2011), but a change in MT density has 
not been reported in patient biopsies. Other labs have reported that overexpression of various 
tubulin folding cofactors (TBCB is one of five cofactors; A-E) destabilizes microtubules (Martin 
et al., 2000). 48 hours after transfection of TBCB into COS7 cells, α-tubulin immunostaining 
was reduced. α-tubulin immunostaining was restored when TBCB was coexpressed with HA-
GIG. Similar findings in WT cortical neurons were also reported (Wang et al., 2005).  
 Cleveland et al. (2009) find that gigaxonin controls vimentin organization through a 
tubulin chaperone-independent pathway. Using human fibroblasts from controls and GAN 
patients, Cleveland et al. show that while vimentin aggregates form upon serum starvation, they 
do not result in altered microtubule distribution or intensity. TBCB levels were measured after 
prolonged serum starvation to enhance vimentin bundling and did not find an increase in TBCB 
levels in patient fibroblasts. Additionally, microtubule disruption by overexpression of TBCB or 





These experiments suggest that in contrast to the report by Wang et al. (2005), IF aggregation in 
GAN patients may not involve TBCB-mediated microtubule disassembly.  
The final reported gigaxonin partner is MAP8 (Ding et al., 2006). In their report of the 
Gan
Δxe3-5 
mouse, Ding et al. observe accumulation of a novel microtubule-associated protein, 
MAP8, in the null mutants. They report that MAP8 interacts with the Kelch – but not BTB – 
domain of gigaxonin in the previously published yeast-two-hybrid screen (Ding et al., 2002). In 
support of this finding, an IP of FLAG-MAP8 was performed to look for HA-GIG. It does 
appear that a band similar to the molecular weight of HA-Gig is present upon HA staining, but 
this experiment could have improved controls: instead of a truncated form of gigaxonin as a 
control (the BTB domain, for example) they use a point mutant. This is problematic because – as 
seen on their Western blots – point mutant forms of gigaxonin are in generally highly unstable 
and thus present at much lower levels than wild type gigaxonin, making them unsuitable controls 
for unspecific binding for IP experiments.  
Ding et al. (2006) go on to report that overexpressed gigaxonin and microtubule 
associated protein 8 (MAP8) interact, and that MAP8 protein (but not mRNA) levels are 
increased in Gan
Δxe3-5 
mice. The authors claim that MAP8 is degraded by the proteasome but 
they only see a modest increase in the MAP8 signal upon addition of MG132 (which can have 
off-target effects). Importantly, all interaction studies in this paper rely solely on overexpression 
of tagged constructs, making it difficult to assess whether these results represent meaningful 
endogenous interactions. 
While the interaction studies performed by the Yang lab are valuable, there are several 





and overexpressed partners, making extension to in vivo scenarios difficult. There are a number 
of caveats associated with yeast two-hybrid screens, most notably that the bait is expressed as a 
fusion protein in the nucleus of yeast. Second, their findings – both from the mouse model and 
interaction studies - seem to be contradicted by several studies from other labs. Third, and most 
importantly, there is no clear link established between the loss of gigaxonin and the main 








Part VI. Use of ES and iPS-derived neurons for disease modeling  
Current treatments for neurodegenerative disease are lacking 
Most of our current knowledge of CNS and neural function in patients with neurological 
disease has been obtained from post-mortem tissues that often represent the end stage of the 
disease (Wang and Doering, 2012). The inability to sample live CNS tissues inhibits our ability 
to understand the neuropathology over the course of the disease. Animal models can mimic 
genetic forms of human neurological diseases, and our understanding of the mechanisms of 
neurological disease has been significantly advanced by transgenic and knockout animal models. 
However, this approach is limited to monogenetic disorders and thus only represents a minority 
of diseases. Additionally, in many cases of neurological disorders with a defined causal gene, 
modeling with animal transgenic technology is inadequate due to species differences, genetic 
backgrounds or other challenges. Importantly, numerous candidate drugs with promise in animal 
models have failed when translated to human clinical trials. Combined, this indicates that 
complementary human models are needed to accurately study neurological disorders (Wang and 
Doering, 2012).   
ES/iPS-MNs offer an opportunity for in vitro screens on human tissue 
Successful derivation of induced pluripotent stem cells (iPSCs) from patient skin 
fibroblasts provides an opportunity to model the pathogenesis and treatment of human heritable 
diseases in cell culture. The seminal work by Takahashi and Yamanaka demonstrated that mouse 
somatic cells could be reprogrammed into an embryonic-like, pluripotent state by the enforced 
expression of a defined set of factors (Takahashi and Yamanaka, 2006). They tested ectopic 





– Oct4, Sox2, Klf4, and c-Myc – together converted a small percentage of cells into a pluripotent 
state. The result was cell colonies with morphology and growth characteristics of embryonic 
stem cells. Further evidence for the similarity between iPSCs and ESCs came from tetraploid 
complementation studies (Boland et al., 2009; Kang et al., 2009; Zhao et al., 2009). In these 
experiments, tetraploid blastocysts - which are incapable of progressing through embryonic 
development – are injected with iPSCs to complement or rescue the defective early embryo-like 
structure. Fertile mice were generated entirely from the injected cells. These data show that iPSC 
can generate adult mice and thus are functionally indistinguishable from ESCs.  
In principle iPSCs can give rise to all somatic cell types. But in practice, in vitro 
differentiation protocols have been developed for only a subset of specific cell types to date. 
Importantly for the field of motor disorders, in 2002 Wichterle et al. used developmentally 
relevant signaling factors to induce mouse ESCs into spinal progenitor cells and subsequently 
into motor neurons. They showed that retinoic acid (RA) specifies spinal progenitor identity and 
that sonic hedgehog (Shh) signaling subsequently ventralizes the progenitors to form motor 
neurons (MNs). MNs were identified by the expression of HB9, a homeodomain (HD) protein 
expressed selectively by somatic MNs, as well as ISL1, a LIM HD protein expressed by a subset 
of spinal MNs. These ESC-derived MNs can populate the chick embryonic spinal cord, extend 
axons and form synapses with target muscles (Wichterle et al., 2002).   
This work was then extended to human ESCs, demonstrating that human ESCs can also 
be differentiated into functional MNs (Li et al., 2005). In a groundbreaking paper, Dimos et al. 
(2008) demonstrated that iPSCs derived from an 82-year-old patient with ALS could be 





differentiated into the very cell types affected in the disease for in vitro studies (Dimos et al., 
2008).  
Limitations of iPSCs 
Despite the promise of iPSCs, like any modeling system they are accompanied by 
caveats. The first major caveat relates to the generation of the iPSCs themselves. Yamanaka and 
co-workers described a reprogramming process that utilized retrovirus-derived ectopic 
expression of defined embryonic transcription factors (OCT4, SOX2, KLF4 and cMYC 
(Takahashi et al., 2007)) and is still the most widely used reprogramming method. While 
efficient, these viruses integrate into the host genome, which could result in unpredictable 
effects. Recently, new methods have been developed to generate iPSCs without genomic 
manipulations. Alternative methods include delivery of the same factors by nonviral methods, 
including nonepisomal plasmids, transposons, mRNA and direct protein delivery (Pietronave and 
Prat, 2012). While iPSCs generated with classical viral reprogramming appear very similar to 
ESCs (Boulting et al., 2011), they must be used with caution. 
   A second limitation of iPSCs is that in many cases, the differentiation process if 
inefficient and produces cultures with mixed cell types. Moreover, it is challenging to make 
genetic modifications to add in tags or reporters to efficiently purify cells. Additionally, cell type 
sorting or selection is often limited by availability of selective surface markers to facilitate 
sorting.  
Last, and perhaps most important, a major issue is the iPS field is that of genetic 
background differences between patients and controls. Genetic variability between individuals 





single gene changes rather than simply background noise from genetic diversity present in the 
human population. As evidenced in Table 1.17 only 4/15 published iPS studies on motor 
disorders have included isogenetic controls. Several papers have attempted to rescue the 
phenotypes described. In addition to pharmacologic approaches, in some cases matched rescue 
iPS lines were created by taking advantage of genetic heterogeneity in the iPSCs; for example, 
mosaic X-inactivation in Rett syndrome and Huntington’s disease iPSCs with normal CAG 
repeat length (Zhang et al., 2010). This approach is only an option in a few diseases, and other 
studies have utilized protein or genetic correct. Pharmacologic rescue - while useful from the 
perspective of therapeutic development – does not eliminate the possibility that different patient 
samples may respond differently to applied drugs. In contrast, viral delivery of the corrected 
protein, or, better yet, replacement of the defective gene or correction of the mutation when 
possible by ZFNs (zinc finger nucleases) or TALENs (transcription activator-like effector 
domains for efficient TALE nucleases) (Wood et al., 2011) allows for one-to-one comparison of 
patients as compared with their rescued counterparts.   
Review of iPS models of motor diseases 
To date, iPSCs derived from a number of patients with specific diseases have been 
differentiated into disease-relevant cell types, creating “disease in a dish” models to facilitate an 
understanding of pathogenesis and treatment of various conditions (Table 1.17). iPS models of 
ALS (amyotrophic lateral sclerosis) highlight many aspects of the promise and challenge of 
iPSCs. ALS is a progressive neurodegenerative disease of the MNs in the brain and spinal cord. 
As a relatively late onset disease (the average age of onset is ~55 years) one concern was 





exciting to see that, in fact, pathological changes can be seen in iPS-neurons, including cytosolic 
aggregates and even reduced cell survival (Bilican et al., 2012; Egawa et al., 2012).  
This is especially encouraging given that, to date ~15 genes have been implicated in 
ALS; iPSC technology will allow researchers to study the pathogenesis of sporadic ALS cases 
with unidentified mutations where animal models would not be possible. Highlighting the 
promise of these human-based models, the first small screen has been performed on ALS iPS-
MNs (Egawa et al., 2012), taking the first step towards so called “in vitro clinical trials,” where 
potential drugs could be tested across a broad and diverse cohort of patient samples to ensure 
efficacy in a disease-relevant human pharmacology model (Dimos et al., 2011).   
Given the shortcomings of the mouse models of GAN and inaccessibility of primary 
human sensory or motor neuron samples, iPSCs present an appealing alternative tool to study 
this disease.  Not only are the patient mutations and genetic background faithfully recapitulated 
in iPSCs, but previously developed differentiation protocols allow for the rapid production of 
unlimited quantities of motor neurons and other nerve cells, providing a resource for biochemical 
studies of the disease mechanisms and cell based screening for new treatments (Boulting et al., 
2011; Wichterle et al., 2002). As a monogenetic recessive disease, gene therapy is an attractive 
treatment strategy for GAN given recent successes in the development of gene therapy for spinal 
muscular atrophy (Bevan et al., 2010; Foust et al., 2010). In this context, an iPSC-based model of 







Table 1.17. iPS models of motor diseases. 
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Table 1.17. iPS models of motor diseases. Summary of iPS models made to date of diseases 
that affect the motor system. To date, 15 iPS papers have been published on motor diseases. 
Most papers (12/15) were able to find some alteration in the differentiated cell type relevant to 
the disease pathology. By contrast, only 4/15 papers included rescue by lentiviral or transgenic 
approaches. DA, dopamine; FXN, frataxin; SMN, survival of motor neuron; HD, Huntington’s 
disease; VAPB, vesicle-associated membrane protein-associated protein B/C; TDP-43, TAR 





Overview of background and thesis work 
 Since the first case report of GAN by Asbury et al. (1972), little progress has made in 
understanding the disease. Autopsy studies have shown that IFs aggregate throughout the 
nervous system of GAN patients, but the process by which that occurs and if/how it leads to 
neuronal vulnerability and dysfunction remains to be determined. Gan null mice display IF 
dysregulation, but this occurs at very late time points. Moreover, the only identified binding 
partners of gigaxonin are microtubule-associated proteins, which do not provide a direct link to 
the IFs disrupted in the disease. I therefore wanted to systematically determine the binding 
partners of gigaxonin as well as to generate a human model of GAN.   
To address these gaps in our understanding of GAN, I undertook several studies to 
determine the functions of gigaxonin as well as to create a novel, human model of GAN. In 
Chapter 2 I describe a proteomic screen I performed to determine the binding partners of 
gigaxonin. I show that gigaxonin associates with the very intermediate filaments that have been 
reported to accumulate in GAN patients. In Chapter 3 I show that MNs derived from GAN iPSCs 
have elevated levels of select nIFs, as seen in patient nerve biopsies. This elevation is not due to 
increased production of nIFs, suggesting that gigaxonin may be important for the degradation of 
nIFs. Importantly, in Chapter 4 I provide evidence that the biochemical phenotypes described in 
Chapter 3 directly result from the loss of gigaxonin by reversing these phenotypes by restoration 
of gigaxonin by viral and transgenic methods. Chapter 5 describes a survival assay I developed 
to identify novel factors and pathways important for the survival of human MNs. GAN iPS-MNs 
do not display survival deficits under trophic support in this assay. In Chapter 6 I examine 
normal nIF turnover in iPS-MN cultures. I show preliminary evidence that both the lysosome 





contribute to nIF turnover, I show that NF-L appears monoubiquitinated and that gigaxonin 
associates with the autophagy-adaptor protein p62. Moreover, GAN iPS-MNs have increased 
sensitivity in the presence of oxidative stress, a stimulus that increases the association between 
gigaxonin and p62. Together these findings suggest that gigaxonin may be important for the 





Chapter 2. Mass spectrometry screen to identify binding partners of gigaxonin  
Introduction 
 A major barrier to understanding the pathogenesis of GAN is a lack of information 
regarding the binding partners and functions of gigaxonin. As described in the introduction, three 
binding partners of gigaxonin have been reported: MAP1B, MAP8 and TBCB. These were 
identified from a yeast two-hybrid screen, which has several pitfalls not addressed by the 
authors. Moreover, I and other researchers have not found levels of these proteins to be altered in 
GAN fibroblasts or iPS-MNs (see Figure 3.7E, K and Cleveland et al. (2009)). Perhaps most 
importantly, the reported binding partners do not offer an explanation for the accumulation of 
intermediate filaments seen in GAN patients.  
  Most protein-protein interactions have previously been identified either by the yeast two-
hybrid system or by co-localization studies (Free et al., 2009). More recently, a combination of 
affinity purification and mass spectrometry has been used to greatly advance our understanding 
of protein-complex composition. The advantages of the mass spectrometry (MS) approach over 
previous technologies are that the protein is used in its fully processed form, the interactions are 
in the native environment of the protein (and often in the relevant organism and cell type), and 
multi-component complexes can be isolated in a single step (Free et al., 2009). To succeed in 
MS-based proteomics, three essential steps must be completed: immunoprecipitation of the 
protein bait, purification of the complex, and identification of the interacting partners. While it 
would be ideal to immunoprecipitate endogenous protein, often lack of a sufficiently high 
affinity and specific antibody is limiting. In these instances, the bait protein can be affinity-





In the case of gigaxonin, overexpression of the bait has several advantages. First, 
endogenous gigaxonin is expressed at relatively low levels (Cleveland et al., 2009). Second, 
although I am able to IP endogenous gigaxonin, an advantage of the overexpression approach is 
that it allows me to express different protein domains to determine the binding partners of 
different domains. This is particularly important in the case of gigaxonin given that it is thought 
to act as a substrate adaptor, bringing Kelch domain targets in contact with BTB binding 
partners. IP of endogenous binding partners allows for a final step of verification of binding 
partners identified by the overexpression/MS approach. Third, the use of affinity-tagged 
recombinant proteins allows for parallel sample preparation without the need to optimize the 
purification protocol for each protein complex (Gingras et al., 2007), particularly important for 
the purification of different protein domains.  
Although several affinity tags and tag combinations have been used successfully, a 
commonly used system is the single Flag epitope which is 8-11 amino acids. Like any technique, 
this approach has advantages and disadvantages. The single-step Flag purification can preserve 
weaker or more transient protein-protein interactions, while another commonly used system, the 
tandem affinity purification (TAP) system, decreases background levels allowing for greater 
confidence in interactors. During Flag purification, the protein of interest is expressed with a 
Flag tag and is purified on anti-FLAG sepharose beads. Elution is accomplished by the addition 
of a large molar excess of the competing FLAG peptide (Gingras et al., 2007).         
MS is currently the method of choice for peptide sequencing. It is sensitive, allowing for 
the identification of peptides present at femtomole levels. MS is also rapid; sequencing of 
individual peptides can be achieved within hundreds of milliseconds, and thousands of peptides 





MS is that while it generates a list of proteins detected in a given sample, it does not necessarily 
reveal the composition of individual protein complexes. This must be further identified through 
follow-up co-IP studies.   
To address the gap in our understanding of the functions of gigaxonin, I undertook an 
unbiased proteomic screen to identify the binding partners of gigaxonin. Full-length and 
truncated flag-tagged gigaxonin were expressed in HEK293 cells to identify binding partners of 
the BTB and Kelch domain of gigaxonin. I identified 218 high-confidence hits, including seven 
intermediate filament proteins. Two of these, vimentin and NF-L, have been observed to 
mislocalize and accumulate, respectively, in GAN patients. Gigaxonin-IF interactions were 
validated by IP of endogenous interacting partners, providing the first clear link between the loss 
of gigaxonin and the IF phenotype seen in patients. Despite their expression in HEK293 cells, I 
did not detect an association in the screen between gigaxonin and the previously reported binding 
partners MAP1B, MAP8 and TBCB. Experiments to determine the functional significance of the 







To understand the normal function of gigaxonin and the consequences of its loss of 
function in GAN, I sought to better understand the protein complexes that gigaxonin forms. I 
therefore performed an open-ended proteomic analysis to determine its binding partners using 
affinity purification followed by MS in HEK293 cells. By homology to Keap1, I reasoned that 
the Kelch domain would interact with substrates. I therefore decided to compare the list of 
proteins that interacted with full-length gigaxonin with those that bound the BTB domain alone. 
Hits that appeared in the first condition but not the latter would be likely Kelch binding partners. 
I performed immunoprecipitation (IP) using as bait either overexpressed Flag-tagged full-length 
gigaxonin or truncated gigaxonin (BTB domain only). I included untransfected HEK293 cells to 
control for non-specific binding to the affinity purification beads (Figure 2.1A, B). Based on the 
hypothesis that gigaxonin may promote proteasomal degradation of its substrates, I also treated 
cells with the proteasome inhibitor MG132 or the cullin inhibitor Millennium (MLN4924, also 
referred to as MIL). 
I first validated expression and IP of the constructs (Figure 2.1C). Truncated gigaxonin 
runs at ~34 kDa, and the band at ~70 kDa in the BTB lanes likely reflects BTB homodimer 
formation (Cullen et al., 2004). I also wanted to ensure that there would be sufficient bait present 
in the cell lysate for the MS analysis. Therefore I ran both the soluble and insoluble fractions in 
this pilot experiment to determine the solubility of the bait (see materials and methods in Chapter 
8 for lysis buffer compositions). Based on the Western blot it appeared that the majority of the IP 





For the MS screen, the pilot experiment was scaled up to improve the odds of detecting 
low-abundance interacting partners. Before running the MS analysis, 2% of the IP eluates were 
run on a gel for silver staining (Figure 2.1D). As in the pilot Western blot (Figure 2.1C) full-
length gigaxonin runs at ~60 kDa and truncated gigaxonin runs at ~34 kDa (indicated by dashed 
white boxes). Bait enrichment appeared much greater in the soluble fraction; therefore only these 
samples were analyzed by MS.   
The MS screen identified 218 total hits that were pulled down with full-length gigaxonin 
and had a confidence interval of >95%. I excluded any hits that appeared in the NC condition, 
and removed BTB hits to identify likely Kelch binding partners. The inclusion of MG132 or MIL 
did not result in the identification of additional binding partners. Table 2.2 categorizes selected 
Kelch hits by possible function relevant to the pathology of GAN (see Table 2.6 for full list of hit 
results). Notable categories included IFs (discussed in detail below), cytoskeletal linkers, 
extracellular matrix anchors, kinases, phosphatases, and proteins involved in axonal transport, 
the UPS and lipid metabolism. BTB hits are described in Chapter 6 and select Kelch domain hits 
are discussed further in Chapter 7. Strikingly, 21% of all Kelch binding partners are found in 
axons or relate to axonal functions. However, I did not identify the previously reported binding 
partners microtubule-associated protein 1b light chain (MAP1B-LC), MAP8, or tubulin-folding 
co-factor B (TBCB), despite the fact that they are expressed in HEK293 (Figure 2.3). I first 
measured transcript levels of these proteins in HEK293 cells, using ESCs as a negative control 
and iPS-MNs as a positive control (Figure 2.3A). All were present in HEK293 cells, and 
expression of MAP1B-LC was confirmed by Western blot (Figure 2.3B). MAP1B-LC was 
consistently present in HEK293 cells and iPS-MNs, but appeared to run at slightly different 





Because of the GAN clinical phenotype I was particularly interested to see that full-
length gigaxonin bound several classes of IFs endogenously expressed in HEK293 cells, 
including neurofilaments (Shaw et al., 2002), in a Kelch-dependent manner (Table 2.2). All IF 
proteins were in the top quarter of the list, with vimentin ranked 2
nd
 and peripherin 49
th 
(perhaps 
reflecting its low abundance in HEK293 cells). Since such interactions had not been previously 
reported, I used IP to confirm them directly. IP of endogenous vimentin from untransfected 
HEK293 cells unambiguously confirmed interaction with endogenous gigaxonin (Figure 2.4A). 
Independent IP experiments also confirmed Kelch-dependent interaction of overexpressed 
gigaxonin with endogenous vimentin and with overexpressed peripherin, which is expressed in 
neurons during development (Figure 2.4B-D).  These data provide strong evidence for an 
interaction between the Kelch domain of gigaxonin and IFs whose levels and localization are 
strongly affected in GAN patients. 
The MS screen did not detect an association between gigaxonin and Cul3, suggesting that 
this interaction is either too transient or weak to detect by MS. However, binding between 
overexpressed gigaxonin and Cul3 was clearly apparent (Figure 2.5A). I then sought to 
determine if IFs and Cul3 form a complex in the presence of gigaxonin. To do so, I pulled down 
vimentin and looked for Cul3 by Western blotting. To determine if the complex was gigaxonin-
dependent, I performed this experiment using fibroblasts from both a control (fibroblast line 18) 
and GAN patient (GAN5). GAN patient fibroblasts have extremely reduced levels of gigaxonin 
(see Chapter 3, Figure 3.4A). The IP of vimentin was successful (Figure 2.5B, top panel), and 
gigaxonin only associated with vimentin in the control sample, as expected (Figure 2.5B, middle 





(Figure 2.5B, bottom panel). This suggests that while vimentin may interact with Cul3, it does 







 In this study I performed an unbiased screen to identify the binding partners of gigaxonin. 
Gigaxonin was found to interact with IFs from three of the five known IF classes, providing the 
first evidence that gigaxonin may interact with intermediate filaments directly rather than 
through other cytoskeletal systems. In support of this, I did not find an association with any of 
the previously reported binding partners, despite the fact that they are expressed in HEK293 
cells. Although an interaction with Cul3 was not found by MS, it could be confirmed by IP. 
However, the vimentin-Cul3 interaction appears to be independent of gigaxonin to some extent 
so the simple model of gigaxonin as an E3 ligase adaptor may not apply.   
 While one could argue that the MS screen would ideally have been performed on 
neurons, using HEK293 cells had multiple advantages. First, HEK293 cells can be easily 
expanded, thus I was able to put much larger quantities of cell lysate into the MS analysis, 
increasing the likelihood of detecting the full range of binding partners. Generating neurons from 
iPSCs is a 28-day procedure and protein yields are low using the mild buffers necessary for co-IP 
experiments. Despite multiple attempts I was unable to make mouse ESC lines expressing flag-
gigaxonin, which would have provided a more feasible - although not human - source of neurons 
for the MS screen. Second, while I am able to IP endogenous gigaxonin, overexpression of Flag-
tagged constructs have the dual advantage of a cleaner IP as well as the ability to express 
different domains of the gigaxonin protein. Because I was able to express full-length and 
truncated protein in HEK293 cells I could cross-reference the hit lists to determine proteins that 
bound to different domains of gigaxonin. A third advantage of using HEK293 cells is that they 
contain large soluble, unincorporated pools of intermediate filaments. However, this does mean 





(unincorporated) or insoluble (assembled) intermediate filaments. This is a limitation of any co-
IP experiment, and while it could be answered by cross linking, this in itself can cause additional 
experimental problems such as introducing much more background (Gingras et al., 2007). Not 
only do HEK293 cells express an abundance of soluble vimentin, but they also express several 
proteins typically found in neurons, including the neurofilament proteins and peripherin. It has 
been observed previously that this is the case and that HEK293 cells (but not primary HEK cells) 
have a transcriptional profile very similar to neurons (Shaw et al., 2002).  
Another - albeit less direct - way to asses gigaxonin’s interacting partners would have 
been to determine substrates that are differentially ubiquitinated in the presence and absence of 
gigaxonin. This approach has the main disadvantage of assuming a priori that the primary role of 
gigaxonin is in the ubiquitination of targets. While there is some evidence that gigaxonin 
interacts with E3 ligases (Furukawa et al., 2003; Xu et al., 2003), these investigations are based 
predominantly on the ~25% homology of gigaxonin with  mouse Keap1 (Bomont et al., 2000). It 
is formally possible that the accumulation of intermediate filaments seen in GAN is due to a 
function of gigaxonin not related to ubiquitination, and the unbiased MS screen allowed me to 
identify BTB partners that may be important for the handling of substrates unrelated to 
ubiquitination. 
Although my results demonstrate that gigaxonin associates with intermediate filaments, it 
remains to be determine if this interaction is direct or indirect. Direct binding could only be 
shown in a cell-free context, an experiment made difficult by the challenge of producing 
sufficient quantities of soluble gigaxonin and intermediate filaments. It was somewhat surprising 
that we did not detect an interaction by MS with previously reported Kelch binding partners 





MAP1B in particular is expressed at levels comparable to those in iPS-MNs. It is possible that 
the lysis conditions disrupted these interactions, that levels were below the detection threshold, 
or that the kinetics of their interaction with gigaxonin are such that detection in the AP-MS 
context is unlikely. In support of the idea that previously published binding partners may be false 
positives from the original yeast two-hybrid screen, I and others do not find levels of MAP1B 
and TBCB to be altered in GAN (see Figure 3.7E, K and Cleveland et al. (2009)). It is important 
to note that the Kelch domain of Keap1 has a high affinity (Kd ~20 nM) for its best characterized 
substrate Nrf2 (Chen et al., 2011), making dissociation seemingly less likely between the Kelch 
domain of gigaxonin and potential substrates.  
It was also surprising that I did not detect an interaction with Cul3 in the MS screen. One 
explanation may be that at any one time very little gigaxonin is associated with Cul3 (a problem 
that could be exacerbated in overexpression studies where the bait is present in large molar 
excess of the prey), or that this interaction is conditional on an external cue. No data is currently 
available for the binding constants between the BTB domain and Cul3. Although we did not 
detect an interaction between Cul3, gigaxonin did associate with other E3 ligases and UPS 
components. Full-length gigaxonin associated with the E3 ligase UBR1, but an interaction was 
not found with the BTB domain alone, making this interaction important for the ubiquitination of 
Kelch binding partners less likely. Full-length and truncated gigaxonin did associate with the 
probable E3 ligase MYCBP2, but this is a common false positive in MS screens. The ubiquitin 
specific peptidase 43 (USP43) - which by similarity to other peptidases may be involved in the 






In support of an interaction between gigaxonin and Cul3, I was able to pull down HA-
Cul3 and detect an interaction with both endogenous and overexpressed gigaxonin. Despite 
multiple attempts I was not successful in performing the reverse IP. An interaction between 
endogenous gigaxonin and HA-Cul3 was also detected in a MS screen performed by Wade 
Harper’s lab (Bennett et al., 2010). Although gigaxonin may interact with Cul3, it is noteworthy 
that IP of vimentin brings down Cul3 in both GAN and control fibroblasts. This could be due to 
a pool of vimentin interacting with Cul3 through gigaxonin, and another pool of vimentin 
interacting with Cul3 independent of gigaxonin. Alternatively, Cul3 may not be the BTB binding 
partner key to the phenotype in GAN. Other BTB and Kelch domain hits of potential relevance 
to GAN pathology will be discussed in Chapter 6. 
To conclude, I have performed the first unbiased screen to determine the binding partners 
of gigaxonin in human cells. I determined that gigaxonin interacts through its Kelch domain with 
vimentin and peripherin, as well as other IFs identified in the MS screen, including α-internexin, 
lamin B2, and neurofilament light, medium and heavy.  This data provides the first clear link 
between the loss of gigaxonin and the IF phenotype seen in patients. Experiments to determine 









































































Figure 2.1. Design of the proteomic screen to determine gigaxonin binding partners. (A) 
Gigaxonin is a BTB/Kelch protein, with an N-terminal BTB domain and a C-terminal Kelch 
domain consisting of six Kelch repeats. (B) To identify potential substrates for 
degradation/modification (Kelch binding partners) we expressed full-length gigaxonin (GAN) or 
its BTB domain (BTB). Binding partners pulled-down using GAN but not BTB were considered 
likely Kelch binding partners. Flag-tagged (F) constructs were expressed in HEK293 cells and 
affinity purified with an anti-Flag antibody. Untransfected cells (NC) were included to control 
for non-specific binding to the antibody or beads. (C) Pilot IP to confirm lysis conditions and 
bait enrichment. 28h after transfection, HEK293 cells were lysed and FLAG IP was performed 
and the membrane blotted for the Flag tag. Flag-tagged gigaxonin is ~62 kDa, while the BTB 
domain is ~34 kDa. Cells transfected with full-length gigaxonin were also treated with the 
proteasome inhibitor MG132 (10 μM) or the cullin inhibitor Millennium (MIL, 2 μM). Two 
fractions were collected for comparison: the soluble fraction and insoluble fraction (see materials 
and methods in Chapter 8 for details).  (D) IP enriches gigaxonin bait (silver stain of 2% of the 
eluate). The same conditions were used as in (C). Flag-tagged gigaxonin is ~62 kDa, while the 
BTB domain is ~34 kDa (boxes indicate the enriched bait). Binding partners were analyzed by 






Table 2.2 Select Kelch domain interacting partners.  
Category  Name (rank out of 218 hits)  
Intermediate filaments  Vimentin (2), neurofilament medium (29), α-internexin (31), lamin B2 (32), neurofilament light (37), 
neurofilament heavy (47), peripherin (49)  
Cytoskeletal linkers  Dystonin (27), CLASP1 (44), WAS/WASL (48), plexins (120), glypican (137)  
ECM anchors  Spectrin (26), ankyrin (40), dystrophin (77), HSPG2 (126), supervillin (135)  
Axonal transport  Dynein (58), kinesin-like protein (105)  
Kinases  MAST2 (42), PRKD1 (64), PRKD3 (79), LRRK2 (84), SPEG (108)  
Phosphatases  SSH2 (35), PTPN9 (164)  
UPS components  KCTD5 (15), DCAF6 (175)  
Lipid metabolism  DAGLB (124), SLC27A2 (149), GBA2 (201)  
 
Table 2.2. Select Kelch domain interacting partners. Kelch partners identified by MS were 
ranked (after removal of hits that bound to the BTB domain or NC conditions) and select hits 
were grouped according to functions that may be disrupted in GAN. See Table 2.6 for a full list 








Figure 2.3. MAP1B, MAP8 and TBCB expression in HEK293 cells. (A) qPCR analysis was 
performed to determine whether MAP1B, MAP8 and TBCB are expressed endogenously in 
HEK293 cells which were used for the MS screen. For comparison, samples were run in parallel 
with human ESCs and control iPS-MNs and expression levels were normalized to the former. 
(B) Expression of MAP1B in HEK293 cells as measured by Western blot. For comparison, a 
control iPS-MN lysate was run in parallel. Although MAP1B-LC was present consistently in 




























































Figure 2.4. Vimentin and peripherin interact with the Kelch domain of gigaxonin. (A) 
Vimentin pulls down endogenous gigaxonin in HEK293 cells. Indicated lysates were subjected 
to IP with either vimentin antibody or control IgG (used as the mock condition throughout), and 
the membrane was probed sequentially for endogenous gigaxonin and then vimentin (not 
shown). (B) Gigaxonin pulls down endogenous vimentin in a Kelch-dependent manner. HEK293 
cell lysates transfected with the indicated constructs were subjected to IP with anti-FLAG beads, 
and the membrane was probed sequentially for vimentin and then gigaxonin (not shown). (C, D) 
Endogenous gigaxonin pulls down overexpressed peripherin in a Kelch-dependent manner. 
HEK293 cells were transfected with a construct expressing mouse peripherin. Cell lysates were 
subjected to IP with anti-FLAG beads or IgG, and the membrane was probed sequentially for 





























    
 
Figure 2.5. Evidence for interaction between gigaxonin and Cul3. (A) HA-Cul3 pulls down 
both endogenous and overexpressed gigaxonin. HEK293 cells were transfected with 
combinations of HA-Cul3 and human gigaxonin. After HA IP, the membrane was probed for 
gigaxonin and HA (not shown). (B) IP of endogenous vimentin from control (18) and GAN 




























Table 2.6. Full list of hits from GAN proteomic screen.             
Name Rank GAN NEG BTB MG MIL 
Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 14 19     18 9 
T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 
SV=4 34 31     34 34 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo 
sapiens GN=GNB2L1 PE=1 SV=3 40 32     44 35 
Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A 
PE=1 SV=2 47 36     60 33 
T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 
SV=3 95 37     122 67 
Spindlin-1 OS=Homo sapiens GN=SPIN1 PE=1 SV=3 84 40     116 51 
40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 41 42     41 41 
Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 
SV=2 51 43     62 39 
T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 
SV=2 56 45     51 61 
BTB/POZ domain-containing protein KCTD5 OS=Homo sapiens 
GN=KCTD5 PE=1 SV=1 159 54     256 62 
Polyadenylate-binding protein 3 OS=Homo sapiens GN=PABPC3 PE=1 
SV=2 64 62     72 56 
T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 
PE=1 SV=4 85 63     76 93 
T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 
SV=1 140 66     90 189 
T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 
SV=4 89 73     65 112 
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 68 75     56 80 
Eukaryotic translation initiation factor 3 subunit I OS=Homo sapiens 
GN=EIF3I PE=1 SV=1 77 77     69 84 
T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 
SV=4 80 79     83 76 
Spectrin alpha chain, brain OS=Homo sapiens GN=SPTAN1 PE=1 
SV=3 167 88     200 134 
39S ribosomal protein L39, mitochondrial OS=Homo sapiens 
GN=MRPL39 PE=1 SV=3 257 110     394 119 
CCAAT/enhancer-binding protein zeta OS=Homo sapiens GN=CEBPZ 
PE=1 SV=3 167 115     203 131 
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X 
PE=1 SV=2 56 121     53 59 
Microtubule-associated serine/threonine-protein kinase 2 OS=Homo 
sapiens GN=MAST2 PE=1 SV=2 245 122     144 346 
Small nuclear ribonucleoprotein-associated protein N OS=Homo sapiens 
GN=SNRPN PE=1 SV=1 212 128     199 224 
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 135 129     117 153 
WAS/WASL-interacting protein family member 1 OS=Homo sapiens 
GN=WIPF1 PE=1 SV=3 415 133     574 256 
Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 
PE=1 SV=1 159 139     112 205 
Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 82 141     48 115 
Histone-lysine N-methyltransferase SETD2 OS=Homo sapiens 
GN=SETD2 PE=1 SV=3 185 148     206 163 
40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 117 149     95 139 
Rotatin OS=Homo sapiens GN=RTTN PE=1 SV=3 318 150     503 132 
Keratin, type II cuticular Hb2 OS=Homo sapiens GN=KRT82 PE=1 
SV=3 101 161     107 94 
Rho guanine nucleotide exchange factor 12 OS=Homo sapiens 
GN=ARHGEF12 PE=1 SV=1 242 162     324 159 
Mitochondrial inner membrane protein OXA1L OS=Homo sapiens 
GN=OXA1L PE=1 SV=3 293 168     296 289 
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 
SV=1 203 172     205 201 
Pleckstrin homology-like domain family B member 1 OS=Homo sapiens 
GN=PHLDB1 PE=1 SV=1 137 177     138 136 
Rho guanine nucleotide exchange factor 1 OS=Homo sapiens 





Table 2.6. (Continued.) 
Name Rank GAN NEG BTB MG MIL 
Uncharacterized protein DKFZp434B061 OS=Homo sapiens PE=2 
SV=2 351 190     250 452 
Rho GTPase-activating protein 22 OS=Homo sapiens GN=ARHGAP22 
PE=1 SV=1 273 201     261 284 
Keratin, type II cuticular Hb5 OS=Homo sapiens GN=KRT85 PE=1 
SV=1 104 209     108 99 
Pre-mRNA-splicing factor 18 OS=Homo sapiens GN=PRPF18 PE=1 
SV=1 375 210     386 364 
Uncharacterized protein KIAA0947 OS=Homo sapiens GN=KIAA0947 
PE=1 SV=5 241 222     161 321 
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 
OS=Homo sapiens GN=SUCLG1 PE=1 SV=4 353 233     280 425 
Insulin receptor substrate 4 OS=Homo sapiens GN=IRS4 PE=1 SV=1 73 239     61 85 
Zinc finger protein 808 OS=Homo sapiens GN=ZNF808 PE=2 SV=2 137 248     167 106 
Zinc finger protein 764 OS=Homo sapiens GN=ZNF764 PE=1 SV=2 288 258     187 388 
Glypican-6 OS=Homo sapiens GN=GPC6 PE=2 SV=1 410 267     441 378 
Zinc transporter 3 OS=Homo sapiens GN=SLC30A3 PE=2 SV=2 483 284     524 441 
Ataxin-2 OS=Homo sapiens GN=ATXN2 PE=1 SV=2 259 288     347 171 
C2 domain-containing protein 3 OS=Homo sapiens GN=C2CD3 PE=1 
SV=4 295 294     420 169 
Nuclear mitotic apparatus protein 1 OS=Homo sapiens GN=NUMA1 
PE=1 SV=2 135 308     150 120 
DDB1- and CUL4-associated factor 6 OS=Homo sapiens GN=DCAF6 
PE=1 SV=1 181 313     164 197 
Interferon regulatory factor 7 OS=Homo sapiens GN=IRF7 PE=1 SV=2 332 325     384 279 
Nucleoprotein TPR OS=Homo sapiens GN=TPR PE=1 SV=3 199 353     136 261 
Protein FAM50B OS=Homo sapiens GN=FAM50B PE=2 SV=1 401 360     580 222 
Gigaxonin OS=Homo sapiens GN=GAN PE=1 SV=1 3 1   3 2 3 
Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1 9 7   8 9 10 
Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 13 12   11 15 12 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 
PE=1 SV=5 69 18   145 36 26 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 
PE=1 SV=4 49 23   75 40 31 
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 86 29   161 58 38 
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 35 30   14 42 49 
ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 39 33   18 45 55 
Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens 
GN=HNRNPA1 PE=1 SV=5 145 34   254 87 95 
POTE ankyrin domain family member F OS=Homo sapiens GN=POTEF 
PE=1 SV=2 37 53   35 33 42 
Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 
SV=2 69 59   30 98 79 
Putative elongation factor 1-alpha-like 3 OS=Homo sapiens 
GN=EEF1A1P5 PE=5 SV=1 58 68   19 92 64 
Nesprin-1 OS=Homo sapiens GN=SYNE1 PE=1 SV=3 132 78   43 111 241 
Zinc finger ZZ-type and EF-hand domain-containing protein 1 
OS=Homo sapiens GN=ZZEF1 PE=1 SV=6 230 81   110 472 107 
Amyloid beta A4 precursor protein-binding family B member 2 
OS=Homo sapiens GN=APBB2 PE=1 SV=3 92 86   55 113 108 
Plexin-A1 OS=Homo sapiens GN=PLXNA1 PE=1 SV=3 94 87   56 139 87 
WD repeat-containing protein 52 OS=Homo sapiens GN=WDR52 PE=1 
SV=1 128 95   68 173 143 
Dynein heavy chain domain-containing protein 1 OS=Homo sapiens 
GN=DNHD1 PE=1 SV=2 217 100   128 328 195 
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 
OS=Homo sapiens GN=PLCB1 PE=1 SV=1 123 114   67 148 154 
Sodium channel protein type 5 subunit alpha OS=Homo sapiens 
GN=SCN5A PE=1 SV=2 198 123   158 245 191 
Poly [ADP-ribose] polymerase 14 OS=Homo sapiens GN=PARP14 





Table 2.6. (Continued.)             
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Protein CIP2A OS=Homo sapiens GN=KIAA1524 PE=1 SV=2 143 144   76 196 158 
Alstrom syndrome protein 1 OS=Homo sapiens GN=ALMS1 PE=1 
SV=3 360 146   133 481 465 
Keratin, type II cuticular Hb4 OS=Homo sapiens GN=KRT84 PE=1 
SV=2 121 154   165 106 92 
Zinc finger HIT domain-containing protein 2 OS=Homo sapiens 
GN=ZNHIT2 PE=1 SV=1 172 166   147 214 155 
Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 124 180   57 240 75 
Tektin-1 OS=Homo sapiens GN=TEKT1 PE=2 SV=1 242 186   108 325 293 
Leucine-, glutamate- and lysine-rich protein 1 OS=Homo sapiens 
GN=LEKR1 PE=2 SV=2 222 194   129 153 384 
Protein Daple OS=Homo sapiens GN=CCDC88C PE=1 SV=3 236 203   81 388 238 
Host cell factor 1 OS=Homo sapiens GN=HCFC1 PE=1 SV=2 308 214   203 565 157 
Probable E3 ubiquitin-protein ligase MYCBP2 OS=Homo sapiens 
GN=MYCBP2 PE=1 SV=3 136 226   91 204 113 
Flotillin-1 OS=Homo sapiens GN=FLOT1 PE=1 SV=3 224 242   119 339 213 
Cation channel sperm-associated protein 2 OS=Homo sapiens 
GN=CATSPER2 PE=1 SV=2 336 260   219 425 363 
Protein argonaute-3 OS=Homo sapiens GN=EIF2C3 PE=1 SV=2 203 272   118 236 254 
Serine/threonine-protein kinase LMTK3 OS=Homo sapiens 
GN=LMTK3 PE=2 SV=2 382 274   143 548 456 
Transcription elongation factor, mitochondrial OS=Homo sapiens 
GN=TEFM PE=1 SV=1 238 303   211 264 240 
Autophagy-related protein 16-2 OS=Homo sapiens GN=ATG16L2 PE=2 
SV=2 312 317   213 454 269 
von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 159 356   138 180 160 
Neurofilament heavy polypeptide OS=Homo sapiens GN=NEFH PE=1 
SV=4 103 132     103   
60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 
SV=1 109 49     109   
Protein arginine N-methyltransferase 1 OS=Homo sapiens GN=PRMT1 
PE=1 SV=2 121 155     121   
Cytoplasmic dynein 2 heavy chain 1 OS=Homo sapiens GN=DYNC2H1 
PE=1 SV=4 124 159     124   
Alpha-internexin OS=Homo sapiens GN=INA PE=1 SV=2 126 103     126   
Dynein heavy chain 3, axonemal OS=Homo sapiens GN=DNAH3 PE=2 
SV=1 131 257     131   
RNA-binding protein 45 OS=Homo sapiens GN=RBM45 PE=1 SV=1 134 235     134   
Neurofilament medium polypeptide OS=Homo sapiens GN=NEFM 
PE=1 SV=3 142 101     142   
Neurofilament light polypeptide OS=Homo sapiens GN=NEFL PE=1 
SV=3 155 116     155   
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 166 51     166   
Dynein heavy chain 8, axonemal OS=Homo sapiens GN=DNAH8 PE=1 
SV=2 182 153     182   
Sickle tail protein homolog OS=Homo sapiens GN=SKT PE=1 SV=2 184 324     184   
Serine/threonine-protein phosphatase with EF-hands 2 OS=Homo 
sapiens GN=PPEF2 PE=1 SV=2 188 192     188   
Tenascin-R OS=Homo sapiens GN=TNR PE=1 SV=3 225 291     225   
Catechol O-methyltransferase domain-containing protein 1 OS=Homo 
sapiens GN=COMTD1 PE=1 SV=1 244 292     244   
Dystonin OS=Homo sapiens GN=DST PE=1 SV=4 257 90     257   
Sciellin OS=Homo sapiens GN=SCEL PE=1 SV=2 273 217     273   
Baculoviral IAP repeat-containing protein 6 OS=Homo sapiens 
GN=BIRC6 PE=1 SV=2 295 337     295   
Myotubularin-related protein 4 OS=Homo sapiens GN=MTMR4 PE=2 
SV=2 314 329     314   
Eukaryotic translation initiation factor 4 gamma 3 OS=Homo sapiens 
GN=EIF4G3 PE=1 SV=2 319 205     319   
Actin filament-associated protein 1 OS=Homo sapiens GN=AFAP1 
PE=1 SV=2 331 261     331   
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Trinucleotide repeat-containing gene 18 protein OS=Homo sapiens 
GN=TNRC18 PE=1 SV=3 336 330     336   
Guanine nucleotide exchange factor VAV2 OS=Homo sapiens 
GN=VAV2 PE=1 SV=2 357 237     357   
Integrator complex subunit 2 OS=Homo sapiens GN=INTS2 PE=1 
SV=2 415 359     415   
Poly [ADP-ribose] polymerase 12 OS=Homo sapiens GN=PARP12 
PE=1 SV=1 457 352     457   
Ankyrin repeat domain-containing protein 5 OS=Homo sapiens 
GN=ANKRD5 PE=2 SV=2 463 198     463   
Pre-mRNA cleavage complex 2 protein Pcf11 OS=Homo sapiens 
GN=PCF11 PE=1 SV=3 482 256     482   
Insulin receptor substrate 1 OS=Homo sapiens GN=IRS1 PE=1 SV=1 501 273     501   
BCL-6 corepressor OS=Homo sapiens GN=BCOR PE=1 SV=1 521 244     521   
Zinc finger protein 142 OS=Homo sapiens GN=ZNF142 PE=1 SV=4 527 343     527   
Laminin subunit beta-4 OS=Homo sapiens GN=LAMB4 PE=2 SV=1 530 318     530   
Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 PE=1 
SV=2 535 286     535   
Hepatocyte growth factor-like protein OS=Homo sapiens GN=MST1 
PE=1 SV=2 550 349     550   
Protein FAM188B OS=Homo sapiens GN=FAM188B PE=2 SV=2 563 344     563   
Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 16 14       16 
Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 63 64       63 
40S ribosomal protein S4, Y isoform 2 OS=Homo sapiens GN=RPS4Y2 
PE=1 SV=3 101 333       101 
40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 104 102       104 
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 121 39       121 
Heat shock protein 75 kDa, mitochondrial OS=Homo sapiens 
GN=TRAP1 PE=1 SV=3 123 70       123 
T-complex protein 1 subunit zeta-2 OS=Homo sapiens GN=CCT6B 
PE=1 SV=5 125 60       125 
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 147 94       147 
CLIP-associating protein 1 OS=Homo sapiens GN=CLASP1 PE=1 
SV=1 152 127       152 
Mediator of RNA polymerase II transcription subunit 14 OS=Homo 
sapiens GN=MED14 PE=1 SV=2 218 281       218 
DnaJ homolog subfamily C member 10 OS=Homo sapiens 
GN=DNAJC10 PE=1 SV=2 259 188       259 
Retrotransposon gag domain-containing protein 1 OS=Homo sapiens 
GN=RGAG1 PE=1 SV=1 264 204       264 
Thrombospondin-4 OS=Homo sapiens GN=THBS4 PE=1 SV=2 334 231       334 
UPF0672 protein C3orf58 OS=Homo sapiens GN=C3orf58 PE=1 SV=1 339 232       339 
Collagen alpha-3(VI) chain OS=Homo sapiens GN=COL6A3 PE=1 
SV=5 345 119       345 
Prolow-density lipoprotein receptor-related protein 1 OS=Homo sapiens 
GN=LRP1 PE=1 SV=2 379 227       379 
Serine/arginine repetitive matrix protein 5 OS=Homo sapiens 
GN=SRRM5 PE=2 SV=3 392 320       392 
Striated muscle preferentially expressed protein kinase OS=Homo 
sapiens GN=SPEG PE=1 SV=4 396 230       396 
Transient receptor potential cation channel subfamily M member 8 
OS=Homo sapiens GN=TRPM8 PE=2 SV=2 405 200       405 
Zinc finger SWIM domain-containing protein 7 OS=Homo sapiens 
GN=ZSWIM7 PE=1 SV=1 407 311       407 
FERM domain-containing protein 5 OS=Homo sapiens GN=FRMD5 
PE=2 SV=1 418 277       418 
UDP-glucose:glycoprotein glucosyltransferase 2 OS=Homo sapiens 
GN=UGGT2 PE=1 SV=4 431 215       431 
AP-5 complex subunit beta OS=Homo sapiens GN=PP1030 PE=1 SV=4 436 252       436 
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 449 206       449 
Sn1-specific diacylglycerol lipase beta OS=Homo sapiens GN=DAGLB 
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Tubulin beta-8 chain OS=Homo sapiens GN=TUBB8 PE=1 SV=2  24         
Lamin-B2 OS=Homo sapiens GN=LMNB2 PE=1 SV=3  105         
Doublecortin domain-containing protein 1 OS=Homo sapiens 
GN=DCDC1 PE=2 SV=2  106         
Protein phosphatase Slingshot homolog 2 OS=Homo sapiens GN=SSH2 
PE=1 SV=1  113         
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4  118         
Ankyrin repeat domain-containing protein 36A OS=Homo sapiens 
GN=ANKRD36 PE=2 SV=3  120         
Transformation/transcription domain-associated protein OS=Homo 
sapiens GN=TRRAP PE=1 SV=3  125         
Peripherin OS=Homo sapiens GN=PRPH PE=1 SV=2  137         
Spectrin alpha chain, erythrocyte OS=Homo sapiens GN=SPTA1 PE=1 
SV=5  143         
Ankyrin repeat domain-containing protein 36B OS=Homo sapiens 
GN=ANKRD36B PE=2 SV=4  152         
Matrix-remodeling-associated protein 5 OS=Homo sapiens 
GN=MXRA5 PE=2 SV=3  158         
Serine/threonine-protein kinase D1 OS=Homo sapiens GN=PRKD1 
PE=1 SV=2  165         
Hyccin OS=Homo sapiens GN=FAM126A PE=1 SV=2  167         
Unconventional myosin-XVIIIa OS=Homo sapiens GN=MYO18A PE=1 
SV=3  169         
Centrosomal protein of 72 kDa OS=Homo sapiens GN=CEP72 PE=1 
SV=2  170         
Nuclear pore complex protein Nup160 OS=Homo sapiens GN=NUP160 
PE=1 SV=3  171         
Probable G-protein coupled receptor 101 OS=Homo sapiens 
GN=GPR101 PE=2 SV=1  174         
Leucine-rich repeat-containing protein 16A OS=Homo sapiens 
GN=LRRC16A PE=1 SV=1  176         
Voltage-dependent T-type calcium channel subunit alpha-1H OS=Homo 
sapiens GN=CACNA1H PE=1 SV=4  178         
Cadherin EGF LAG seven-pass G-type receptor 3 OS=Homo sapiens 
GN=CELSR3 PE=1 SV=2  179         
Dystrophin OS=Homo sapiens GN=DMD PE=1 SV=3  184         
Serine/threonine-protein kinase D3 OS=Homo sapiens GN=PRKD3 
PE=1 SV=1  189         
60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2  191         
Folliculin-interacting protein 1 OS=Homo sapiens GN=FNIP1 PE=1 
SV=3  193         
Leucine-rich repeat serine/threonine-protein kinase 2 OS=Homo sapiens 
GN=LRRK2 PE=1 SV=2  197         
Rab3 GTPase-activating protein non-catalytic subunit OS=Homo sapiens 
GN=RAB3GAP2 PE=1 SV=1  199         
Cadherin EGF LAG seven-pass G-type receptor 2 OS=Homo sapiens 
GN=CELSR2 PE=2 SV=1  202         
Uncharacterized protein C19orf48 OS=Homo sapiens GN=C19orf48 
PE=2 SV=1  208         
Transcription regulator protein BACH1 OS=Homo sapiens GN=BACH1 
PE=1 SV=2  213         
Rho GTPase-activating protein 11A OS=Homo sapiens 
GN=ARHGAP11A PE=1 SV=2  216         
Scavenger receptor class F member 2 OS=Homo sapiens GN=SCARF2 
PE=1 SV=3  218         
Guanine nucleotide exchange factor VAV3 OS=Homo sapiens 
GN=VAV3 PE=1 SV=1  220         
60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1  221         
Limkain-b1 OS=Homo sapiens GN=LKAP PE=1 SV=5  223         
Kinesin-like protein KIF1C OS=Homo sapiens GN=KIF1C PE=1 SV=3  224         
Calponin-1 OS=Homo sapiens GN=CNN1 PE=1 SV=2 
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60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=1  234         
cAMP-dependent protein kinase type I-beta regulatory subunit 
OS=Homo sapiens GN=PRKAR1B PE=1 SV=4  236         
Growth arrest-specific protein 6 OS=Homo sapiens GN=GAS6 PE=1 
SV=2  238         
Neurogenic locus notch homolog protein 1 OS=Homo sapiens 
GN=NOTCH1 PE=1 SV=4  243         
Plexin-A3 OS=Homo sapiens GN=PLXNA3 PE=1 SV=2  245         
Proline/serine-rich coiled-coil protein 1 OS=Homo sapiens GN=PSRC1 
PE=1 SV=1  247         
Keratin, type II cytoskeletal 75 OS=Homo sapiens GN=KRT75 PE=1 
SV=2  249         
Basement membrane-specific heparan sulfate proteoglycan core protein 
OS=Homo sapiens GN=HSPG2 PE=1 SV=4  253         
Forkhead box protein P1 OS=Homo sapiens GN=FOXP1 PE=1 SV=1  254         
Proline-rich transmembrane protein 2 OS=Homo sapiens GN=PRRT2 
PE=2 SV=1  255         
BAG family molecular chaperone regulator 2 OS=Homo sapiens 
GN=BAG2 PE=1 SV=1  262         
Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3  264         
Supervillin OS=Homo sapiens GN=SVIL PE=1 SV=2  265         
Peroxisome proliferator-activated receptor gamma coactivator-related 
protein 1 OS=Homo sapiens GN=PPRC1 PE=1 SV=1  266         
Probable ATP-dependent RNA helicase YTHDC2 OS=Homo sapiens 
GN=YTHDC2 PE=1 SV=2  269         
UPF0498 protein KIAA1191 OS=Homo sapiens GN=KIAA1191 PE=1 
SV=1  270         
Ankyrin repeat domain-containing protein 27 OS=Homo sapiens 
GN=ANKRD27 PE=1 SV=2  271         
Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens 
GN=HNRNPR PE=1 SV=1  275         
Lysosomal-trafficking regulator OS=Homo sapiens GN=LYST PE=1 
SV=3  278         
Solute carrier family 12 member 6 OS=Homo sapiens GN=SLC12A6 
PE=1 SV=2  279         
Voltage-dependent calcium channel subunit alpha-2/delta-4 OS=Homo 
sapiens GN=CACNA2D4 PE=1 SV=2  280         
Smoothelin OS=Homo sapiens GN=SMTN PE=1 SV=7  282         
Very long-chain acyl-CoA synthetase OS=Homo sapiens GN=SLC27A2 
PE=1 SV=2  283         
Collagen alpha-5(VI) chain OS=Homo sapiens GN=COL6A5 PE=1 
SV=1  285         
DNA repair protein complementing XP-G cells OS=Homo sapiens 
GN=ERCC5 PE=1 SV=3  290         
Protein zyg-11 homolog B OS=Homo sapiens GN=ZYG11B PE=1 
SV=2  293         
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial OS=Homo sapiens GN=PDHA1 PE=1 SV=3  295         
E3 ubiquitin-protein ligase UBR1 OS=Homo sapiens GN=UBR1 PE=1 
SV=1  296         
StAR-related lipid transfer protein 9 OS=Homo sapiens GN=STARD9 
PE=1 SV=3  297         
Malcavernin OS=Homo sapiens GN=CCM2 PE=1 SV=1  298         
RIMS-binding protein 2 OS=Homo sapiens GN=RIMBP2 PE=1 SV=3  299         
Tyrosine-protein phosphatase non-receptor type 9 OS=Homo sapiens 
GN=PTPN9 PE=1 SV=1  300         
Pre-mRNA-processing factor 6 OS=Homo sapiens GN=PRPF6 PE=1 
SV=1  301         
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U3 small nucleolar RNA-interacting protein 2 OS=Homo sapiens 
GN=RRP9 PE=1 SV=1  304         
RILP-like protein 1 OS=Homo sapiens GN=RILPL1 PE=1 SV=1  305         
Protein PRRC2B OS=Homo sapiens GN=PRRC2B PE=1 SV=2  306         
Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 
SV=2  307         
Protein kinase C-binding protein 1 OS=Homo sapiens GN=ZMYND8 
PE=1 SV=2  310         
Hydrocephalus-inducing protein homolog OS=Homo sapiens 
GN=HYDIN PE=1 SV=3  312         
G protein-activated inward rectifier potassium channel 4 OS=Homo 
sapiens GN=KCNJ5 PE=1 SV=2  314         
ATP-dependent RNA helicase DDX51 OS=Homo sapiens GN=DDX51 
PE=1 SV=3  316         
Zinc finger protein 236 OS=Homo sapiens GN=ZNF236 PE=2 SV=2  319         
Dynein heavy chain 17, axonemal OS=Homo sapiens GN=DNAH17 
PE=2 SV=2  321         
Protein Red OS=Homo sapiens GN=IK PE=1 SV=3  322         
Putative MAGE domain-containing protein MAGEA13P OS=Homo 
sapiens GN=MAGEA13P PE=5 SV=1  323         
Replication factor C subunit 2 OS=Homo sapiens GN=RFC2 PE=1 
SV=3  326         
Protocadherin-18 OS=Homo sapiens GN=PCDH18 PE=2 SV=3  327         
Nuclear autoantigenic sperm protein OS=Homo sapiens GN=NASP 
PE=1 SV=2  328         
WD repeat-containing protein 87 OS=Homo sapiens GN=WDR87 PE=2 
SV=3  334         
Pituitary adenylate cyclase-activating polypeptide type I receptor 
OS=Homo sapiens GN=ADCYAP1R1 PE=1 SV=1  338         
ER degradation-enhancing alpha-mannosidase-like 3 OS=Homo sapiens 
GN=EDEM3 PE=1 SV=2  340         
FAM75-like protein FLJ43859 OS=Homo sapiens PE=2 SV=1  341         
Ribosomal protein S6 kinase delta-1 OS=Homo sapiens GN=RPS6KC1 
PE=1 SV=2  345         
Adenosine deaminase OS=Homo sapiens GN=ADA PE=1 SV=3  346         
Non-lysosomal glucosylceramidase OS=Homo sapiens GN=GBA2 PE=1 
SV=2  347         
DENN domain-containing protein 5B OS=Homo sapiens 
GN=DENND5B PE=1 SV=2  348         
Synembryn-A OS=Homo sapiens GN=RIC8A PE=1 SV=3  350         
Keratin, type II cuticular Hb3 OS=Homo sapiens GN=KRT83 PE=1 
SV=2  354         
Angiomotin-like protein 2 OS=Homo sapiens GN=AMOTL2 PE=1 
SV=3  355         
Kinesin light chain 3 OS=Homo sapiens GN=KLC3 PE=1 SV=2  357         
Ras-specific guanine nucleotide-releasing factor 2 OS=Homo sapiens 
GN=RASGRF2 PE=1 SV=2  358         
Coiled-coil domain-containing protein 129 OS=Homo sapiens 
GN=CCDC129 PE=2 SV=2  361         
Plexin-B1 OS=Homo sapiens GN=PLXNB1 PE=1 SV=3  362         
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3  364         
Fibrocystin OS=Homo sapiens GN=PKHD1 PE=1 SV=1  365         
TATA element modulatory factor OS=Homo sapiens GN=TMF1 PE=1 
SV=2  367         
Cysteinyl leukotriene receptor 1 OS=Homo sapiens GN=CYSLTR1 
PE=2 SV=1  369         
Tubulin beta-2B chain OS=Homo sapiens GN=TUBB2B PE=1 SV=1 11 9   10 11   
Tubulin beta-4A chain OS=Homo sapiens GN=TUBB4A PE=1 SV=2 13 13   13 13   
Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 SV=1 24 22   22 26   
       
 





Table 2.6. (Continued.) 
Name Rank GAN NEG BTB MG MIL 
ADP/ATP translocase 1 OS=Homo sapiens GN=SLC25A4 PE=1 SV=4 39 47   21 57   
Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 120 93   146 94   
Pericentrin OS=Homo sapiens GN=PCNT PE=1 SV=4 82 85   62 102   
Catenin alpha-2 OS=Homo sapiens GN=CTNNA2 PE=1 SV=5 218 135   216 219   
Dynein heavy chain 2, axonemal OS=Homo sapiens GN=DNAH2 PE=1 
SV=3 206 259   173 239   
Dynein heavy chain 6, axonemal OS=Homo sapiens GN=DNAH6 PE=1 
SV=3 210 175   73 346   
Protein ALO17 OS=Homo sapiens GN=KIAA1618 PE=1 SV=2 330 173   198 461   
Kelch-like protein 5 OS=Homo sapiens GN=KLHL5 PE=2 SV=3 371 228   228 513   
Sodium channel protein type 1 subunit alpha OS=Homo sapiens 
GN=SCN1A PE=1 SV=2 323 96   82 564   
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 52 107   59   44 
Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens 
GN=HNRNPF PE=1 SV=3 44 65   42   46 
Coiled-coil domain-containing protein 158 OS=Homo sapiens 
GN=CCDC158 PE=2 SV=2 217 315   152   282 
Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 295 339   183   406 
Zinc finger homeobox protein 3 OS=Homo sapiens GN=ZFHX3 PE=1 
SV=2 315 246   156   474 
ATPase family AAA domain-containing protein 3A OS=Homo sapiens 
GN=ATAD3A PE=1 SV=2 23 91   23     
60 kDa heat shock protein, mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 34 138   34     
Mitogen-activated protein kinase kinase kinase kinase 3 OS=Homo 
sapiens GN=MAP4K3 PE=1 SV=1 71 108   71     
Disheveled-associated activator of morphogenesis 1 OS=Homo sapiens 
GN=DAAM1 PE=1 SV=2 77 211   77     
Granzyme M OS=Homo sapiens GN=GZMM PE=1 SV=2 107 366   107     
Piwi-like protein 2 OS=Homo sapiens GN=PIWIL2 PE=1 SV=1 112 195   112     
Phosphoacetylglucosamine mutase OS=Homo sapiens GN=PGM3 PE=1 
SV=1 135 131   135     
Histone acetyltransferase KAT6A OS=Homo sapiens GN=KAT6A 
PE=1 SV=2 150 351   150     
Histone-lysine N-methyltransferase MLL2 OS=Homo sapiens 
GN=MLL2 PE=1 SV=2 185 332   185     
Programmed cell death protein 7 OS=Homo sapiens GN=PDCD7 PE=1 
SV=1 202 251   202     
Ubiquitin carboxyl-terminal hydrolase 43 OS=Homo sapiens 
GN=USP43 PE=1 SV=2 215 207   215     
Kinesin-like protein KIF11 OS=Homo sapiens GN=KIF11 PE=1 SV=2 3 2 2 4 3 2 
Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A 
PE=1 SV=5 3 3 3 2 4 4 
Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 
PE=1 SV=4 6 5 4   6 5 
RNA-binding protein 10 OS=Homo sapiens GN=RBM10 PE=1 SV=3 20 26 5   22 18 
Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 10 8 6   12 7 
Heat shock 70 kDa protein 1-like OS=Homo sapiens GN=HSPA1L 
PE=1 SV=2 7 4 7 5 8 8 
Thyroid hormone receptor-associated protein 3 OS=Homo sapiens 
GN=THRAP3 PE=1 SV=2 27 27 8   30 23 
Heat shock 70 kDa protein 6 OS=Homo sapiens GN=HSPA6 PE=1 
SV=2 13 10 9 9 16 15 
Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens 
GN=EIF3A PE=1 SV=1 25 56 10   17 32 
Serine/threonine-protein kinase 38 OS=Homo sapiens GN=STK38 PE=1 
SV=1 25 17 11 27 25 22 
Eukaryotic translation initiation factor 4B OS=Homo sapiens 
GN=EIF4B PE=1 SV=2 36 25 12   27 45 
Eukaryotic translation initiation factor 3 subunit L OS=Homo sapiens 





Table 2.6. (Continued.)             
Name Rank GAN NEG BTB MG MIL 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 17 69 15 26 5 19 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 22 48 16 28 19 20 
Heat shock-related 70 kDa protein 2 OS=Homo sapiens GN=HSPA2 
PE=1 SV=1 23 16 17 20 24 24 
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 13 11 18 17 10 11 
Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens 
GN=HNRNPH1 PE=1 SV=4 35 35 19   43 27 
Table 2.6. (Continued.)             
Name Rank GAN NEG BTB MG MIL 
Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 7 6 20 7 7 6 
U4/U6 small nuclear ribonucleoprotein Prp31 OS=Homo sapiens 
GN=PRPF31 PE=1 SV=2 72 57 21   86 58 
Eukaryotic translation initiation factor 3 subunit B OS=Homo sapiens 
GN=EIF3B PE=1 SV=3 62 117 22   55 68 
Eukaryotic translation initiation factor 3 subunit C OS=Homo sapiens 
GN=EIF3C PE=1 SV=1 107 97 23   37 177 
Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 11 15 24 6 14 13 
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 42 20 25   32 52 
Bcl-2-associated transcription factor 1 OS=Homo sapiens GN=BCLAF1 
PE=1 SV=2 83 104 26   89 77 
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 28 44 27 32 21 30 
E3 ubiquitin-protein ligase TRIM21 OS=Homo sapiens GN=TRIM21 
PE=1 SV=1 35 50 28 15 63 28 
Kinesin-like protein KIFC3 OS=Homo sapiens GN=KIFC3 PE=1 SV=4 62 58 32 41 74 70 
Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 29 67 33   29 29 
Uncharacterized protein C11orf84 OS=Homo sapiens GN=C11orf84 
PE=1 SV=3 39 55 34 53 38 25 
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 73 38 35   67 78 
Spectrin beta chain, erythrocyte OS=Homo sapiens GN=SPTB PE=1 
SV=5 290 136 38   290   
40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 50 71 39   52 47 
Eukaryotic translation initiation factor 3 subunit D OS=Homo sapiens 
GN=EIF3D PE=1 SV=1 86 109 41   82 90 
TRIO and F-actin-binding protein OS=Homo sapiens GN=TRIOBP 
PE=1 SV=3 159 289 42   177 140 
Replicase polyprotein 1ab OS=Human SARS coronavirus GN=rep PE=1 
SV=1 114 134 43   114   
IQ motif and SEC7 domain-containing protein 2 OS=Homo sapiens 
GN=IQSEC2 PE=1 SV=1 259 335 45   259   
Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens 
GN=HNRNPM PE=1 SV=3 251 92 46   198 304 
Titin OS=Homo sapiens GN=TTN PE=1 SV=3 60 52 47 51 70 60 
Mucin-16 OS=Homo sapiens GN=MUC16 PE=1 SV=2 94 287 50 94     
Polycystin-1 OS=Homo sapiens GN=PKD1 PE=1 SV=3 265 84 52   368 161 
Protein CASP OS=Homo sapiens GN=CUX1 PE=1 SV=2 228 187 53   228   
Kinesin-like protein KIF21B OS=Homo sapiens GN=KIF21B PE=1 
SV=2 109 80 56 60 125 142 
Immunoglobulin superfamily member 3 OS=Homo sapiens GN=IGSF3 
PE=1 SV=3 261 181 57   292 230 
40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 34 28 58   31 37 
Peroxisomal proliferator-activated receptor A-interacting complex 285 
kDa protein OS=Homo sapiens GN=PRIC285 PE=1 SV=6 177 82 59   185 168 
Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3 104 99 60 38 99 176 
Zinc finger protein 616 OS=Homo sapiens GN=ZNF616 PE=2 SV=2 231 111 65   312 149 
Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 SV=2 275 151 67   287 263 
Serine/threonine-protein kinase RIO1 OS=Homo sapiens GN=RIOK1 





Table 2.6. (Continued.)             
Name Rank GAN NEG BTB MG MIL 
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 
PE=1 SV=1 51 46 70   59 43 
Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 
SV=1 54 61 77     54 
Semaphorin-5B OS=Homo sapiens GN=SEMA5B PE=2 SV=4 258 156 78     258 
Coiled-coil domain-containing protein 73 OS=Homo sapiens 
GN=CCDC73 PE=1 SV=2 84 185 79 84     
Nebulin-related-anchoring protein OS=Homo sapiens GN=NRAP PE=2 
SV=2 280 196 80   260 299 
Zinc finger CCCH domain-containing protein 13 OS=Homo sapiens 
GN=ZC3H13 PE=1 SV=1 391 140 81 245 536   
Teneurin-3 OS=Homo sapiens GN=ODZ3 PE=2 SV=3 122 130 85 92 133 141 
Leucine zipper protein 1 OS=Homo sapiens GN=LUZP1 PE=1 SV=2 223 342 88 90   356 
Nesprin-2 OS=Homo sapiens GN=SYNE2 PE=1 SV=3 115 98 91 99 129 117 
Rootletin OS=Homo sapiens GN=CROCC PE=1 SV=1 168 76 96 78 343 82 
Zinc finger C3H1 domain-containing protein OS=Homo sapiens 
GN=ZFC3H1 PE=1 SV=3  183 99       
C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens 
GN=MTHFD1 PE=1 SV=3 131 112 101   115 146 
Thioredoxin domain-containing protein 5 OS=Homo sapiens 
GN=TXNDC5 PE=1 SV=2 341 331 102     341 
Zinc finger protein 618 OS=Homo sapiens GN=ZNF618 PE=1 SV=1 308 157 105   305 310 
Zinc finger protein 469 OS=Homo sapiens GN=ZNF469 PE=1 SV=3 211 164 111   211   
Spectrin beta chain, brain 4 OS=Homo sapiens GN=SPTBN5 PE=1 
SV=1 165 74 117 182 147   
Lymphoid-restricted membrane protein OS=Homo sapiens GN=LRMP 
PE=1 SV=3 367 163 120   458 276 
Dual specificity protein kinase TTK OS=Homo sapiens GN=TTK PE=1 
SV=2 179 219 121   175 183 
E3 ubiquitin-protein ligase TRIM9 OS=Homo sapiens GN=TRIM9 
PE=1 SV=1 296 368 127   327 265 
Ninein-like protein OS=Homo sapiens GN=NINL PE=1 SV=2 144 147 130 79   209 
Selenocysteine-specific elongation factor OS=Homo sapiens 
GN=EEFSEC PE=1 SV=4 424 126 133   512 335 
Putative UPF0607 protein FLJ37424 OS=Homo sapiens PE=2 SV=1  268 134       
ATP synthase subunit alpha, mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 256 309 141 36 499 234 
Microtubule-associated serine/threonine-protein kinase 4 OS=Homo 
sapiens GN=MAST4 PE=1 SV=3 268 363 143     268 
Protein piccolo OS=Homo sapiens GN=PCLO PE=1 SV=4 371 212 151   409 333 
Ryanodine receptor 2 OS=Homo sapiens GN=RYR2 PE=1 SV=3 310 240 155   447 172 
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase 
(cyclizing) OS=Homo sapiens GN=DAK PE=1 SV=2 157 229 156 157     
Neuron navigator 2 OS=Homo sapiens GN=NAV2 PE=1 SV=3 235 263 160   235   
60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 110 83 174     110 
Zinc finger protein 14 OS=Homo sapiens GN=ZNF14 PE=2 SV=3 246 276 176   258 233 
Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 130 72 179 69 143 178 
Dynein heavy chain 10, axonemal OS=Homo sapiens GN=DNAH10 
PE=1 SV=4 171 160 181 74 197 243 
Bromodomain-containing protein 1 OS=Homo sapiens GN=BRD1 PE=1 
SV=1 219 241 197 65   372 
Disks large homolog 5 OS=Homo sapiens GN=DLG5 PE=1 SV=4 155 89 199   96 214 
Tubulin alpha-8 chain OS=Homo sapiens GN=TUBA8 PE=1 SV=1 20 21 202 16 23 21 







Table 2.6. Full list of hits from GAN proteomic screen. All hits with CI>95% are listed here. 
Hits are ranked according to their abundance overall (Rank column), in the full-length gigaxonin 
condition (GAN), in the negative control (NEG), in the BTB domain condition (BTB) and in the 
full-length gigaxonin condition treated with MG132 or Millennium (MG or MIL, respectively). 
Only hits that were found in two or more categories were given an overall rank. A blank cell 
indicates that a protein was not present in that sample. Likely false positive hits are indicated in 
red and these were not included for the generation of the ranked list of Kelch domain hits shown 







Chapter 3. Studies of iPS-derived motor neurons from GAN patients  
Introduction 
As discussed in the introduction, Gan
-/-
 mice, while recapitulating some aspects of human 
GAN biochemical dysregulation, have several shortcomings. The relatively mild and late onset 
phenotype (when observed) suggests that gigaxonin may be compensated for by homologs in 
mice. Alternatively, it may be that gigaxonin plays a minor role in the maintenance of mouse 
axons given their relatively shorter length and the reduced lifespan of mice compared to humans. 
Regardless, the inability of the current mouse models to phenocopy the severity and early onset 
of the human disease led me to explore whether a humanized model may be more informative for 
the study of GAN.  
To this end, I sought to make iPSCs from several patients with GAN. As noted in the 
introduction, iPSC technology comes with both advantages and disadvantages. However, 
because we are currently unable to biopsy and culture living motor neurons from patients with 
GAN, iPSCs are our only approach to have access to the cell type functionally affected in the 
disease. While some insight into the disease has been gained by biopsy studies (Ionasescu et al., 
1983) as well as functional studies on patient fibroblasts (Cleveland et al., 2009), no information 
was previously available as to the function of living GAN MNs.    
GAN affects both the motor and sensory systems (Berg et al., 1972). Patients have severe 
ataxia and muscle weakness, and lose the ability to walk early in the disease. Although the 
limited number of patients affected by the disease makes epidemiological studies difficult to 
perform, patients usually succumb in the second or third decade, usually from complications 





complications from being dependent on ventilator support, such as pneumonia or asphyxiation 
secondary to food aspiration (Koch et al., 1977; Kumar et al., 1990). Evidence from other 
neurodegenerative conditions such as ALS suggests that respirator support is required due to 
denervation of the motor muscles of respiration (de Carvalho et al., 2010). Thus I prioritized 
making MNs from GAN iPSCs to study one of the crucial cell type affected in the disease.    
Although GAN is a rare disease, dysregulation of IFs is a common theme of 
neurodegenerative disease. One potential benefit of making iPS lines from patients with GAN is 
that if they recapitulate the IF accumulation phenotype, they may be a valuable tool to study 
human nIF turnover. In vivo nIFs have a very long half-life (Barry et al., 2007) and there are no 
published reports of the dynamics of human nIF turnover. Thus if we are able to study nIF 
turnover in human iPS-MN this would represent the first in vitro, humanized system to study this 
important cellular process.  
 I generated iPS lines from several patients with GAN. iPS lines were characterized for 
morphology, pluripotency, karyotype, and viral and pluripotency gene expression. Lines were 
derived with the assistance of Faizzan Ahmad and David Kahler at the New York Stem Cell 
Foundation (NYSCF). Pluripotency staining was performed by Faizzan and viral and 
pluripotency gene expression were measured by Faizzan and myself. iPSCs were differentiated 
into MNs as defined by the expression of the key transcription factors HB9 and ISL1. While 
GAN iPSCs were able to make functional neurons and MNs with efficiencies comparable to 
control, GAN iPS-MNs had significantly elevated levels of PRPH and NF-L. By contrast, levels 
of non-IF proteins were comparable to control including MAP1B, a previously reported binding 





derived from GAN patients recapitulate key aspects of the human disease and should serve as a 







To establish a human model of GAN I generated induced pluripotent stem cells (iPSCs) 
from skin fibroblasts of patients affected by the disease in collaboration with NYSCF. To 
represent the clinical and genetic heterogeneity of GAN patients, I included samples from 
patients of different sex, ages, and mutations (Table 3.1). Fibroblast biopsies were collected by 
Drs. Wendy Chung at Columbia University, Rudy Van Coster at the University Hospital Ghent 
and Paul Maertens at the University of South Alabama. Fibroblast samples are indicated by a 
unique number for each unique patient. Fibroblasts were transduced with retroviral vectors 
encoding OCT4, SOX2, KLF4, and c-MYC as previously described (Takahashi et al., 2007). All 
iPS lines were assayed for formation of ES-like colonies (Figure 3.2A-D), nuclear and surface 
markers characteristic of human stem cells (Figure 3.2FE), karyotype (Figure 3.2F) and viral 
transgene expression (Figure 3.3). Lines from patients 1 and 4 were excluded because of 
inadequate morphology or high persistent transgene expression, respectively, but those from 
patients 2, 3 and 5 satisfied all criteria. Throughout the study the line number refers to a unique 
GAN patient and the letter after the line number refers to a particular clone. At least 4 clones 
were isolated per patient. For MN differentiation studies one clone per patient was selected based 
on colony morphology.  
As a first step toward analyzing the effects of the GAN mutations in neurons, I 
differentiated one iPSC line per patient into motor neurons using a 28-day embryoid body-based 
protocol (Boulting et al., 2011) that generates mixed cultures of spinal cord identity in which 
iPS-MNs constitute ~20-35% of total cells (Figure 3.5A). Most patients with GAN have low, 
sometimes undetectable levels of gigaxonin protein (Cleveland et al., 2009). Similarly marked 





(Figure 3.4A, B, and C, respectively), including patient 5, whose mutation remains to be 
identified. GAN iPSCs generated MNs and total neurons with comparable efficiency to a control 
line (Figure 3.5B-J), as measured by the MN marker Islet (ISL1) and the neuronal marker 
microtubule-associated protein 2 (MAP2). Line 18c was described by Boulting et al. (2011) and 
was used here and in all subsequent experiments as the control iPS line. Neurons that express the 
key MN markers HB9 or ISL1 are referred to as MNs throughout the study.  
To determine if the resulting neurons were physiologically active, spontaneous electrical 
activity was monitored by visualization of spontaneous Ca
2+
 transients (Figure 3.6). Intracellular 
Ca
2+
 dynamics were monitored using the Ca
2+
-sensitive dye Fluo-4 AM (Boulting et al., 2011). 
Spontaneous calcium transients were visible in the cell bodies and processes of multiple cells 
from each line (Figure 3.6A, B). I compared the spontaneous activity of neurons from two GAN 
lines with neurons from two control iPS lines. The GAN2E neurons I monitored appeared 
significantly less active than both control 1 and 2 (p = 0.002 and 0.036, respectively). However, 
the GAN3X neurons were more active than control 2 (p = 0.044). With the exception of one 
GAN2E neuron, all GAN neurons displayed spontaneous calcium transients. Thus I have 
generated functionally active GAN MN cultures and, in this small sample, detected no consistent 
GAN-related change in activity.     
I next asked whether GAN iPS-derived neurons displayed any of the cytoskeletal 
dysregulation seen in patients, with a particular focus on the binding partners identified in the 
MS screen. I focused first on accumulation of nIF subunits. One study found that a peripheral 
nerve from a GAN patient contained two-fold more NF-L than a control sample, whereas levels 
of NF-M and NF-H were unchanged (Ionasescu et al., 1983). In a striking parallel, iPS-neurons 





3.7A, G), whereas levels of NF-M were comparable to control or reduced (Fig. 3B, H). Levels of 
NF-H were not measured due to lack of a reliable signal on Western blot. These findings are also 
in agreement with reports of an increased abundance of the NF-L subunits in GAN mouse 
models at later time points, while NF-M and NF-H are less affected (Dequen et al., 2008; Ganay 
et al.). As in the mouse model described by Dequen et al. (2008), peripherin also was elevated 2 
to 3-fold in GAN cultures (Fig. 3C, I).  
Interestingly, vimentin levels appeared not to differ greatly between patients and control 
(Fig. 3F, L). My observations agree with the published findings of a change in the subcellular 
distribution of vimentin rather than in overall levels in GAN patient fibroblasts (Pena, 1982). A 
similar absence of striking accumulation in GAN cells was seen for non-IF proteins, including 
tau (Fig. 3D, J) and MAP1B-LC (Fig. 3E, K), which although previously reported to accumulate 
in GAN-null neurons (Allen et al., 2005) was not identified as a gigaxonin interactor in my MS 
screen. Overall, therefore, a subset of neuronal IFs implicated in the human axonal pathology is 
selectively upregulated in spinal neuron cultures derived from GAN patients.  
I next focused on potential changes in subcellular localization of nIFs, using peripherin as 
a model. Moreover, I needed to confirm that the observed changes in nIF levels in these mixed 
cultures occurred in motor neurons. Immunostaining revealed no expression of peripherin in 
non-neuronal cells in GAN cultures (Figure 3.8E). In identified ISL1
+
 motor neurons I observed 
clear perinuclear accumulation of peripherin in GAN (Figure 3.8E, F) but not control (Figure 
3.8B, C) cultures. This is reminiscent of the perinuclear IF aggregates seen in patient fibroblasts 
(Bomont and Koenig, 2003) and the accumulations seen in the giant axons of patients (Asbury et 
al., 1972). In contrast, in a parallel stain, no change in MAP2 intensity or localization was 





cell-by-cell basis. The distribution of MAP2 intensities did not differ between the two genotypes 
(Figure 3.8G). In contrast, peripherin was clearly increased in GAN motor neurons: only >30% 
of control neurons have peripherin intensities greater than 2000 units whereas for GAN neurons 
this figure is >70% (Figure 3.8H). Cumulative relative frequency plots were generated using the 
nonparametric Kolmogorov-Smirnov test (two sample K-S test). The p value for the MAP2 
intensity data shown in (G) is 0.598; for PRPH (peripherin) shown in (H) p < 0.001. Thus the 
GAN genotype is associated with a selective increase of nIF levels in motor neurons.  
Last, I wanted to determine if the elevated levels of select nIF proteins observed in Figure 
3.7 was due to increased production of transcript. I therefore analyzed transcript levels for a 
panel of nIF and non-nIF proteins by qPCR (Figure 3.9). Expression was measured at the same 
time point as in Figure 3.7. No significant differences were detected between GAN patients and 
control. This suggests that as previously reported by Dequen et al. (2008), this elevation does not 
appear to be due to increased production of IF transcripts (Figure 3.9).  










In summary, my findings suggest that we have created a reasonable approximation of 
GAN pathology using iPS-MNs derived from patients. iPS lines were derived from GAN 
patients with unique mutations, and it was encouraging to observe that despite the variation of 
mutations, gender, and age of the donors, all iPS lines generated MNs with severely reduced 
levels of gigaxonin as well as elevated levels of NF-L and peripherin, suggesting that I have 
generated an iPS model that faithfully recapitulates aspects of GAN. While early results are 
encouraging several areas require further investigation. 
Further studies are required to carefully determine the composition of the nIF aggregates 
I observe in the GAN iPS-MNs. Further validation of the iPS model would be greatly advanced 
by more detailed characterization of the nIF aggregates seen in patients. My iPS model appears 
to recapitulate the increase in NF-L observed in patient sural nerve described by Ionasescu et al. 
(1983) (without a concomitant increase in NF-M), but further comparisons between the 
aggregates that I see and those in patients are limited by the fact that no autopsy studies have 
determined the composition of the aggregates seen throughout the nervous system of GAN 
patients. Aggregates are present in both the posterior and anterior horns of the spinal cord of 
GAN patients (Figure 1.2F, G), but sections have not been stained for specific nIFs. However, it 
is promising that I observe aggregates of nIFs forming at early time points in culture. A major 
question in the iPS field is that of genetic background differences: are the phenotypes we see 
compared with controls the result of single mutations or simply background from the genetic 
diversity present in the human population? I provide evidence in the next chapter to suggest that 
the biochemical phenotypes described in this chapter are the result of a loss of gigaxonin rather 





The selective accumulation of certain IFs is another open question. Since the disease was 
first described it was known that total vimentin levels are unchanged in patient fibroblasts (Pena, 
1982), but that levels of NF-L were increased two-fold in patient nerve samples (Ionasescu et al., 
1983). In the same report, levels of NF-M were less elevated than those of NF-L (Ionasescu et 
al., 1983), suggesting that gigaxonin may have different effects on different IF proteins. While 
the previously reported association between gigaxonin and Cul3 (Figure 2.5 and (Bennett et al., 
2010)) suggests that a role of gigaxonin is ubiquitination of substrates, it may have other roles, 
and ubiquitination itself may play roles in subcellular localization, as well as or in addition to 
degradation by the proteasome or autophagosome. A few reports have shown that IFs are 
degraded by the proteasome (Balastik et al., 2008; Jaitovich et al., 2008); there is less support for 
degradation by the autophagosome. However, gigaxonin is emerging as a key regulator of IFs 
and understanding the mechanism by which it achieves this will be essential to both GAN and 
other neurodegenerative diseases where IFs accumulate.     
While it is encouraging that I observe elevated nIF levels as well as aggregation of nIFs 
in the cell bodies of GAN neurons, thus far I have not observed the formation of “giant axons” in 
culture. There could be several explanations for this. First, experiments were carried out over a 
relatively short period of time – 12 days past the end of the differentiation protocol – which may 
not be sufficient time for the nIF accumulation to advance to more severe pathology. Second, 
few studies have compared iPS-MN development in vitro in the presence of support cells such as 
astrocytes and glia, and it may be that the GAN MNs react differently to signals released from 
these cells as opposed to healthy control MNs. Finally, it remains a possibility that a disease 
cascade is triggered in the presence of a stressor, or multiple stressors over time. It is unknown 





performed several years after disease onset (Asbury et al., 1972). Moreover, giant axons are not 
specific to GAN; they are also present in Charcot-Marie-Tooth disease types 1F, 2E and 4C (Yiu 
and Ryan, 2012) suggesting that the unique aspects of GAN pathophysiology could be studied in 
the iPS model even in the absence of giant axons.    
Although MNs derived from our 28-day protocol express the canonical MN markers HB9 
and ISL1 and display spontaneous activity, further parsing of these cultures into MN subtypes 
may be informative for our understanding of GAN. As my analysis stands now all MNs are 
considered together but it is very possible that the protocol favors the generation of a specific 
subtype of MN, such as lateral motor column or hypaxial motor column MNs (Amoroso et al., 
2012). For example, I observe that GAN MNs have a higher intensity of PRPH staining as 
compared to control, but it remains to be determined if a particular subtype of MN more strongly 
affected in this context. Based on the clinical presentation of GAN patients LMC MNs are 
predominantly affected early in the disease compared with HMC MNs; could it be possible to 
more precisely define biochemical – or functional - abnormalities based on these identity 
divisions?  
Since I began this study, exciting advances have been made in the field of iPS 
reprogramming technology. Classically, Yamanaka described a reprogramming process that 
utilized retrovirus-derived ectopic expression of defined embryonic transcription factors (OCT4, 
SOX2, KLF4 and cMYC (Takahashi et al., 2007)) which was the favored reprogramming 
method at the start of this study. These viruses integrate into the host genome, and have the 
advantage of resulting in a high efficiency of reprogramming; most iPS lines created to date have 
been generated using this technology (Pietronave and Prat, 2012). Since then, new methods have 





delivery of these same factors but by nonviral methods, including nonepisomal plasmids, 
transposons, mRNA and direct protein delivery (Pietronave and Prat, 2012). Additionally, the 
microRNA cluster miR-302/367 has been shown to be sufficient to reprogram fibroblasts with 
high efficiency (Anokye-Danso et al., 2011; Subramanyam et al., 2011). This new strategy is 
faster and ~100-fold more efficient than conventional protocols, and does not require 
transcription factors or genomic integration (Pietronave and Prat, 2012). While iPSCs generated 
with classical viral reprogramming appear very similar to ESCs (Boulting et al., 2011), further 
characterization of the GAN phenotype may benefit from production of integration-free iPS 
lines.       
In conclusion, I have generated iPS lines from several patients with GAN and iPS lines 
were characterized for morphology, pluripotency, karyotype, and viral and pluripotency gene 
expression. iPSCs were differentiated into MNs, the key cell type affected in GAN. GAN iPSCs 
were able to make functional neurons and MNs with efficiencies comparable to control, but 
GAN iPS-MNs had significantly elevated levels of PRPH and NF-L. While my MS findings 
(described in Chapter 2) clearly link gigaxonin and IFs, the functional consequences of this 
interaction are an area of active investigation. The finding that levels of nIF are increased in the 
absence of an increase of transcription suggests that there is a degradation defect in GAN 
neurons; however, this remains to be shown. Potential functional phenotypes and disease 
mechanisms will be discussed in Chapter 6 and changes in nIF stoichiometry will be commented 
on in Chapter 7. 






Table 3.1. GAN patient demographics.  
FB sample  Gender  Age  Mutation (domain)  
1  F  8  Deletion exon 10/11 (Kelch/3’ UTR)  
2  F  19  S52G (BTB), C393X (Kelch)  
3  M  8  A49E (BTB)  
4  M  10  E486K (Kelch), microdeletion at 16q23.2  
5  M  12  Unidentified  
 
 
Table 3.1. GAN patient demographics. Demographics of patient fibroblast samples and 
summary of identified gigaxonin mutations. Fibroblast biopsies were collected by Drs. Wendy 
Chung at Columbia University, Rudy Van Coster at the University Hospital Ghent and Paul 
Maertens at the University of South Alabama. Mutations were sequenced by clinical providers 
and were collected as demographic information in accordance with the IRB. Lines generated 
from the patients shaded in grey met iPS quality control criteria (see text for details) and were 
included in the study. Throughout the text the line number refers to a unique GAN patient and 









Figure 3.2. Characterization of GAN patient iPS lines. Representative normal morphologies of 
(A) control iPSCs (line 18c from Boulting et al. (2011) used here and in all subsequent 
experiments as the control iPS line), and GAN2E, 3X, and 5L iPS lines (B-D, respectively). (E) 
Immunocytochemical analysis of pluripotent marker expression (TRA-1-60, OCT3/4 and 







































   
  
 
Figure 3.3. Levels of viral and pluripotency gene expression in GAN iPS lines measured by 
qRT-PCR. Viral levels (v) were normalized to HEK293 cells expressing the viruses 3 days post-
infection. Endogenous levels (e) were normalized to an embryonic stem cell line, HUES42. 
8064hFb is an uninfected control fibroblast line. The experiment was repeated twice with similar 










































































































         
Figure 3.4. Gigaxonin levels in GAN fibroblasts, iPSCs and MNs are severely reduced as 
compared with control. Gigaxonin levels in patient samples detected by Western blot of 
fibroblast (A), iPS cell line (B) and differentiated iPS-MN samples (C). GIG, gigaxonin; HISH3, 
histone H3 used as loading control. Control fibroblasts were from male (M) and female (F) 
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Figure 3.5 Generation of iPS-derived motor neurons from GAN patients. (A) Schematic of 
differentiation protocol used to make MNs. Differentiations are performed in suspension 
cultures, and the differentiating iPSCs spontaneously form balls of differentiating cells called 
embryoid bodies (EBs). SAG, smoothened agonist; PUR, purmorphamine. (B-I) After the 28 day 
differentiation period EBs were dissociated, plated and 3 days later fixed and stained for 
neuronal (MAP2, NF-H) and MN (ISL1, HB9) antigens. Scale bar represents 50 μM. (J) 
Quantification of the percentage of all cells (as labeled by DAPI) that express MAP2 or ISL1 
using MetaMorph image analysis software (> 675 cells were scored in three technical replicates 
from automatically-acquired images, n = 4-5 independent experiments). Plot represents the mean 
± SEM. All p values (Student’s t-test) are non-significant (p>0.05) for comparisons between 
patients and control. ISL1 was used for automated quantitation due to a higher signal-to-noise 







Figure 3.6. Calcium imaging of GAN and control neurons. Twelve days after dissociation 
cells were loaded with the calcium indicator Fluo-4 and images were acquired at approximately 2 
Hz. Ca
2+
 transients were determined from the soma of individual neurons (A), using raw pixel 
intensities. Scale bar represents 50 μM.  (B) Three representative tracings from GAN3X neurons. 
Clusters of neurons tended to fire in a synchronized manner. (C) From these individual tracings 
the frequency of spontaneous activity was determined for each neuron and plotted for multiple 
neurons per line. The horizontal blue bars represent the average of individual neurons. Control 1 
is the female line 18c; control 2 is the male line 11a and both are described in Boulting et al. 
(2011). p values were significant for control compared with GAN2E (p = 0.002) and control 2 









































































Figure 3.7. GAN motor neurons exhibit selectively elevated levels of IFs. (A-F) Accumulation 
of neuronal IFs, but not other cytoskeletal proteins, in patient-derived motor neurons. Levels of 
indicated nIF and non-nIF proteins were assessed by Western blot at day 40 (n = 3). (G-L) 
Quantification of Western blot data by densitometry confirmed that increases were reproducible 
and selective. Plots represent the mean ± SEM for three independent experiments. The change in 






























































































































































































































































Figure 3.8. GAN motor neurons have selectively elevated levels of peripherin. (A, B, D, E) 
Immunofluorescence analysis was carried out at 7 days post-dissociation in UFdU treated control 
and GAN2E cultures. Arrowheads indicate MNs (as identified by ISL1 staining, not shown) used 
in the quantification in (G) and (H). Scale bar, 50 µM. (C, F) GAN2E and control neurons were 
stained for peripherin 7 days post-dissociation and imaged using confocal microscopy. Scale bar, 
25 µM. (G, H) Peripherin and MAP2 intensity levels in the cell body region of individual control 
and GAN2E MNs (>55 per condition) were measured using MetaMorph and plotted as 
cumulative frequency of two independent experiments using the Kolmogorov-Smirnov 
nonparametric test. The p values are 0.6 for the data shown in (G) and <0.0001 for the data 








Figure 3.9. qPCR of IF and non-IF proteins in iPS-MNs. qPCR analysis was performed on 
control and GAN iPS-MN cultures. Samples (between 2 and 4 independent samples per line) 
were normalized to control. Expression ratios were generated using the REST (relative 
expression software tool) program, which uses a mathematical model based on the PCR 
efficiencies and the mean crossing point deviation between sample and control groups (Pfaffl et 
al., 2002). Subsequently, the expression ratios of the 8 investigated transcripts were tested for 
significance by a randomization test. By this test, all p values were non-significant (p>0.05) 






































Chapter 4. Viral and genetic rescue experiments in GAN iPS-derived motor neurons  
Introduction 
While iPS technology is a powerful tool, one of the major criticisms of the iPS field is the 
lack of isogenic controls in most studies. Even more than in animal studies, significant genetic 
differences may exist between patients and controls, leading to false conclusions regarding 
disease phenotypes. Only four of 15 iPS-neuron papers published to date have included isogenic 
controls (Table 1.13). Several more studies include pharmacologic rescue, but that still leaves 
open the possibility that different human lines may react differently to drugs depending on their 
unique gene expression profiles.   
Thus far, three approaches have been taken to create isogenic controls. The first is viral 
delivery of the missing gene to the differentiated cells. The second is nucleofection of the iPS 
lines to insert the missing or defective gene. The third takes advantage of genetic heterogeneity 
in certain diseases, such as differing CAAG repeat lengths in Huntington’s disease or mosaicism 
in Rett syndrome (Cheung et al., 2011; Zhang et al., 2010). While this last option is certainly 
appealing, it is not a viable option in most disease scenarios.  
In addition to serving as matched controls, viral delivery of genes to iPS cultures can also 
provide a model to test viral vectors for the eventual goal of gene therapy. iPSCs and ESCs are 
currently the only method to perform experiments on living human MNs. Whether similar tissue 
tropisms are maintained across different species is an active area of investigation (Asokan, 
2010). Therefore, the iPS/ES model system provides an important complement to animal models 






While gene therapy has applications in many systems, the CNS is a particularly attractive 
candidate for gene therapy given the long-term treatment that many CNS disorders require, as 
well as the difficulty of accessing the CNS with peripheral drugs. The gene transfer technology 
relies on the delivery of DNA to target cells and expression of the protein it encodes for 
therapeutic or protective purposes (Terzi and Zachariou, 2008). In cases where a causative gene 
has not been identified, gene therapy has been tried experimentally as a strategy for general 
neuroprotection, for example in the case of genetic delivery of neurotrophic factors (see Table 
5.3 for examples).  
In the case of GAN, all evidence suggests the disease results from a loss of functional 
gigaxonin. The disease is inherited in an autosomal recessive fashion and patients have severely 
reduced levels of gigaxonin protein (Cleveland et al., 2009). Since the pathophysiology of GAN 
remains unclear, it is tempting to consider gene replacement for patients while mechanistic 
studies are ongoing. Gene therapy is becoming a reality for monogenetic loss-of-function disease 
such as GAN; recently the disease process was halted in two patients with X-linked 
adrenoleukodystrophy (ALD) who were auto-infused with CD34
+
 cells genetically corrected ex 
vivo with a lentiviral vector (Cartier et al., 2009). This study represents the first time a severe 
neurodegenerative disease was treated successfully by gene therapy.    
Adeno-associated virus (AAV) has emerged as an attractive vector for more widespread 
gene therapy in the CNS, selected for its long-term gene expression, inability to autonomously 
replicate without a helper virus, transduction of dividing and non-dividing cells, and the lack of 
pathogenicity from wild-type infections (Grieger and Samulski, 2012). AAV serotypes and 
promoters have been compared in several studies for their ability to transduce neurons of the 





amino acid structure but the mechanism triggering distinct tropisms remain unknown. AAV2 has 
a strong neural tropism but limited spread. AAV1, 5 and 6 also transduce neurons. AAV8 and 9 
can be more efficient in transducing neurons after intravascular and/or intraventricular delivery 
in mice (Nizzardo et al., 2012). Aside from the innate tropism of the AAV serotype, the choice 
of promoter reflects a balance between the levels of expression required, the target cell type, and 
the size of the promoter that can be accommodated in the cassette.  
Given the recent experimental success with AAVs, here I focus on the specifics of their 
use in human clinical trials. The most widely used is the AAV2 serotype, which shows specific 
expression in neurons (Table 4.1) (Terzi and Zachariou, 2008). Approximately 80 AAV2clinical 
trials are currently open, have been completed or are in review (Grieger and Samulski, 2012), 
among them several trials for CNS disorders including age-related macular degeneration, 
Alzheimer’s, Parkinson’s, congenital blindness, Batten disease and Canavan disease. AAV1, 2 
and 5 have all been approved by the U.S. Food and Drug Administration for use in clinical trials 
(Nizzardo et al., 2012).  
In this chapter I describe three methods to determine the gigaxonin-dependence of the 
biochemical phenotypes described in Chapter 3. First, I use a lentivirus to provide proof-of-
concept evidence that gigaxonin replacement can reduce peripherin and NF-L levels. 
Lentiviruses were made by Alejandro Garcia Diaz. Second, I show similar preliminary results 
with a more clinically relevant vector, AAV9. AAVs were produced and titered by Steven Gray 
at the UNC gene therapy center. Last, I generate GAN iPS lines with stable expression of 
gigaxonin. All three rescue methods show that levels of peripherin and NF-L can be reduced by 
replacement of gigaxonin in GAN neurons, suggesting that the biochemical phenotypes observed 





controls. Importantly, overexpression of gigaxonin does not appear to be toxic to human neurons, 






Table 4.1. AAV-mediated gene delivery approaches for the treatment of CNS disorders. 
Serotype Relative 
expression* 
Cell types transduced Favored uses 
AAV1 ++ Striatal neurons (as well as some glia and ependymal cells) 




+ Neurons in the brain, retina and spinal cord (Burger et al., 
2004) 
Most clinical trials to date 
AAV4 + Ependymal cells (Davidson et al., 2000)  
AAV5 + Neurons and astrocytes (Davidson et al., 2000) Broad expression through CNS 
(Davidson et al., 2000) 
AAV6  Muscle (Grieger and Samulski, 2012) Broad neuromuscular transduction 
(Towne et al., 2008) 
AAV7 
 
+++ Muscle (Grieger and Samulski, 2012)  
AAV8 
 
+++ Neurons (Nizzardo et al., 2012) 
 
 
AAV9 +++ Neurons (Nizzardo et al., 2012) Neurons (pre and post-natal) and adult 
astrocytes in mice (Duque et al., 2009; 
Foust et al., 2009) 




+ Up to 1 yr (Tenenbaum et al., 2000) 
 




+++ Up to 25 months (Klein et al., 1997) 
 
Neurons and oligodendrocytes (Klein 




++ At least 12 weeks post injection (Kaplitt and During, 2005) Promoter activity in neurons varies 
significantly across different brain 











Table 4.1. AAV-mediated gene delivery approaches for the treatment of CNS disorders. 
Expression in specific cell types and duration may vary according to brain region. *Relative 
expression data is based on Zincarelli et al. (2008). In this study, luciferase transgene expression 
and biodistribution were compared for different AAV serotypes after tail vein injection into male 
mice. The CMV promoter was used. †Relative strength of expression data is based on a review 











The phenotype for GAN iPS-MNs described in Chapter 3 could reflect direct effects of 
the GAN mutation or, alternatively, unrelated inter-individual genetic differences between 
patients and control. I therefore asked whether the GAN phenotypes could be rescued by 
restoration of gigaxonin by viral replacement of gigaxonin after nIF accumulation, as well as 
prevention of nIF accumulation by restoration of gigaxonin in the GAN iPSCs before 
differentiation.  
We built lentiviral vectors expressing myc-GAN or GFP (as a control) under the control 
of the strong PGK promoter (Figure 4.2A). A woodchuck hepatitis virus element post-
transcriptional regulator (WPRE) was added downstream of the transgene as a way to stabilize 
gene expression (Terzi and Zachariou, 2008). Viruses were titered on NSC43 cells, a mouse 
MN-like cell line (Figure 4.2B). Four different volumes of each virus were added to the cells, 
and the number of myc or GFP positive cells were scored 4 days later by whole well imaging. 
The viral titer (TU/μL) is the slope of the resulting plot of μL of virus versus the total number of 
cells infected in the well. Based on the resulting titers, I subsequently added GFP and GAN virus 
at a ratio of 1:3.88.  
  These lentiviruses were used to infect GAN and control iPS-MN cultures (Figure 4.3). 
After differentiation, control and GAN2E MNs were dissociated and plated. Twelve days later 
they were infected with GFP or GAN expressing lentiviruses (Figure 4.3A-G). Seven days post-
infection, peripherin staining was reduced to control levels in GAN motor neurons infected with 
myc-GAN virus (Figure 4.3H). The reduction was observed selectively in those neurons that 





cytoskeletal proteins in the culture, cell extracts were analyzed by densitometry of Western blots 
in three independent experiments (Figure 4.3I). Peripherin levels in GAN cells were significantly 
reduced (2.9 ± 0.5-fold compared to GFP-infected cells; n = 3; mean ± SEM) whereas levels of 
tau were not significantly different (Figure 4.3I; 1.1 ± 0.2-fold). Overexpression of gigaxonin 
also reduced NF-L levels (Figure 4.3I; 1.89 ± 0.1-fold; mean ± range). This result appeared 
reproducible in two blots; a third blot did not give an NF-L signal after stripping. I also blotted 
for NF-M, but a signal could not be detected after stripping of the membrane. Thus, even when 
initiated at a time point at which nIF accumulation is already apparent (12 days post-
dissociation) overexpression of gigaxonin can fully rescue the patient-specific accumulation of 
peripherin and NF-L. 
Despite the high levels of gigaxonin generated by the strong PGK promoter, total 
numbers of peripherin-positive cells were indistinguishable in control and experimental 
conditions (Figure 4.4A), demonstrating that gigaxonin overexpression is not neurotoxic. 
Examples of GFP and myc staining are shown in Figure 4.4B. It was observed that despite the 
correction for the virus titer between the GFP and GAN viruses (Figure 4.2B), the GFP virus 
consistently infected more neurons, or at least produced more detectable staining (Figure 4.4C).  
In addition to using lentivirus as a proof of concept for viral rescue, I also wanted to 
determine if potentially clinically relevant viruses could also rescue the biochemical phenotype. 
In collaboration with Steven Gray at the UNC Gene Therapy Center I tested a variety of AAV 
serotypes and promoters on human iPS-MN cultures using a GFP transgene (Figure 4.5). Given 
that different serotypes and promoters have tendencies to transduce different cell types, I 
therefore looked at the total number of GFP
+
 cells, as well as the percentage of neurons (as 
indicated by TUJ1) and MN (HB9) that were GFP
+





percentage of all cells (~60%), and also performed the best in terms of selectivity for neurons 
and MNs (~45% and ~10% of all GFP
+
 cells were co-positive for TUJ1 and HB9, respectively).  
In parallel to my in vitro work, Steven Gray tested the same panel of viral vectors in 
mice. Because of his results as well as recent gene delivery success described in the work of 
Brian Kaspar and others (Foust et al., 2009; Samaranch et al., 2012), he selected AAV9 as the 
serotype of choice for optimization studies. One of the major disadvantages of using AAV as a 
vector is its limited packaging capacity (Grieger and Samulski, 2012). The vector cassette 
including the ITRs should not exceed 4.7-5.0 kb. While single stranded AAV (ssAAV) vectors 
can generally deliver 4.4 kb of unique transgene sequence, self-complementary AAV (scAAV) 
will be able to carry only half that because the unique transgene sequence is in duplex form in 
the scAAV genome. Although scAAVs reduce the vector space, they increase transduction rates 
by bypassing conversion of the single-stranded DNA vector genome in the double-stranded DNA 
prior to gene expression (Grieger and Samulski, 2012). These tight packaging limitations require 
optimization of the promoter, transcriptional and posttranscriptional regulatory elements, and 
codon optimization of the transgene sequence itself.  
To be able to package the myc-gigaxonin transgene in a scAAV, Steven Gray designed a 
small synthetic promoter (JET). In two independent experiments I was able to show that 
gigaxonin expression from AAV9-scJET reduces peripherin levels in GAN MN cultures (Figure 
4.6). Overexpression of GFP using the same virus did not reduce peripherin levels. However, I 
was unable to detect the Flag tag, either by WB or IF, although I was able to detect increased 
levels of gigaxonin expression in culture upon addition of increasing amounts of the virus. This 
may have been due to fusion of the Flag tag to gigaxonin, as well as general difficulty detecting 





The experiments so far used viral vectors that, although of relevance to gene therapy, are 
subject to batch-by-batch variation. Moreover, the PGK promoter using a lentivirus leads to 
levels of gigaxonin that are >15-fold above those of the endogenous protein. Therefore I wanted 
to confirm the rescue in a more physiologically relevant and less intrinsically variable context by 
using stable expression at lower levels. GAN iPSCs were nucleofected with a construct for 
expression of EF1α::FLAG-gigaxonin as well as puromycin resistance (Figure 4.7A). 
Approximately one week after nucleofection cultures were exposed to high doses of puromycin 
and about one week later resistant clones (20-25 per patient) were picked and expanded for test 
differentiations (Figure 4.7B).  
Differentiated clones were then screened for Flag expression by Western blot (Figure 
4.8A). Of the 70 or so clones picked, no positive clones were found for GAN2E; 3 clones 
expressed FLAG-gigaxonin on the GAN3X background and two on the GAN5L background. 
Individual clones are indicated by their clone number. For example, GAN3X is the parental line 
(“P”) and GAN3X cl.20 is the rescue line stably expressing gigaxonin. Clones positive on 
Western blot were then stained for the Flag antigen in dissociated cultures (Figure 4.8B). Of the 
5 clones positive on Western blots, only two of those had sufficient FLAG expression for 
detection by immunostaining. FLAG-GAN expression was confirmed in these positive clones 
using qPCR (Figure 4.8C).     
These positive clones express only very low levels of gigaxonin compared to control 
(Figure 4.9C).  However, even these levels were sufficient to reduce peripherin and NF-L levels 
compared to the parental line (Figure 4.9A, B; 2-3 independent differentiations for each clone). p 
< 0.05 for all GAN3X rescue clones compared to the parental line; for the GAN5L rescue lines 





neurons is remarkably sensitive to gigaxonin levels and can be reduced from pathological levels 
even using gigaxonin doses that are lower than normal controls. The level of gigaxonin 
expression in the GAN5L lines is not sufficient to significantly reduce peripherin and NF-L 
levels, suggesting that the critical level of gigaxonin necessary is closer to that found in the 
GAN3X rescue lines.   
Lastly, I wanted to confirm that the reduction in peripherin and NF-L levels observed in 
the rescued GAN lines was not simply due to the rescue lines producing fewer neurons as 
compared with the non-corrected parental lines. I therefore differentiated and dissociated MNs 
from each line, and stained for the neuronal marker MAP2 and the MN marker ISL1 (Figure 
4.10A). In 3-5 independent differentiations, the rescue clones did not display significant 
differences in their propensity to make neurons and MNs as compared with their parental lines 
(Figure 4.10B). Therefore replacement of gigaxonin, even at low levels, is sufficient to rescue 









 In this chapter I have provided evidence that the elevated levels of peripherin and NF-L 
observed in GAN iPS-MN cultures are directly tied to the loss of gigaxonin. I have demonstrated 
this using three methods: lentiviral rescue, AAV-mediated rescue and genetic rescue by 
nucleofection of gigaxonin into the GAN iPSCs.  
 Thorough pre-clinical testing is clearly an important step on the way to gene therapy in 
patients. Testing viral vectors on human iPS neurons in vitro - in addition to in vivo animal 
studies - provides valuable data for optimizing viral construct design and packaging. The 
lentiviral experiments provide useful proof-of-concept rescue, and it was reassuring that even 
high levels of gigaxonin overexpression do not result in neuronal toxicity. This was particularly 
important to demonstrate give that gigaxonin is thought to be involved in protein degradation 
pathways. While experiments with AAV9 scJET provide a more realistic framework for gene 
therapy, these experiments were limited by difficulties detecting FLAG expression on Western 
blots. Future studies should attempt to confirm expression by qPCR. Additionally, it would be of 
use to determine the dynamics of nIF accumulation and rescue in vitro. I have not examined nIF 
levels at multiple time points, so while we see rescue at 7 days, looking at levels before and after 
this time point could shed light on the kinetics of nIF accumulation and disappearance.  
Four out of five rescue lines generated by nucleofection had consistently reduced levels 
of peripherin and NF-L, despite relatively low levels of gigaxonin expression compared to a 
control line (Figure 4.9C). One GAN5L rescue line (clone 4) had significantly lower levels of 
peripherin, but NF-L did not appear reduced by stable expression of gigaxonin. This may be due 
to the differential regulation of NF-L by gigaxonin. However, these results in general suggest 





with the observed low levels of endogenous gigaxonin expression (Cleveland et al., 2009). Also 
in agreement with previous reports, I do not observe a strong correlation between gigaxonin 
levels and nIF levels (Cleveland et al., 2009).  
Recently novel technologies have emerged for more targeted genetic correction. Wood et 
al. (2011) describe two methods for targeted genome editing using site-specific nucleases. These 
engineered nucleases have fusions between the DNA cleavage domain of the restriction 
endonuclease FokI and a custom-designed DNA binding domain C2H2 zinc-finger motifs for 
zinc-finger nucleases (ZFNs) or transcription activator-like effector (TALE) domains for 
efficient TALE nucleases (TALENs) (Wood et al., 2011). ZFNs and TALENs induce double-
strand breaks at specified loci that can be repaired by insertions and deletions at the break sites. 
These techniques have been utilized to make hESC and iPSC reporter lines (Hockemeyer et al., 
2009; Hockemeyer et al., 2011). ZFNs have also been used to generate sets of isogenic disease 
and control human pluripotent stem cells that differ exclusively at either of two susceptibility 
variants for Parkinson's disease by modification of the underlying point mutations in the α-
synuclein gene (Soldner et al., 2011). The spread of this technology should make the generation 
of isogenic controls more widespread, at least for diseases caused by point mutations.  
In this chapter I described three methods to determine the gigaxonin-dependence of the 
biochemical phenotypes described in Chapter 3. All three rescue methods show that levels of 
peripherin and NF-L can be reduced by replacement of gigaxonin in GAN neurons, suggesting 
that the biochemical phenotypes observed are gigaxonin-dependent, rather than from genetic 
differences between patients and controls. These studies constitute the first in vitro data for the 









Figure 4.2. Lentiviral construct design and titer. (A) Schematic of lentiviruses constructed to 
express myc-GAN or CD2-GFP under the control of the ubiquitous PGK promoter. WPRE, 
woodchuck hepatitis posttranscriptional regulator element. (B) Lentiviruses were titered on 
NSC34 cells. 20,000 NSC43 cells were seeded in each well of a 96-well plate. 24 h later, cells 
were infected with GFP or GAN expressing lentiviruses. 4 d post-infection cells were fixed and 
stained for either GFP or the myc-tag and imaged for quantification. The viral titer (TU/μL) is 







y = 26941x + 6323.1
R² = 0.9516







































































































Figure 4.3. Gigaxonin overexpression rescues elevated peripherin levels in GAN iPS-MN 
cultures. (A) Experimental design. (B-G) Gigaxonin rescues peripherin accumulation. Day 40 
control and GAN iPS-MN cultures were infected with PGK::myc-GAN or PGK::CD2-GFP 
lentivirus. Seven to nine days post-infection, cultures were stained for viral markers (myc or 
GFP, respectively), peripherin (PRPH) and MAP2. Scale bar, 50 μM. (H) Peripherin staining 
intensity is reduced to control levels by GAN expression. Levels of PRPH were quantified in the 
cell body of virus-positive neurons (>30 per condition in two independent experiments). Y axis 
represents arbitrary units (a.u) of fluorescence intensity. p < 0.0001 for GAN2E + GFP as 
compared with the other three conditions. p = 0.69 for GAN2E + GAN versus Ctrl + GAN. (I) 
Levels of gigaxonin, nIF and non-nIF proteins were assessed using Western blotting (n = 3). 
Only peripherin and NF-L show significant changes in response to GAN virus; peripherin levels 
in GAN cells were reduced (2.9 ± 0.5-fold compared to GFP-infected cells; n = 3; mean ± SEM, 
p = 0.01) as well as NF-L levels (Figure 4.3I; 1.89 ± 0.1-fold; mean ± range, n = 2, p = 0.01). 
Levels of tau were not significantly different (1.1 ± 0.2-fold, p = 0.36). The HISH3 blot 







Figure 4.4. Gigaxonin overexpression is not toxic to neurons. (A) GAN overexpression has no 
effect on survival of peripherin
+
 cells at 7 days post-infection (mean ± S.D., n = 3 independent 
infections); p value between control conditions is 0.069; between GAN2E conditions p = 0.193 
(Kruskal-Wallis test). (B) Day 40 control and GAN iPS-MN cultures infected with the viruses 
(sample images from a GAN culture). Scale bar represents 50 μM. (C) The percentage of 
peripherin-positive cells infected was quantified after staining for GFP or myc (mean ± range of 
three technical replicates, at least 500 peripherin-positive cells were scored for each sample, 
reflecting a whole-well image acquired on the Trophos Platerunner). Despite being infected with 
the same number of transducing units per cell the percentage of GFP
+
 cells was consistently 
higher than myc
+



















































Figure 4.5. Testing of different AAV serotypes and promoters on motor neurons. (A) 
Several serotypes and promoters if AAVs expressing GFP were tested on human iP MNs. 32,000 
cells were seeded per well in 96-well plates. The same number of viral genomes (vg) were added 
to each well. vg/mL were determined by qPCR titer. Cells were fixed 4 d post-infection, and 
were stained for GFP as well as the neuronal marker TUJ1 and the MN marker HB9. Plot 
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Figure 4.6. Preliminary evidence for AAV9-GAN rescue of elevated peripherin levels in 
GAN iPS-MN cultures. Control (18c) and GAN2E d28 MNs were thawed and plated in 6-well 
plates (~300,000 cells/well). Cells were infected 12 d post-plating with two viral doses: 222,000 
vg/cell (++) or 22,200 vg/cell (+). Due to limitations on the number of cells an uninfected control 
was not included. Cells were collected and lysed for Western blot 7 d post-infection. Viral 
protein was detected using an antibody to gigaxonin (for GAN virus) or GFP (for GFP virus). 
GAN virus was not detectable by myc staining. Blot is representative of two independent 
experiments. Increasing doses of the gigaxonin-expressing virus reduced peripherin in a dose-
dependent manner in GAN cultures only. No reduction in peripherin levels were seen from 
















    
 
Figure 4.7. Strategy for making rescue GAN lines stably expressing gigaxonin. (A) Construct 
design. (B) Schematic of work flow for making lines. GAN iPS lines were nucleofected with 
EF1α::FLAG-GAN. Clones underwent puromycin selection. After screening the iPS clones for 
Flag expression, positive clones were differentiated into MNs. 
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Figure 4.8. Verification of FLAG-GAN-positive iPS clones. (A) WB for flag. “P” represents 
the parental GAN line, while the numbers indicate individual clones nucleofected and selected 
for EF1α::FLAG-GAN expression. (B) Flag staining, while weak, is visible in the cell bodies and 
neurites and co-localizes with NF-H. Individual clones are indicated by their clone number. For 
example, GAN3X is the parental line and GAN3X cl.20 is the rescue line stably expressing 
gigaxonin. Flag immunostaining was not visible for other clones identified as positive by WB. 
Scale bar, 50 μM. (C) qPCR was used to measure FLAG-GAN expression in rescue clones. 
Expression was normalized to the parental line. Shown for comparison are expression levels in 
HEK293 cells transfected with FLAG-GAN.  
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Figure 4.9. Genetic replacement of gigaxonin rescues elevated levels of peripherin and NF-
L. (A) Western blots from 2-3 independent experiments are quantified in (B). Outlined bars 
represent the mean ± SEM for three experiments; other bars represent the mean ± range for two 
experiments. The levels of peripherin and NF-L were measured in the parental lines (“P”) as well 
as clones stably expressing gigaxonin (indicated by their clone number). The signal intensity was 
measured and normalized to the parental line in (B); the red line indicates the intensity of the 
parental line. p < 0.05 for all GAN3X rescue clones compared to the parental line; for the 
GAN5L rescue lines these changes are not statistically significant.  (C) Levels of gigaxonin 
expression after nucleofection with FLAG-GAN compared with parental and control lines. 
Stable expression of gigaxonin is much lower than control levels but is still sufficient to reduce 
PRPH and NF-L levels in GAN MNs.    
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Figure 4.10. Differentiation efficiency of rescue lines. (A) Control, GAN and GAN rescue 
(GAN + GIG) iPS lines were differentiated into MNs and plated in 96-well plates. 3 d later 
cultures were fixed and stained for the neuronal marker MAP2 and the MN marker ISL1. Scale 
bar represents 50 μM. (B) Plot represents the mean ± SEM of 3-5 independent differentiations. p 
= 0.42 and 0.86 respectively for %ISL for GAN3X and GAN5L compared to their corresponding 
rescue lines. p = 0.23 and 0.060 respectively for %MAP2 for GAN3X and GAN5L compared to 
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Chapter 5. Survival studies on HBG1 ES- and GAN iPS-derived motor neurons  
Introduction 
 Autopsy studies on GAN patients reveal two key findings: accumulation of IFs likely 
causing MNs and sensory neurons dysfunction and chromatolysis and death of nerve cell bodies 
(Thomas et al., 1987). To determine if functional phenotypes such as cell death can be 
recapitulated in vitro it is essential to develop effective MN survival assays.  Such assays will be 
useful not only to further investigation of pathologic pathways engaged during neuronal 
degeneration in GAN but independently will guide discovery of drugs that might support MN 
survival.  Such drugs might slow down disease progression not only in GAN but also in other 
MN degenerative diseases. 
During embryonic development, approximately one half of the spinal motor neurons 
initially generated are lost (Yamamoto and Henderson, 1999). At the beginning of the 20
th
 
century, Viktor Hamburger and Rita Levi-Montalcini observed that when a limb in a developing 
chick embryo is removed the corresponding sensory and motor neurons become hypoplastic; 
conversely, when an additional limb is transplanted the innervating areas become hyperplastic 
(Hamburger, 1958). Experiments to find the muscle-derived factor followed. When small pieces 
of sarcoma were transplanted near chick embryo sympathetic ganglion there was an excessive 
outgrowth of nerve fibers from the ganglion (Levi-Montalcini et al., 1954). It was later 
discovered that the protein responsible for the effect is nerve growth factor (NGF). These 
observations led to the formation of the “neurotrophic hypothesis”, according to which neurons 





supply is limited, only a small portion of post-mitotic neurons in a population are able to obtain 
sufficient amounts and thus survive (Oppenheim et al., 1991).  
Since the discovery of NGF, several major neurotrophic factor families have been 
identified and characterized (Table 5.1). While the list continues to grow, the main neurotrophic 
factor families include the neurotrophins (NGF, BDNF, NT-3 and NT-4/5), the glial derived 
neurotrophic factor (GDNF) family, the insulin-like growth factor (IGF) family, the neuropoietic 
cytokines (e.g. ciliary neurotrophic factor; aka CNTF), and the fibroblast growth factors (e.g. 
bFGF). It is now known that in addition to their targets (whether neuronal or non-neuronal) 
neurons may also acquire neurotrophic factors in a paracrine fashion from neighboring cells or 
by autocrine signaling. Additionally, factors can be transported anterogradely or retrogradely 
from the periphery (Ekestern, 2004).  
Many of these neurotrophic factors have been shown to be active in preventing motor 
neuron death in vivo (either during programmed cell death, after axotomy, or in mouse models of 
motor neuron degeneration) and in vitro (Henderson et al., 1998). For example, CNTF supports 
the survival of motor neurons in chick embryos (Oppenheim et al., 1991), prevents the 
degeneration of motor neurons after axotomy in newborn rats (Sendtner et al., 1990) and in the 
progressive motor neuronopathy (pmn) mouse (Sendtner et al., 1992), and supports most 
embryonic chick spinal motor neurons in vitro (Arakawa et al., 1990). Importantly, no single 
trophic factor has been shown to be able to support all motor neurons for extended periods; 
combinations of factors are more efficient (Henderson et al., 1998). This indicates that motor 
neurons do not have homogeneous survival requirements. Moreover, some factors may act 
synergistically. For example, GDNF and CT-1 are members of distinct neurotrophic families, 





support motor neuron survival significantly more than either factor alone (Arce et al., 1998). As 
these factors promote survival through different pathways, it may be that the synergy occurs at 
the level of intracellular signaling.  
Neurotrophic factors act through binding to their receptors - in many cases tyrosine 
kinase receptors -  which transduce the signal to cytoplasmic and finally nuclear effector proteins 
(Frebel and Wiese, 2006). A key consequence of neurotrophic factor activation is the increased 
expression of intracellular proteins that protect against apoptotic death (Frebel and Wiese, 2006). 
Two signaling cascades triggered by neurotrophic factors important for the survival of neurons 
are the mitogen-activated protein (MAP) kinase pathway and the phosphoinositide-3-kinase 
(PI3K) pathway (Figure 5.2) (Pettmann and Henderson, 1998). An important task for both 
pathways is the phosphorylation of Bad (nonphosphorylated Bad can bind to the anti-apoptotic 
protein Bcl-x and inhibit its activity) (Pettmann and Henderson, 1998). The phosphorylation of 
Bad also prevents the release of cytochrome c from the mitochondria, inhibiting the activation of 
caspases through the apoptosome complex (Frebel and Wiese, 2006). Unless rescued by 
extracellular neurotrophic factors, embryonic neurons are programmed to die by an apoptotic 
pathway. Apoptosis following neurotrophic factor deprivation involves mitochondrial release of 
cytochrome c into the cytosol which initiates the caspase cascade (Benn and Woolf, 2004).  
Neurotrophic factors have been shown to play important roles beyond embryonic 
development in both the healthy and diseased adult CNS. For example, BDNF is necessary for 
normal striatal neuron dendrite morphology during the period when BDNF levels peak in the 
cortex (at ~P30 in mice) (Baquet et al., 2004). Neurotrophins also play a role in the adult in 
hippocampal plasticity and exercise-induced neuroprotection (Hennigan et al., 2007). Moreover, 





role for them in disease pathology and possibly regeneration. Infants with spinal muscular 
atrophy (SMA) have elevated CSF levels of GDNF (Chiaretti et al., 2009), and patients with 
another motor neuron disease, amyotrophic lateral sclerosis (ALS), have multiple changes in the 
expression of neurotrophic factors and their receptors (Rabin et al., 2009). Moreover, there are 
several reports of neurotrophic factor polymorphisms playing a role as ALS disease modifiers 
(Giess et al., 2002; Lambrechts et al., 2003). While a deficiency of neurotrophic factors is almost 
certainly not the underlying cause of motor neuron disease, neurotrophic factors may be able to 
act as disease modifiers in SMA and ALS until we understand the disease pathophysiology 
better. Several studies reported that neurotrophic factors are beneficial in treating animal models 
of ALS and SMA (Table 5.3). Although pre-clinical data appear promising, no neurotrophic 
factors have succeeded in a clinical phase III trial to date (Henriques et al., 2010). While delivery 
problems may account for this discrepancy, studying human motor neurons directly may give us 
insight into their most important survival pathways.  
 In this chapter I describe work towards developing a survival assay for human ES-MNs. 
A major challenge to progress is the fact that MNs continue to be born even after the end of the 
differentiation protocol. In collaboration with Nuno Lamas, another graduate student, we 
undertook two strategies to get around this limitation: treatment of cultures with anti-mitotics as 
well as FACS purification of differentiated motor neurons. All the data presented here was 
generated independently. I first show optimization of the survival assay media in the presence of 
UFdU to generate a survival assay with a 5-fold difference between the positive control (PC, 
consisting of a cocktail of neurotrophic factors) and the negative control (NC). I extended this 
assay to GAN MN cultures but did not find a survival difference compared with control MNs 












Table 5.1 Neurotrophic factor families and the major members. 
Classification  Factor  Receptor(s)  
Neurotrophins  Brain-derived neurotrophic factor (BDNF) trkB, p75
 NTR
  
Neurotrophin-3 (NT-3) trkC, trkA, trkB, p75
 NTR
  
Neurotrophin-4/5 (NT-4/5) trkB, trkC, p75
 NTR
  





Ciliary neurotrophic factor (CNTF) CNTF-Rα, LIFRβ, gp130 
Leukemia inhibitory factor (LIF) LIFRβ, gp130 
Cardiotrophin-1 (CT-1) LIFRβ, gp130 
TGFβ family  Glial cell-derived neurotrophic factor (GDNF) GFR-α1 (preferred), GFR-α2, GFR-α3, Ret  
Neurturin (NRTN) GFR-α1, GFR-α2 (preferred), Ret  
TGFβ2  TGFβR  
IGF family Insulin-like growth factor-1 (IGF-1) IGF-R1 
FGF family Fibroblast growth factor (FGF) FGF-R 
Scatter factor Hepatocyte growth factor (HGF) c-met 






Table 5.1. Neurotrophic factor families and the major members. Neurotrophic factors are a 
large class of molecules that can influence neuronal survival, function and axonal growth. They 








Figure 5.2. Trophic factor receptor signaling promotes cell survival. Adapted from Frebel 
and Wiese (2006) and Pettmann and Henderson (1998). Neurotrophic factors act through binding 
to their specific receptors, which transduce the signal to cytoplasmic and finally nuclear effector 
proteins. Two important downstream signaling cascades triggered by neurotrophic factors 
include the mitogen-activated protein (MAP) kinase pathway and the phosphoinositide-3-kinase 
(PI3K) pathway. An important task for both pathways is the phosphorylation of Bad which 
inhibits Bcl-x and prevents the release of cytochrome c from the mitochondria and thus the 
activation of caspases and cell death pathways.  
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Table 5.3 Neurotrophic factors as modifiers for motor neuron disease.  
Factor Mouse  Delivery  Start  Onset change (%)  Survival change (%)  Reference  




KO  --  ↓ (reduced 
sprouting and 
strength)  
ND  Simon, 2010  (Simon et al., 2009) 
LIF  SOD1G93A  IP (25 μg/kd/d)  d60  ↑  NS  (Azari et al., 2003) 




IM AV  neonate  ND  ↑ (33) (Lesbordes et al., 2003) 
GDNF  SOD1G93A  IM AV  d5-7  ↑ (7) ↑ (12) (Acsadi et al., 2002) 
IM AAV  d63  ↑ (13) ↑ (14) (Wang et al., 2002) 
Myo-GFP  --  ↑ (15)  ↑ (15)   (Li et al., 2007) 
GFAP-GDNF  --  NS  NS  (Li et al., 2007) 
TGFβ2  SOD1G93A  IP, 3x/wk, 2 μg  d84 ↑ ND (Day et al., 2005) 
IGF-1  SOD1G93A  IS (continuous, 
0.1, 1 mg/kg)  
d140  ↑ (10, 15)  ↑ (8, 11)  (Nagano et al., 2005) 
MLC-IGF-1  --  ↑ (9)  ↑ (24)  (Dobrowolny et al., 2005) 
IGF OE  --  ND  NS  (Messi et al., 2007) 
SMAΔ7  ICV injection 
along with trans-
splicing vector  
d2  ND  ↑ (greater than trans-
splicing vector alone)  
(Shababi et al., 2011) 
FGF  SOD1G93A  IP, 2x/wk (15-500 
μg/kg)  
d30  NS  NS  (Upton-Rice et al., 1999) 
HGF  SOD1G93A  NSE-HGF  --  ↑ (12)  ↑ (11)  (Sun et al., 2002) 
VEGF  SOD1G93A  IP, 1x/wk, 1 
μg/kg  
d74  ↑ (10)  ↑ (8)  (Zheng et al., 2004) 
IP, 3x/wk, 1, 8 
μg/kg  
d78  NS  NS  (Zheng et al., 2007) 
EIAV-VEGF D90  ND  ↑ (15) (Azzouz et al., 2004) 
NSE-VEGF  --  ↑  ↑ (17) (Wang et al., 2007) 






Table 5.3. Neurotrophic factors as modifiers of motor neuron disease. Several studies have 
shown that neurotrophic factors are beneficial in treating animal models of ALS and SMA, 
improving survival and delaying disease onset in a variety of disease models through several 
delivery methods. KO, knockout; IP, intraperitoneal injection; IM intramuscular injection; AV, 








 In order to facilitate a live cell readout, I used an hESC reporter line in which GFP is 
under the control of the murine Hb9 promoter, termed the HBG1 line (Di Giorgio et al., 2008). 
Differentiated cells were stained for both GFP and HB9 to validate that the transgenic line is 
accurately reporting HB9 transcription, and thus MNs (Figure 5.4D). ~70% of GFP
+
 cells were 
co-positive for HB9, suggesting that the reporter has relatively high fidelity. Conversely, ~85% 
of HB9
+
 cells were co-positive for GFP, giving us confidence that the reporter is sampling a 
majority of MNs.   
As described above, numerous neurotrophic factors have been reported to support the 
survival of rodent and chick motor neurons. However, such detailed studies have not yet been 
conducted on human motor neurons.  For screening purposes, it is necessary to have a positive 
control (PC) that reliably supports motor neuron survival. I focused on members of the main 
neurotrophic factor families in order to efficiently determine an appropriate positive control. In 
preliminary studies, the factors in the PC included 10 ng/mL each of BDNF, CNTF, GDNF and 
IGF-1 (Figure 5.4A). In addition, 10 μM forskolin (an activator of adenylyl cyclase) was 
included in the positive control as cAMP elevation has also been shown to promote motor 
neuron survival (Hanson et al., 1998). The negative control (NC) was the basal media without 
trophic factors or forskolin. HBG1 MNs were plated in these two conditions and survival 
followed over 15 days by live imaging. By day 3 there was a small but measurable reduction in 
survival in the NC condition; this was amplified by day 9. However, when cultures were 
continued to be monitored I observed a striking increase in the number of GFP
+
 cells after day 9 





This finding suggested the occurrence of ongoing neurogenesis in the cultures. Indeed, 
BrdU studies revealed that at any given time ~75% of GFP
+
 MNs in the culture are newly born 
(Nuno Lamas, unpublished data). The newborn MNs presumable arise from undifferentiated 
precursors remaining at the end of the differentiation; as the differentiation efficiency is close to 
30%, any undifferentiated precursors remaining could confound the assay results by 
differentiating into MNs.  
To eliminate this confound, two strategies were employed. One strategy was to prevent 
the generation of new MNs by treatment with the anti-mitotics uridine and 5-fluoro-2-
deoxyuridine (UFdU, Figure 5.4B) (Giller et al., 1973; Wood, 1976). Since neurons are post-
mitotic these compounds are not expected to be directly toxic to them; this was confirmed 
empirically; a titration suggested no difference in survival between MNs treated with 0, 1, 5 and 
10 μM UFdU (thereafter 5 μM UFdU was used for all assays). UFdU treatment revealed a small 
but reproducible difference between the PC and NC at days 5, 7 and 9 (1.6-fold difference 
between the PC and NC at day 7), and importantly, no increase in MN counts at later time points. 
Figure 5.4B shows a representative plot.     
 The second strategy was to use FACS to isolate the differentiated MNs; MN precursors 
and other undifferentiated cells to not express GFP. This strategy also revealed a 1.35 ± 0.19-fold 
effect of NTFs on MN survival (mean ± standard deviation between the PC and NC, n = 7 
independent experiments; Figure 5.4C shows a representative plot). This approach was further 
optimized in the thesis work of Nuno Lamas and will not be described further here.  
While encouraging, these experiments suggested only a small survival effect of NTFs in 





greater dynamic range in survival in the PC and NC conditions. Seeing that I was already using a 
cocktail of 5 supportive factors in the PC, I focused on removing supportive factors from the 
basal media to accentuate the effects of defined survival factors. In the previous experiments the 
basal media consisted of Neurobasal (NB) media supplemented with B-27, N2, glutamine, 
glutamate, ascorbic acid and β–mercaptoethanol (BME). I tested the effect on survival of the 
most supportive components – NB, B-27 and N2 (see below for a discussion of their 
composition) – as well as trying the addition of two other NTFs to the PC to optimize the ratio 
between the PC and NC for survival studies.  
Experiments done to optimize the survival assay were monitored by live, whole-well 
imaging on days 0, 1, and 5 using the Trophos Platerunner (Bordet et al., 2007). Early time 
points were included for normalization purposes. Preliminary experiments showed that day 5 is 
an ideal time point to make a survival readout because the difference between the PC and NC is 
largest at that point. Since the media is not changed during the duration of the assay, neurons in 
the positive control begin to die at a greater rate after day 5, presumably due to depletion of the 
neurotrophic factors. Images were analyzed using the Metamorph Neurite Outgrowth 
Application module, and only GFP
+
 motor neurons with total outgrowth longer than 8 cell body 
diameters were scored to eliminate the scoring of debris as cells.  
Figure 5.5 shows representative experiments from these optimization studies. In Figure 
5.5A and B I compared survival in NB media to that in M199 media, a less supportive media 
commonly used in screening (Mullenders et al., 2009). NB media contains ~38 supplements and 
must be custom made to remove phenol red (a pH indicator present in the media) for live 
fluorescence imaging. M199 is a much less expensive and simpler media. I did not observe 





going forward to optimize the media (Figure 5.5A). Similarly, the addition of additional NTFs to 
the PC (“modified NTFs” included the addition of FGF2 and NT3) did not confer a survival 
benefit (Figure 5.5A, B).  
I then focused on the additional basal media supplements N2 and B-27 (Figure 5.5C, D). 
N2 contains insulin, progesterone, putrescine, transferrin and sodium selenite. B-27 contains 
more components and is a mixture of amino acids, vitamins, hormones and antioxidants, among 
other ingredients. I reasoned that these factors might be so supportive as to minimize the effect 
of the NTFs. I also looked at the effects of B-27 without antioxidants (B27-AO) as well as the 
antioxidants ascorbic acid and BME. As shown in Figure 5.5D, I was able to achieve the largest 
(~5-fold) difference between the PC and NC when B-27 and N2 were removed from the media.  
As such, going forward I used M199 as a basal media, and supplemented with as few 
other components as possible to 1) reduce variability between experiments and 2) achieve the 
largest difference between the survival in the positive and negative controls. Consequently, 
M199 was supplemented with glutamine, glutamate, UFdU, penicillin, and streptomycin. Cells 
were scored using whole-well imaging followed by neurite tracing (Figure 5.6A, B). Data from 
preliminary experiments were used to calculate a p-value and perform a prospective power 
analysis. Experiments (n = 3) show that this combination improves survival by ~4.7 fold over the 
negative control (Figure 5.6C-G; PC survival is 52.7 ± 9.52 cells, NC is 11.3 ± 7.98 cells, mean 
± S.D.; p = 0.03). In the positive control approximately 75% of the cells scored on day 1 survive 
to day 5; in the negative control less than 20% of cells survive as measured on day 5. A power 
analysis was conducted to calculate the probability that there is a statistically significant 
difference between the positive and negative controls, as a function of the size of the true 





sufficient considering that 0.80 is usually considered adequate power (Rosner, 1999). However, 
the cumulative Z-factor is weak (-0.25) due to variability in the Z-factor across the three 
experiments (0.34, 0.43 and -0.43 respectively; Z-factors between 0-0.5 are considered to be 
borderline in their significance, while 0.5-1 is considered to be excellent).  
An important feature of a survival assay to be used for a screen is that the effect of 
individual supportive factors be observable. Thus I looked at the effect of individual factors to 
see if my assay allowed for this, and additionally used this as opportunity to titer some of the 
NTFs used in the PC cocktail (Figure 5.7). Indeed I was able to see the effect of BDNF, GDNF 
and NT3 individually (survival in the NC condition is ~10 cells across experiments) and this 
survival increase was further increased by the presence of FGF2. In the case of GDNF the 
addition of FGF2 appeared additive, suggesting that these factors act through the same signaling 
pathways (Figure 5.7B). In the case of NT3 the addition of FGF2 resulted in a survival curve that 
appeared typical for a synergistic pair, suggesting that they are through different signaling 
pathways (Figure 5.7C, D).  
I next wanted to determine if GAN iPS-MNs display any survival vulnerabilities. Few 
autopsies have been performed on GAN patients, but one autopsy showed a loss of cell bodies on 
the ventral horn of the cervical and lumbar spinal cord, suggesting that MNs die in the disease 
pathology (Peiffer et al., 1977). To do so I adapted the survival assay described above to 
compare survival between GAN and control iPS-MN cultures. In preliminary experiments with 
the survival media used for HBG1 ES-MNs survival in both conditions was too low, so I used a 
more supportive media, consisting of NDM, N2, B-27, BME and AA, as well as NTFs. In these 
conditions, I did not observe a difference in neuronal survival (as indicated by NF-H
+
 cells) 





Before pursuing optimization of these experiments, I needed a robust way to identify 
MNs over longer periods in culture. Survival assays in ES-MNs have been greatly facilitated by 
the Hb9::GFP HBG1 reporter line. The reporter allows for live scoring of MNs throughout the 
duration of the assay, even at later time points when HB9 expression may be downregulated and 
difficult to detect by immunofluorescence. Thus to aid in looking for a GAN survival phenotype, 
I sought to make GAN iPS lines with the Hb9::GFP reporter (Figure 5.9). I nucleofected three 
GAN lines with the Hb9::GFP reporter that additionally contained a neomycin resistance cassette 
(Figure 5.9A). After neomycin selection of several days, 24 resistant clones were picked per 
patient. These were differentiated into MNs in 96-well plates for screening purposes. Positive 
clones (Figure 5.9B) were then expanded and differentiated in a larger scale and stained for GFP 
as well as the pan-MN markers Islet and HB9. (Figure 5.9C-E). Cultures were then scored for the 
overlap between GFP and pan-MN markers. While I obtained several GFP
+
 clones for each 
patient, none displayed acceptable selectivity comparable to that of the HBG1 reporter line. 
Quantification of the best reporter line generated is shown in Figure 5.9F; in general ~45-60% of 
GFP
+
 cells co-stain for HB9 or Islet and a wide range - ~5-60% of pan-MN
+
 cells - stain for 
GFP. One line (GAN5L cl.7) had decent overlap between GFP and MN markers (~60%) but the 
number of GFP
+
 cells as a percentage of DAPI was very low. Given the relatively poor overlap 
between GFP and MN markers and low GFP counts overall, these new lines were not acceptable 







 In this study I performed a series of optimization studies as a first step toward the 
development of a survival assay using human MNs. The first challenge was to prevent the 
generation of new MNs, accomplished either by FACS purification of differentiated GFP
+
 MNs 
or treatment of cultures with the anti-mitotic UFdU. The second challenge was to then determine 
media conditions that would allow us to see the greatest effect of NTFs on survival. I was able to 
generate a reproducible survival assay which yielded a PC/NC ratio of ~5-fold. This assay allows 
us to see the survival effect of individual NTFs, and efforts are underway to extend the assay to 
look for a survival phenotype in GAN iPS-MNs.   
 Although the UFdU-based survival assay has the benefits of being simple to set-up and 
cost effective, it does have some drawbacks. The most important of these is the low cell counts 
of surviving cells with significant outgrowth in both the PC and NC conditions. These low 
counts hurt the robustness of the assay and larger numbers would improve the Z-factor of the 
assay. Unfortunately, the seeding density cannot simply be increased – doubling of the seeding 
density results in clumping of cells which causes difficulty in cell scoring. Another possibility 
that could cause lower cell counts is that over time GFP is downregulated, which could result in 
surviving cells not being scored. Calcein, a fluorescent dye taken up by live cells is used on 
FACS-purified cultures to increase the signal intensity of surviving cells. This would be difficult 
to apply to unpurified cultures, however, because all living cells would take up the dye, making 
the identification of MNs impossible. Thus until a way to increase cell counts – either by 
improved visualization or overall survival - is found the UFdU-based assay has limited 
application. However, the optimization studies I performed on UFdU-treated cultures should be 





 These studies were greatly facilitated by the establishment of a human ESC Hb9::GFP 
reporter line. Reporters allow for a simple, live cell readout, which makes using them for screens 
preferable to antibody staining. However, the GFP signal can diminish over time in culture, and I 
and others have found that the live stain calcein is a useful tool to boost the signal to noise ratio 
to visualize neurites in FACS sorted cultures. Efforts to make iPS control and ALS reporter lines 
are underway, and will be a valuable tool for screening. As evidenced by the difficulty I had 
making GAN reporters, this process can be challenging and positive clones may not provide the 
specificity needed to be bona fide MN reporters.   
A potential drawback of using embryonic motor neurons for screening is that the survival 
requirements of embryonic motor neurons are likely to be different than those of the adult (Benn 
and Woolf, 2004; Ebert and Svendsen). However, embryonic stem cell-derived motor neurons 
represent a renewable supply of human motor neurons from which we can begin to gain insight 
into the trophic requirements of human motor neurons. Moreover, there is evidence to suggest 
that neurotrophic factors play important roles even in adult animals (see above) Additionally, 
Fas-triggered death pathways specific to embryonic MNs have been shown to be predictive of 
vulnerabilities in MNs from adult SOD1 mice (Raoul et al., 2002). There is also evidence to 
suggest that MN disease may involve non-cell-autonomous processes (Marchetto et al., 2008; 
Nagai et al., 2007). Screening on human astrocytes, microglia or other cells had long been 
unfeasible given the long duration of differentiation protocols as well as challenges in purifying 
specific cell types; however, recent work suggests that screens utilizing stem cell-derived MNs 
and astrocytes are now within reach (Hoing et al., 2012). Screening on human MNs – in the 
presence or absence of support cells - may be a way to accelerate translation from pre-clinical 





 In summary, I have described two strategies taken towards developing a survival assay 
for human ES-MNs: treatment of cultures with anti-mitotics as well as FACS purification of 
differentiated motor neurons. I first showed optimization of the survival assay media in the 
presence of UFdU to generate a survival assay with a 5-fold difference between the positive and 
negative control. This assay was extended to GAN iPS-MN cultures but I did not find a survival 
difference in the number of neurons compared with control under supportive growth conditions. 
To improve this assay and make it more specific for MNs, I attempted to make GAN HB9::GFP 
reporters. Unfortunately these reporters did not have sufficient specificity for MNs. Further 















































































































































Figure 5.4. Two approaches to a human MN survival assay. (A, B) Day 28 Hb9::GFP (HBG1) 
hESC-MNs were seeded at 10,000 cells/well in 96-well plates. Cells were seeded in the presence 
or absence of trophic factors. Survival was monitored by imaging every other day for 15 days. 
Twelve 10X images were taken for scoring per well and plots represent the mean ± S.D. of three 
technical replicates. Surviving cells were scored in the absence (A) or presence (B) of 5 μm 
UFdU. (C) Hb9::GFP (HBG1) MNs were FACS sorted and plated at a density of 1,250 
cells/well. Cells were seeded, monitored and scored in the same manner as in (A, B). UFdU 
treatment (B) and FACS sorting (C) eliminate the neurogenesis seen in (A). A small effect of 
NTFs is seen in both conditions. (D) HBG1 MNs were fixed and stained 3 days after the end of 



























































































































































Figure 5.5. Optimization of survival assay media. All optimization experiments were 
performed on day 28 HBG1 MNs seeded at 10,000 cells/well with 5 μM UFdU in 96-well plates. 
Survival was monitored at day 5 using whole-well live cell imaging on the Trophos Platerunner. 
Cells were only scored if they had neurites greater than 8 cell body widths (~200 μm) in length. 
The effect on MN survival of Neurobasal (NB) and M199 was tested. NTFs include BDNF, 
CNTF, GDNF and IGF1, as well as forskolin. Modified NTFs include these as well as NT3 and 
FGF2. Plots represent the total number of MNs with significant outgrowth (A; mean ± S.D. of 
four technical replicates) as well as the fold change to show the effect of NTFs in different media 
combinations (B). M199 is not significantly different from NB. (C,D) The effect on MN survival 
of N2, B-27, B27-AO (B27 without antioxidants), AA (ascorbic acid) and BME (β-
mercaptoethanol) was tested using M199 as the basal media. Plots represent the total number of 
MNs with significant outgrowth (C; mean ± S.D. of four technical replicates) as well as the fold 
change to show the effect of NTFs in different media combinations (D). For all conditions 
supplemented with NTFs in (C) p < 0.01 as compared with their basal matched conditions. The 








Figure 5.6. UFdU survival assay is reproducible and gives a ~5-fold difference between the 
NTF and basal condition. HBG1 MNs were imaged live on day 5 (A) and scored using the 
MetaMorph Neurite Outgrowth module (B). Scale bar, 50 μM. Cells were only scored if they 
had neurites greater than 8 cell body widths (~200 μm) in length. Whole wells were imaged on 
the Trophos Platerunner (C-F) for scoring. Scale bar represents 200 μm, the cell outgrowth 
scoring criteria. (G) Plot represents the mean ± S.D. of three independent experiments (p = 0.03).   
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Figure 5.7. Individual neurotrophic factor titrations. HBG1 MNs were fixed on day 5 and 
stained for GFP for scoring. Plots represent the mean ± S.D. of three technical replicates. 
Survival was measured in the presence of an individual neurotrophic factor and forskolin (Forsk) 
as well as in addition to FGF2. B, BDNF in (A); G, GDNF in (B); NT3 in (C). The plot in (D) 
represents the difference in the survival in the presence and absence of the combination of 
forskolin, FGF2 and another individual neurotrophic factor. The maximum concentration tested 
was 100 ng/mL for GDNF and NT3 and 20 ng/mL for BDNF. FGF2 supplementation has little 
effect on survival with BDNF, but some positive effect with GDNF and a striking positive effect 






Figure 5.8. GAN neurons do not display reduced survival. Day 28 control (18c) and GAN2E 
iPS-MNs were seeded at a density of 10,000 cells/well with 5 μM UFdU in media (NDM, N2, B-
27, BME and AA, as well as NTFs). Cells were fixed on day 1 and 7 and stained for NF-H. 
Plates were imaged using the Trophos Platerunner and cells were only scored if they had neurites 
greater than 8 cell body widths (~200 μm) in length. (A) Total number of neurons with 
significant outgrowth. Plot represents the mean ± S.D. of four technical replicates. Similar results 
were found in an independent experiment. (B) Cells with significant outgrowth on day 7 
normalized to day 1 counts. On day 1, cells were counted if they had outgrowths greater than 2 
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Figure 5.9. GAN Hb9::GFP reporters. GAN iPS lines (one per patient) were nucleofected with 
a plasmid (A) containing enhanced GFP (eGFP, under the control of the mouse Hb9 promoter)) 
as well as a neomycin resistance cassette (Neo, under the control of the ubiquitous human PGK 
promoter). After several days of high dose neomycin selection, resistant clones (~24 per patient) 
were selected for expansion and differentiation in 96-well plates. Positive clones (B) were 
selected based on GFP expression at day 28 and expanded for larger scale differentiations. Scale 
bar, 50 μM. (C-E) Sample images from larger-scale differentiations fixed and stained for GFP 
and the MN markers HB9/ISL 3 days after the 28 day differentiation protocol. (F) Cells were 
scored for expression of GFP and HB9/ISL and overlap of the markers was compared. Plot 
represents the mean ± S.D. of six technical replicates. One line (GAN5L cl.7) did better than 






Chapter 6. Preliminary studies on novel binding partners and functions of gigaxonin  
Introduction 
 The biochemical phenotype described in the GAN iPS-MN model raises two questions, 
relevant to both the pathophysiology of GAN. First, how are IFs normally degraded in human 
MNs? Second, how does nIF accumulation lead to neuronal dysfunction? In this chapter I 
provide preliminary data attempting to address these outstanding questions.   
 Previous studies have found that in postnatal animals nIFs have half-lives on the order of 
three weeks (Millecamps et al., 2007; Nixon and Logvinenko, 1986). There is some evidence 
that nIFs are tagged by ubiquitin and degraded by the proteasome. For example Jaitovich et al. 
(2008) found that ubiquitin was covalently associated with GFP-keratin immunoprecipitated 
from shear-stressed human A549 cells and pretreatment with the proteasomal inhibitor MG132 
prevented degradation of the keratin IF network. Under unstressed conditions GFP-keratin was 
not associated with ubiquitin. Additionally, deficiency of the E3 ligase TRIM2 results in 
accumulation of NF-L in the axons of null mice and NF-L filled axonal swellings in the 
cerebellum, retina, spinal cord and cerebral cortex (Balastik et al., 2008). By overexpressing 
tagged forms of NF-L, ubiquitin and TRIM2, TRIM2 coexpression leads to a significant increase 
in NF-L ubiquitination in the presence of MG132.  
 These studies are suggestive, but it remains to be demonstrated that endogenous nIFs can 
be ubiquitinated. Moreover, although both of the previously mentioned studies utilize the 
proteasome inhibitor MG132 they do not compare it to other inhibitors of degradation to 
determine the contribution that the proteasome plays in the potential degradation of nIFs. No 





degradation of nIFs, although there is some evidence that IFs may be important for the 
sequestration of proteins targeted for autophagy (Doherty et al., 1987; Earl et al., 1987). Further 
experimental data is needed to better understand the pathway(s) by which nIFs are degraded, and 
to date, no studies have been performed on endogenous nIF turnover in human tissue.   
 Turning to the second question, there is some data to suggest that elevated levels of nIFs 
can cause neuropathy in their own right. Intranuclear injection of the peripherin gene induces 
death of cultured mouse MNs (Robertson et al., 2001). Sustained overexpression of peripherin in 
mice results in a 35% loss of L5 motor axons during aging (Beaulieu et al., 1999a). 
Overexpression of NF-H results in dose-dependent increases in perikaryal NF accumulation as 
well as decreases in radial growth in wild-type mice. (Marszalek et al., 1996).  Moreover, 
peripherin is a component of inclusion bodies found in ALS patients and rare mutations have 
been found in the peripherin gene in ALS patients (Corrado et al., 2011); one mutant form of 
peripherin found in patients was demonstrated to be prone to forming aggregates, indicating that 
the mutation adversely affects peripherin assembly (Leung et al., 2004). On the one hand, 
peripherin overexpression has been shown to slow axonal transport of NF proteins, suggesting a 
mechanisms by which high levels of peripherin may cause axonal death (Millecamps et al., 
2006). However, overexpression of NF-M was observed to accelerate axonal transport of 
neurofilaments in the L5 lumbar motor root and sciatic nerve (Xu and Tung, 2000), and how 
dysregulated levels of the NF triplet proteins may lead to axonal dysfunction remains unclear.      
  There is also some evidence to suggest that elevated levels of nIFs may cause increased 
vulnerability to stressors. The death of cultured MNs overexpressing peripherin could be rescued 
by the addition of TNF-α-neutralizing antibody, suggesting that these cells are triggered to die by 





isoform-specific expression and ratio changes in peripherin in a neuroblastoma cell line (McLean 
and Robertson, 2011), suggesting that stressors can affect peripherin levels which in turn may 
affect cellular health. Ratio changes in the expression of different isoforms of peripherin can also 
be seen in models of traumatic neuronal injury as well as ALS (McLean et al., 2010) indicating 
that they may be indicative of a pathological state.     
 In this study I investigate the pathways by which nIFs are normally turned over in iPS/ES 
MN cultures. I show that peripherin is predominantly degraded by the lysosome, whereas NF-L 
is degraded by both the proteasome and lysosome. In support of lysosomal degradation of NF-L, 
I show that NF-L appears to be monoubiquitinated under normal conditions. Additionally, I 
show  preliminary evidence for an interaction between gigaxonin and p62/SQSTM1, a central 
molecule involved in the autophagic clearance of ubiquitin aggregates (Fan et al., 2010). I then 
explore other potential binding partners of gigaxonin, including the chaperone HSP90. I examine 
the negative effects of elevated levels of nIFs by testing a variety of stressors on GAN and 
control MNs and looking for survival vulnerabilities. I show that GAN neurons have increased 
sensitivity to oxidative stress, but not to TNF-α (tumor necrosis factor-α) or CPA (cyclopiazonic 
acid). This phenotype can be rescued by replacement of gigaxonin, suggesting that it is caused 
by the absence of gigaxonin rather than a result of genetic differences between patient lines. 
Finally, the observation that the association between gigaxonin and the autophagy protein p62 is 
increased in the presence of oxidative stress suggests that gigaxonin forms a substrate adaptor 
complex leading to proper degradation of nIFs under stress and that in its absence nIFs 






 Before describing my findings, I would like to state that the data in this chapter are 
preliminary. However, I wanted to include this data for the purpose of sharing my findings and to 
obtain feedback. Several experiments need reproducing, but for the purposes of this thesis I will 
interpret the findings as if they are real. 
 I first set out to determine the pathway(s) by which nIFs are degraded in human iPS/ES 
MN cultures to better understand the pathways that gigaxonin may be involved in. Previous 
studies found that nIFs have a relatively long half-life: weeks to months depending on the 
experimental system and cell type studied (Millecamps et al., 2007; Nixon and Logvinenko, 
1986). I therefore first wanted to determine if I could detect any nIF turnover within a shorter 
time frame of 24 hrs. Towards this end, I treated control iPS-MN cultures with a cocktail of 
inhibitors for 24 hours and looked for a change in peripherin and NF-L levels (Figure 6.1). The 
cocktail included 1 mM 3-MA, 5 μM MG132 and 20 μM leupeptin. 3-MA, although not entirely 
specific, inhibits the early stages of autophagy (Klionsky et al., 2008). Leupeptin partially 
inhibits lysosomal degradation, and MG132, although also not entirely specific, inhibits the 
proteasome. I analyzed the effects of the inhibitor cocktail at a time point where I have 
previously observed exacerbation of the GAN phenotype - at 12 days in culture. I therefore 
treated MN cultures at 11 days in culture and performed the Western blot 24 hours after. 
 The resulting Western blot showed a ~3-fold increase in the levels of peripherin upon 
inhibition of degradation (Figure 6.1A, B). Levels of NF-L were also elevated, but with greater 
variability across experiments (1.4, 6.4 and 17-fold in three independent experiments). By 
contrast, actin levels were not increased. This suggested that in fact there is some degradation of 





6.2). In the first experiment I tested the inhibitors at one dose; in the second experiment, shown 
in Figure 6.2, I tested 2-3 concentrations of each inhibitor. The reduction in PRPH and NF-L 
signal at the highest dose tested for 3-MA and MG132 are likely due to toxicity. The Western 
blot and quantifications shown are consistent with the first experiment performed with one dose 
of each inhibitor. Levels of peripherin were increased ~5-fold in the presence of 1 mM 3-MA 
(the lower dose), and 3-4-fold in the presence of 20 and 100 μM leupeptin (both doses tested, 
Figure 6.2A, B). Peripherin levels increased only slightly in the presence of MG132 (~1.8-fold). 
In general, increasing doses of inhibitors tended to not increase protein levels further, possibly 
due to cellular toxicity. These findings suggest that peripherin is degraded by microautophagy, 
with eventual degradation by the lysosome. 
 In contrast, levels of NF-L were increased in the presence of both proteasome and 
lysosome inhibitors (Figure 6.2A, C). Levels were increased ~6.8-fold with 1 mM 3-MA and 
~14-fold with 20 μM leupeptin. Levels were increased ~19-fold in the presence of 10 μM 
MG132. These elevations are quite striking, and some of the increased may be inflated to some 
extent by cellular toxicity, resulting in reduced HISH3 signal and consequently a greater ration. 
However, no overt toxicity was observed from treatment of the cultures with inhibitors. 
Although these experiments need refining, these data suggest that NF-L may be degraded by 
both the lysosome and proteasome.      
 Gigaxonin has long been thought to act as an E3 ligase substrate adaptor, important for 
the ubiquitination of appropriate substrates. I therefore asked if NF-L is ubiquitinated, and if so, 
if it depends on gigaxonin. Moreover, the data in Figure 6.2C suggest that if NF-L is degraded by 
the proteasome that it should be polyubiquitinated. I first did an IP of NF-L from control and 





cocktail (1 mM 3-MA, 10 μM MG132 and 20 μM leupeptin) for 24 hours and were lysed in 
buffer containing N-Ethylmaleimide, an inhibitor of deubiquitinases. In two independent 
experiments I was not able to detect polyubiquitinated NF-L; NF-L runs at ~68 kDa, and I 
consistently detected a band at ~68 kDa, which may represent mono-ubiquitinated NF-L, but 
certainly not a polyubiquitinated form, which normally ads ~32 kDa to the weight of a protein. A 
band at ~200 kDa was present in both control and GAN lanes, but it is unlikely that this 
represents polyubiquitinated NF-L given that the Westerns are run under denatured, reduced 
conditions. Additionally, there was no distinguishable difference in the ubiquitin signal from IP 
of NF-L between GAN and control cultures. I then performed the reverse experiment; I 
immunoprecipitated ubiquitin and blotted for NF-L (Figure 6.3B) under the same experimental 
conditions described above. The IP lanes contain the same two bands: 68 and 200 kDa. Taken 
together, these findings suggest that if NF-L is polyubiquitinated, that constitutes a very small, 
difficult to detect fraction of the NF-L pool.      
 Traditionally, proteins are thought to be polyubiquitinated for degradation by the 
proteasome (Tai and Schuman, 2008). Although the inhibitor experiments suggested that NF-L 
may be degraded by the proteasome as well as the lysosome, since the latter finding is novel I 
wanted to determine if gigaxonin associated with any autophagy components that could aid in 
the lysosomal degradation of nIFs. I therefore looked for an interaction with the autophagy 
protein p62 which has been implicated in the clearance of ubiquitin aggregates by the lysosome 
(Figure 6.4A). I performed a FLAG IP from HEK293 cells transfected with flag-tagged full-
length and truncated gigaxonin and probed for p62. There was a clear association between full-
length gigaxonin and endogenous p62 (isoform 2, ~38 kDa); this association was not found with 





association was dramatically increased in the presence of oxidative stress (Figure 6.4A, right-
hand side). A previous study showed that Keap1 (a BTB/Kelch protein like gigaxonin) associates 
with p62, and this association is increased in the presence of oxidative stress (Fan et al., 2010).  
 Given the association between the Kelch domain of gigaxonin and p62, I next wanted to 
determine if levels of p62 are altered in GAN iPS-MN cultures. It is thought that gigaxonin binds 
substrates (such as IFs) for degradation through its Kelch domain. Increased levels of p62 could 
suggest that either gigaxonin assists in the degradation of p62 or that autophagic flux is disrupted 
in GAN samples. In two independent experiments levels of p62 were comparable to control in 
GAN iPS-MN cultures or reduced (Figure 6.4B). Levels of LC3, a binding partner of p62 and 
another autophagy-related protein were also comparable to control. This suggests that a) 
autophagy is not grossly dysregulated in GAN iPS-MNs and b) the association between 
gigaxonin and p62 does not lead to the degradation of p62.     
 Although there is some evidence that gigaxonin may interact with Cul3 to act as an E3 
ligase substrate adaptor (Figure 2.5A and (Bennett et al., 2010)) the finding that NF-L is not 
widely polyubiquitinated raised the possibility that gigaxonin may act as another type of adaptor 
to bring a different protein class in contact with nIFs. BTB binding partners found in the MS 
screen that might be important for the turnover and regulation of nIFs are listed in Table 6.5. 
These generally fall into two classes: autophagy components and heat shock proteins. Gigaxonin 
has previously been reported to associate with the autophagy protein ATG16L1 (Behrends et al., 
2010), but I was unable to confirm the interaction given the lack of a reliable signal from 
commercial antibodies. However, vimentin has been found previously to interact with HSP90 





 I first sought to confirm HSP90 as a bona fide hit from the MS screen. To do so, I 
transfected HEK293 cells with flag-tagged full-length and truncated gigaxonin and performed a 
FLAG IP (Figure 6.5A). Blotting for HSP90 revealed enriched levels as compared with 
untransfected HEK293 cells (compare BTB to NC lane in Figure 6.5A). I hypothesized that 
given the previous evidence that Hsp90 and vimentin interact, as well as new evidence that 
gigaxonin interacts with Hsp90, the three may form a complex. I therefore immunoprecipitated 
vimentin from GAN and control fibroblasts and blotted for HSP90 (Figure 6.5B). I was able to 
detect an interaction between vimentin and Hsp90. Moreover, this interaction was lessened in the 
GAN fibroblasts, suggesting that, at least in part, the interaction between vimentin and gigaxonin 
may be mediated by gigaxonin.  
 As seen in patients, GAN iPS-MN cultures have elevated levels of nIFs. However, I have 
not observed a functional consequence of this elevation – GAN neurons survive just as well as 
control (Figure 5.8) under normal culture conditions. I therefore wanted to determine under what 
conditions a neuron with elevated levels of nIFs might be vulnerable. It has been shown 
previously that HSPs (such as HSP25 and α-crystallin) associate with IFs in vitro (Nicholl and 
Quinlan, 1994). HSP25 has been shown to increase the solubility of GFAP. Purified GFAP 
forms a stiff gel that can support a metal ball. However, upon addition of HSP25, the ball is able 
to travel through the soluble GFAP to the bottom of the tube (Perng et al., 1999). It has been 
hypothesized that HSPs help prevent the non-covalent interactions that occur when IFs come into 
close proximity. HSP90s account for 1-2% of cellular proteins under normal conditions and these 
proteins can be activated under conditions of cellular stress, such as oxidative stress (Csermely et 





its role in the oxidative stress response (Zhang et al., 2005), I first focused on hydrogen peroxide 
as a stressor that could potentially reveal vulnerability in GAN MN cultures.    
 A titration of H2O2 on control and GAN MNs suggested that in fact GAN neurons do 
have increased susceptibility to oxidative stress (Figure 6.6A). Above 25 μM, this effect was 
quite striking (~2-fold and 3-fold reduction in survival at 25 and 50 μM, respectively). For 
subsequent experiments I focused on 25 μM, the lowest dose of H2O2 that had an effect, given 
that H2O2, like many stressors or drugs, could have off-target effects at higher doses. 
Importantly, these survival differences appeared to be gigaxonin-dependent; the effect could be 
rescued by stable expression of gigaxonin in the GAN neurons (Figure 6.6B and E-J). I also 
wanted to determine if GAN neurons are more vulnerable to all stressors in general, or if there is 
something specific about oxidative stress. I therefore looked at two other stressors: the inhibitor 
of the Ca
2+
-ATPase cyclopiazonic acid (CPA) and the cytokine tumor necrosis factor-α (TNF-α) 
(Figure 6.6C and D). Neither stressor had a significant selective effect on GAN neurons, 
suggesting that gigaxonin may be important specifically in the oxidative stress response.    








 In this study I have shown that nIFs are degraded in human iPS-MNs within a 24-hour 
period, and tentatively concluded that the lysosome and proteasome contribute to varying 
degrees in the degradation of peripherin and NF-L, two nIFs that accumulate in GAN MNs. In 
support of the lysosomal degradation of nIFs I could not find evidence that NF-L is 
polyubiquitinated. Additionally, preliminary data suggest that gigaxonin is capable of interacting 
with the autophagy-related protein p62.  
 It is important to note that the inhibitor results shown in Figure 6.1 and 6.2 are 
preliminary and require further refinement. It was difficult for me to detect increased levels of 
p62 and ubiquitin upon treatment of lysosome and proteasome inhibitors, respectively. Seeing an 
increase in their levels would provide greater confidence that the inhibitors are working properly. 
In addition, these inhibitors are not 100% specific, and other strategies, such as shRNAs to 
specific proteasome or autophagy components could provide a finer degree of specificity. 
However, the trend in the results seems consistent across multiple experiments, suggesting that 
the increased levels in the presence of inhibitors may be real. HISH3 was used as a loading 
control in these experiments for two main reasons: a) it should provide an estimate of the number 
of living cells; and b) its molecular weight is similar to that of the proteins I am interested in, and 
thus should transfer with similar consistency. However, an issue with any such degradation 
experiment is selective of an appropriate loading control. I decided to not use actin for a loading 
control because expression levels may vary in different cell types in the culture and thus it may 
give a less accurate representation of the number of cells.     
I was not able to detect polyubiquitination of endogenous NF-L, in agreement with 





in the context of shear stress and TRIM2 knockout mice, respectively (Balastik et al., 2008; 
Jaitovich et al., 2008), but endogenous IFs have not been found to be ubiquitinated. It appears 
that NF-L is monoubiquitinated, or alternatively that for a technical reason I am not able to 
detect it in polyubiquitinated forms. The band present at ~200 kDa may be a polyubiquitinated 
form of NF-L, but this seems unlikely given that a polyubiquitinated form of NF-L should run at 
~100 kDa. Because these experiments are run under denatured and reducing conditions, the 
formation of polyubiquitinated NF-L dimers is unlikely. One possibility is that the high 
molecular weight band results from cross-reactivity of the NF-L antibody with NF-M present in 
the sample, but this remains to be determined.  
 I have shown that gigaxonin binds IFs (Figure 2.4), and the finding that nIFs may be 
degraded by polyubiquitin-independent pathways raises that possibility that gigaxonin aids in the 
degradation of nIFs by the lysosome. This is bolstered by the finding that that gigaxonin interacts 
with p62. The association was Kelch-dependent, which seems surprising given that it is widely 
thought that the BTB domain of gigaxonin would bind to Cul3 or other proteins for processing of 
its Kelch domain targets. However, it has been demonstrated that the BTB domain of gigaxonin 
can homodimerize (Cullen et al., 2004), and it is thought that most BTB/Kelch proteins act on 
their substrates as dimers (Stogios et al., 2005). Therefore, this raises the possibility that 
gigaxonin forms a complex as a heterodimer, with one Kelch domain bound to p62 and the other 
bound to a nIF protein. In support of this hypothesis, levels of p62 are comparable or reduced 
between GAN patient iPS-MNs and controls, suggesting that the association of gigaxonin and 
p62 serves another purpose than the degradation of p62.  
My MS and IP data suggest an interaction between gigaxonin and HSP90; moreover, I 





gigaxonin-dependent fashion. In Figure 6.6A it is striking that the BTB domain of gigaxonin 
seems to bind more HSP90 than the full-length protein. This may be due to accessibility of 
binding site or, alternatively, I have observed that the BTB domain alone is usually expressed at 
slightly higher levels compared with full-length gigaxonin after transfection. IP of vimentin pulls 
down HSP90, suggesting that they may form a gigaxonin-dependent complex. This is supported 
by the observation that less HSP90 associates with vimentin in GAN fibroblasts; the fact that 
some association remains suggests that there may be some vimentin-HSP90 interactions 
independent of gigaxonin, which would not very surprising given the high abundance of HSP90 
(Csermely et al., 1998). Taken together, these data suggest that gigaxonin interacts with HSP90 
through its BTB domain and IFs through its Kelch domain, possibly forming a complex 
important for linking chaperones with IFs. However, some vimentin is able to interact with 
HSP90 even in the absence of gigaxonin, and the functional consequences of this association 
remain to be determined.  
I also show preliminary data that GAN neurons have increased sensitivity to oxidative 
stress. Further work should be done to repeat this with different patient lines as well as their 
corresponding rescue lines. Peroxide treatment is a fairly nonselective tyrosine kinase activator 
and activates several different tyrosine kinase cascades (Clayton et al., 2009). Given that 
hydrogen peroxide may have off-target effects, it would also be beneficial to test more specific 
oxidative stressors (such as the superoxide dismutase inhibitor 2-ME), and to repeat these 
experiments with non-oxidative stressors as controls (including CPA and TNF-α) to show 
specificity. Additionally, it would be informative to perform this experiment at earlier time 
points in culture, and to determine if GAN neurons are less susceptible to oxidative stress when 





specifically to MNs - and these assays would be greatly aided by MN reporters to be able to 
identify and make conclusions regarding the survival of GAN MNs specifically in the face of 
oxidative stress.   
In summary, I have shown data that suggest that peripherin is predominantly degraded by 
the lysosome, whereas NF-L is degraded by both the proteasome and lysosome in human iPS-
MN cultures. In support of possible lysosomal degradation of nIFs by gigaxonin, I show that NF-
L appears to be monoubiquitinated under normal conditions and evidence for an interaction 
between gigaxonin and p62. I have shown that GAN neurons have increased sensitivity to 
oxidative stress, but not to TNF-α or CPA. This phenotype can be rescued by replacement of 
gigaxonin, suggesting that it is caused by the absence of gigaxonin rather than a result of genetic 
differences between patient lines. The observation that the associated between gigaxonin and p62 
is highly increased in the presence of oxidative stress suggests that gigaxonin may form a 
substrate adaptor complex leading to proper folding or degradation of nIFs under oxidative stress 
conditions and that in its absence nIFs accumulate, leading to cellular toxicity. A more complete 








Figure 6.1. nIFs are degraded over a 24 hr period in iPS-MN cultures. (A) Day 28 Control 
iPS-MNs (line 18c) were thawed and 250,000 cells were seeded into each well of a 6-well plate. 
Eleven days later, cells were treated with a combination of degradation inhibitors (1 mM 3-MA, 
5 μM MG132 and 20 μM leupeptin) or DMSO carrier. 24 hours later, cells were collected for 
Western blot. The membrane was probed first for PRPH and HISH3, then for NF-L and actin. 
(B) PRPH band sizes and intensities were measured using ImageJ and were normalized to 

























































Figure 6.2. Peripherin is predominantly degraded by the lysosome whereas NF-L is 
degraded by the proteasome and lysosome. (A) Day 28 Control iPS-MNs (line 18c) were 
thawed and 250,000 cells were seeded into each well of a 6-well plate. Eleven days later, cells 
were treated with degradation inhibitors individually, in combination (“Combo”) or with DMSO 
carrier (“Ctrl”). The doses tested for the different inhibitors are as follows: 1 and 5 mM for 3-
MA; 10, 50 and 250 μM for MG132 (“MG”); 20 and 100 μM for leupeptin (“Leup”). The lower 
dose combination consisted of 1 mM 3-MA, 10 μM MG132 and 20 μM leupeptin. The higher 
dose combination consisted of 4 mM 3-MA, 50 μM MG132 and 100 μM leupeptin. 24 hours 
later, cells were collected for WB. The membrane was probed first for PRPH and HISH3, then 
for NF-L and actin. (B,C) PRPH (B) and NF-L (C) band sizes and intensities were measured 
using ImageJ and were normalized to HISH3 loading control. Data shown is representative of 








Figure 6.3. NF-L is monoubiquitinated. (A) NF-L was immunoprecipitated from control (line 
10013.13) and GAN3X iPS-MN cultures after a 24 h treatment with a protein degradation 
inhibitor cocktail (1 mM 3-MA, 10 μM MG132 and 20 μM leupeptin). Cells were lysed in buffer 
containing N-Ethylmaleimide, an inhibitor of deubiquitinases. The membrane was probed first 
for ubiquitin, followed by NF-L. NF-L is ~68 kDa, the size of the strong band in the IP lanes on 
the ubiquitin membrane. The identity of the faint band present at ~200 kDa (present in both 
GAN and control lanes) is unknown. (B) Ubiquitin was immunoprecipitated from HBG1 hES-
MN cultures treated for 24 h with degradation inhibitors (1 mM 3-MA, 5 μM MG132 and 20 μM 
leupeptin) and/or 25 μM H2O2. Cells were lysed in buffer containing N-Ethylmaleimide. The 
membrane was probed for NF-L, followed by ubiquitin.  
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Figure 6.4. Evidence for an interaction between gigaxonin and p62. (A) HEK293 cells were 
transfected with full-length or truncated flag-tagged gigaxonin. A subset of transfected cells were 
treated with 200 μM for 1 hr. After FLAG IP, the membrane was probed for p62. Shown are two 
exposures (30 sec at top and 1 sec at bottom). Only full-length gigaxonin associates with p62. 
(B) Levels of p62 and LC3 proteins were assessed in GAN and control iPS-MN cultures by 

























Table 6.5. MS hits that may play a role in GAN pathophysiology.  
BTB binding partner  Function  Hypothesized role in GAN  
HSP90  Chaperone; important for folding of newly synthesized proteins or 
stabilizing and refolding denatured proteins after stress (Zhang et 
al., 2006) 
May interact with nIFs through gigaxonin 
for protection of nIFs from adhesion with 
other nIFs  
ATG16L2  Autophagy related 16-like 2 is not well characterized but  is an 
isoform of ATG16L1, essential for the formation of 
phagophores during autophagy (Ishibashi et al., 2011)  
Degradation of nIFs by autophagy  
Kelch binding partner  Function  Hypothesized role in GAN  
ATXN-2  Ataxin-2 is an RNA binding protein. Mutations cause  the 
neurodegenerative disease spinocerebellar ataxia type 2 (SCA2) 
(McCann et al., 2011)  
SCA2 can be inherited in an autosomal 
dominant manner (Sinha et al., 2004), 
suggesting that higher than normal levels 
can result in neuronal dysfunction  
LRRK2  Leucine-rich repeat kinase 2 may play a role in the phosphorylation 
of proteins central to Parkinson’s disease (Deng et al., 2011)  
Degradation may be dependent on 
gigaxonin; higher than normal levels may 
lead to aberrant phosphorylation and 
aggregation of nIFs  
 
Table 6.5. MS hits that may play a role in GAN pathophysiology. Proteins included in the 






Figure 6.6. Evidence for complex formation between gigaxonin, vimentin and Hsp90. (A) 
HEK293 cells were transfected with full-length or truncated gigaxonin. A subset of cells 
transfected with flag-tagged full-length gigaxonin were also treated with MG132 (MG). 24 hours 
later, immunoprecipitation was performed using anti-FLAG antibody. The membrane was 
probed for HSP90 as well as FLAG (not shown). The BTB of gigaxonin clearly associates with 
HSP90. (B) Endogenous vimentin was immunoprecipitated from GAN (from GAN patient 5) 
and control (from control 18) fibroblasts. The membrane was probed for vimentin followed by 
endogenous HSP90. IP of vimentin brings down HSP90, and the absence of gigaxonin lessens 

























































































































































































































































Figure 6.7. GAN neurons show increased sensitivity to oxidative stress. (A) Day 28 control 
(line 18c or 10013.13) MNs were thawed and 10,000 cells per well were plated into 96-well 
plates. Eleven days later, wells were treated with different concentrations of H2O2 (0-200 μM). 
For this 24-hour treatment compounds with antioxidant properties (B27, BMA and AA) were 
removed from the media. Plates were fixed and stained for DAPI, PRPH and MAP2. PRPH or 
MAP2 was used to score neurons with significant outgrowth (~3 cell body widths) in three 
independent experiments. Plot represents three independent experiments; mean ± SEM. (B) 
Experiment was performed as in (A) but a rescue line was added (GAN3X + GAN) and a single 
concentration of 25 μM H2O2 was used. Plot represents three independent experiments; mean ± 
SEM., p = 0.008 and 0.009 for control compared to GAN3X and GAN3X compared to the rescue 
line respectively (p = 0.16 for control compared to rescue). (C) Experiment was performed as in 
(A) but cells were treated with 10 uM CPA (cyclopiazonic acid, an inhibitor of the Ca
2+
-
ATPase). Plot represents the mean ± range of two technical replicates; p = 0.15. (D) Control 
(18c) and GAN2E d28 MNs were seeded at a density of 5,000 cells/well into 96-well plates. 9 
days later, TNF-α (tumor necrosis factor-α) was added at final concentrations of 10 and 200 
ng/mL. 24 h later plates were fixed and stained, and neurons (as identified by MAP2) with 
significant outgrowth (~3 cell bodies) were scored using whole-well imaging on the Trophos 
Platerunner. Plot represents the number of neurons with significant outgrowth normalized to the 
control condition for each line (no TNF-α); mean ± S.D. of four technical replicates. (E-J) 
Representative images from experiments plotted in (B). E, G and I represent untreated cells, and 
F, H and J represent cells treated with 25 μM H2O2. Cells were stained for MAP2 before being 






Chapter 7. General Discussion  
Our understanding of GAN has been limited by difficulties with mouse models that do 
not recapitulate the early onset and severity of the disease. I therefore wanted to make the first 
human model of GAN, taking advantage of iPS technology. I was able to generate iPS lines from 
three patients with this rare disease. In a parallel to what we know about GAN pathology, MNs 
generated from these iPS lines displayed a striking accumulation of NF-L and peripherin. 
Moreover, I showed that these phenotypes are gigaxonin-specific and can be reversed by the 
replacement of gigaxonin by viral or transgenic methods. This represents the first human 
neuronal model of GAN, and the tools I have generated should be useful for future studies on the 
pathogenesis and mechanism of GAN.   
In addition, I performed the first proteomic screen to identify the normal binding partners 
of gigaxonin. Arguably the most significant finding to emerge from my research is that 
gigaxonin interacts with IFs, and that the replacement of gigaxonin is sufficient to reverse and 
prevent the accumulation of IFs, identifying gigaxonin as an essential and novel regulator of IFs. 
Preliminary experiments suggest that in iPS-MNs nIFs are degraded by contributions from both 
the proteasome and lysosome. My experiments also suggest that gigaxonin interacts with the 
autophagy protein p62 which has been implicated in the clearance of ubiquitin aggregates by the 
lysosome, and this interaction is greatly enhanced in the presence of oxidative stress, a stressor 
that selectively kills GAN iPS-MNs. 
 Further identification of regulators of IFs as well as the mechanism by which they 
contribute to IF turnover would greatly advance our understanding of the many diseases in which 





range of human conditions, from the rarest of diseases – according to the Progeria Research 
Foundation 93 patients are living with Hutchinson-Gilford progeria, in which the absence of 
lamin A results in an unsupported nuclear envelope (De Sandre-Giovannoli et al., 2003) – to 
Alzheimer’s disease, in which cortical Lewy bodies contain phosphorylated neurofilament 
protein (Julien and Mushynski, 1998; Lowe et al., 1988) and which is predicted to affect 1 out of 
85 people by the year 2050 (Brookmeyer et al., 2007).   Few of these diseases have treatments, 
and understanding the mechanisms by which IFs are regulated would be a first step towards the 
development of therapeutics.  
Working model of gigaxonin’s role in nIF turnover: gigaxonin as a substrate adaptor for 
autophagy 
The key remaining question of my project is how exactly gigaxonin contributes to the 
turnover of IFs. As a step toward addressing this, I have extrapolated from my preliminary 
findings presented in Chapter 6 to put together a working hypothesis of how gigaxonin may 
contribute to IF turnover. I will then discuss other outstanding questions and future avenues of 
research opened up by my findings. I will focus this discussion on the novel hypothesis that 
emerges from my data: that gigaxonin acts conditionally for the turnover of IFs in the face of 
stress by autophagy. I will then present alternative hypotheses in the proceeding sections.   
 Several of my findings point to a role for gigaxonin in the degradation of IFs via the 
lysosome. First, based on the inhibitor experiments (Figure 6.2) it appears that the lysosome may 
play a role in the degradation of both peripherin and NF-L, two nIFs that accumulate in GAN 





Second, my MS screen identified an interaction with the autophagy protein ATG16 
isoform 1; ATG16 isoform 2 was the top interactor of gigaxonin in a MS screen performed by 
another lab (Behrends et al., 2010). I and others have found an association between gigaxonin 
and ATG16 (autophagy related-16). Over 30 ATG genes have been identified, and they 
constitute the core machinery of autophagy. ATG16 interacts with ATG12-ATG5 conjugates to 
form multimers in pre-autophagosomal structures (Periyasamy-Thandavan et al., 2009). Wade 
Harper’s lab at Harvard performed a MS screen to map interactions between the ATG proteins 
by expressing HA-tagged forms in HEK293 cells undergoing basal autophagy. Somewhat 
surprisingly, the top interactor of ATG16 was gigaxonin (Behrends et al., 2010). In my MS 
screen I detected an interaction between gigaxonin and ATG16, but a different isoform than 
reported by the Harper lab. The Harper lab used isoform 1 of ATG16 for their screen, but I 
detected an interaction between gigaxonin and ATG16 isoform 2. Few studies have examined the 
difference between these two isoforms; one study found that ATG16L2 (isoform 2) is not 
essential for classical autophagy despite participation in an ATG12-5-16L2 complex (Ishibashi et 
al., 2011). Unfortunately I was unable to confirm an interaction between gigaxonin and 
ATG16L1 or 2 due to poor and nonspecific signal from the ATG16 antibodies. However, my MS 
results showed that ATG16 interacts with the BTB domain of gigaxonin, suggesting another 
possible pathway by which gigaxonin could bring IFs into contact with autophagy components.      
Third, my data imply an interaction of gigaxonin with p62 and nIFs. The protein p62, 
also known as sequestosome 1 (SQSTM1), is a shuttle protein that transports polyubiquitinated 
proteins for their degradation by the lysosome. p62 contains a C-terminal ubiquitin-associated 
(UBA) domain that selectively binds lysine 63 (K63) or polyubiquitinated protein. p62 also 





delivery of its polyubiquitinated cargo for lysosomal degradation (Nogalska et al., 2009; Wooten 
et al., 2005). p62 appears to associate with gigaxonin through the Kelch domain.   
Although gigaxonin associated with p62 in normal culture conditions, the large increase 
in conditions of oxidative stress suggests that the function of gigaxonin may be to coordinate part 
of the cellular stress response. Keap1, a homolog of gigaxonin and a well-known regulator of the 
cellular stress response (Itoh et al., 1999) is also able to associate with p62 and this association is 
also increased in conditions of oxidative stress (Fan et al., 2010). Interestingly, I found that 
oxidative stress – but not TNF-α or CPA – selectively kills GAN MNs in a gigaxonin-dependent 
fashion. Taken together, these results suggest that gigaxonin may be important for the 
degradation of IFs in conditions of stress.   
In further support of a link between gigaxonin and the stress response, it has been 
observed that GAN fibroblasts behave differently under starvation conditions as compared with 
control fibroblasts. Under normal culture conditions (~10% serum) ~5-12% of GAN fibroblasts 
display vimentin aggregation. This percentage strikingly jumps to ~50-90% under starvation 
conditions (~0.1% serum) (Bomont and Koenig, 2003) while control fibroblasts do no form 
aggregates in either normal conditions or following starvation (Leung et al., 2007). Serum 
starvation can activate autophagy (Mizushima, 2007). Therefore, in these conditions GAN cells 
may be attempting to catabolize intermediate filaments to generate nutrients but may encounter a 
missing link in the process, leading to the generation of aggregates rather than the orderly 
dissolution of the IF network.  
In light of these experiments and given my findings that nIFs are degraded by both the 





proteasome in the degradation of NF-L (Balastik et al., 2008), I propose that nIFs are degraded 
by different pathways under different cellular contexts (Figure 7.1A). Basal turnover of damaged 
or unneeded nIFs would be accomplished by degradation of lysine 48 (K48)-polyubiquitinated 
nIFs by the proteasome. By contrast, in the face of stress – starvation, oxidation – lysine 63 
(K63)-polyubiquitinated nIFs would be degraded by autophagic pathways.  I will expand on this 
hypothesis in the following paragraphs.  
One model for a way in which this interaction could occur comes from the literature on 
Keap1. Keap1 forms a complex with p62 and its degradation substrate Nrf2 in a similar fashion 
to that shown in Figure 7.1B. Komatsu et al. used a combination of protein crystallography and 
biochemistry to map the precise interaction site between p62 and Keap1 (Komatsu et al., 2010). 
This site overlaps with the C-terminal domain in Keap1, which is known to be crucial for its 
interaction with Nrf2. The authors propose a model in which two Keap1 molecules form a dimer 
through their BTB domain, and one Kelch domain is able to bind one molecule of p62 and the 
other Nrf2. Based on this data, I propose that in a similar fashion, gigaxonin could form a dimer 
through its BTB domain. One Kelch domain could bind IFs, while the other Kelch domain could 
bind p62 (Figure 7.1B). According to this model, in stressful conditions p62 would interact with 
polyubiquitinated nIFs through a gigaxonin-dependent substrate adaptor complex. 
This rapid response would serve as a way to provide nutrients to the cell or to prevent 
apoptosis. Autophagy is critical for survival of starvation by the production of amino acids. In 
addition to its role in degradation, some publications have shown that sequestration of cellular 
components in autophagic membranes, even in the absence of degradation, can be important for 
cell survival. For example, autophagy can be induced by several stresses, including ER stress, 





and mammals (Bernales et al., 2006; Ogata et al., 2006). How autophagy is protective during ER 
stress is not known, but it has been suggested that sequestration of ER into autophagosomes may 
be sufficient to relieve ER stress (Bernales et al., 2006). Taken with the evidence that IFs can 
bind cellular components that would otherwise activate cell death pathways (Inada et al., 2001), 
and that IF phosphorylation can prevent apoptosis (Toivola et al., 2010), a model in which 
sequestration of IFs and their binding partners during times of cellular stress emerges.  
Further experiments should be done to definitively determine a role for gigaxonin in the 
degradation of nIFs by autophagy. A recent siRNA screen identified autophagy factors for 
selective cargo, and such an approach could be used to more specifically inhibit autophagy 
components that could be important for the degradation of nIFs (Orvedahl et al., 2011). As a 
complement to the degradation inhibitor experiments, it would be very informative to look for 
the presence of IFs in autophagosomes. This experiment is challenging to perform, mainly 
because of the amount of cellular material required to perform such an experiment: two 
incubators of T175 flasks of HeLa cells or one dozen mouse brains. While this experiment is 
certainly feasible, another complicating factor is that isolation of autophagosomes results in 
contamination from other organelles, especially lysosomes (Marzella et al., 1982). One approach 





However, producing the amount of cellular material required from GAN fibroblasts or GAN iPS-
MNs would be quite challenging. Ai Yamamoto has purified autophagosomes; she looked for the 
presence of IFs in them but her MS results are overwhelmingly dominated by mitochondrial 
proteins (personal communication). This of course does not mean that IFs are not present, but it 
does mean that with respect to the mitochondrial proteins there is so much less that any possible 





As alternatives to looking for IFs directly in autophagosomes, other approaches include 
looking for an interaction between gigaxonin and additional autophagy components as well as 
dysregulation of autophagy in GAN null cells. Individual IP studies could be performed to look 
for an interaction between gigaxonin and the ATG proteins; it could be particularly informative 
to do a MS screen in the presence and absence of oxidative stress. Immunofluorescence co-
localization studies are limited because FLAG-GAN is distributed homogeneously throughout 
the cytoplasm. However, an antibody to endogenous gigaxonin could be helpful to look for co-
localization between gigaxonin, IFs, and p62 or LC3. Another – albeit indirect – route could be 
to determine if autophagy is dysregulated in GAN iPS-MNs by microarray analysis with an 
emphasis on components of the mTor signaling pathway, which are important for the regulation 































Figure 7.1. Working model for the role of gigaxonin in nIF turnover. (A) nIFs may be 
degraded by multiple pathways depending on the cellular context. (i) Turnover of lysine 48 
(K48)-polyubiquitinated nIFs by the proteasome. (ii) Turnover of lysine 63 (K63)-
polyubiquitinated nIFs in conditions of stress. p62 binds ubiquitinated cargo for degradation by 
the autophagolysosome. (B) Model of the putative gigaxonin-p62-nIF complex. Gigaxonin could 
form a dimer by self-association of the BTB domain. The two Kelch domains could bind p62 and 
nIFs, respectively, to target the nIFs for degradation by the autophagolysosome. (C) In GAN 
neurons, stress may lead to the accumulation of ubiquitinated nIFs. This could lead to neuronal 
toxicity and death. Methods to reverse this pathological process may include (i) increased 
degradation of nIFs through p62-independent lysosomal pathways; (ii) association with HSPs for 
increased degradation, either by the proteasome or chaperone-mediated autophagy; or (iii) 






Gigaxonin as an E3 ligase substrate adaptor  
While a role for gigaxonin in autophagy-dependent degradation of nIFs seems most 
plausible at this point, is it important to note that other possibilities remain open for how 
gigaxonin may be involved in the degradation of nIFs.  
I will first explore the widely accepted theory that gigaxonin acts as an E3 ligase 
substrate adaptor for the ubiquitination and subsequent degradation of IFs by the proteasome. 
The MS screen did not identify an interaction between gigaxonin and the E3 ligase Cul3, but I 
was able to detect an association by independent IP. In addition the MS screen did identify an 
association between the BTB domain of gigaxonin and the probable E3 ligase MYCBP2 (myc-
binding protein 2) as well as USP43 (ubiquitin specific peptidase 43). Full-length gigaxonin (but 
not the BTB domain alone) associated with the E3 ligase UBR1. Unfortunately MYCBP2 is a 
common false positive in MS screens. USP43 is a de-ubuiquitinating enzyme (Sowa et al., 2009), 
so while it may interact with gigaxonin it is hard to imagine how loss of an association of this 
protein with IFs through gigaxonin could lead to their accumulation. Last, the fact that UBR1 
interacts with gigaxonin in a Kelch-dependent manner is clearly different than the presumed 
gigaxonin-Cul3 interaction through the BTB domain. Where binding has been demonstrated, to 
date all BTB-Kelch proteins have been shown to interact with E3 ligases through their BTB 
domains. Therefore, UBR1 could nonetheless possibly mediate ubiquitination of IFs although the 
data do not precisely fit the model. 
Other pieces of data the hypothesis that gigaxonin acts as an E3 ligase substrate adaptor 
even less likely. First, I have been unable to detect polyubiquinated forms of nIFs and no 





both gigaxonin and Keap1 are able to form complexes with Cul3 and vimentin, suggesting that 
there is a lack of specificity in this interaction. However, further experiments could be done to 
address this hypothesis. There are some reports of denaturing Western blots by incubation in 
harsh buffers or autoclaving to further expose ubiquitin epitopes (Bloom and Pagano, 2005). 
Polyubiquitinated forms of IFs are likely formed for degradation by either the proteasome or 
lysosome, so perhaps I am not able to detect them for technical reasons. Additionally, if 
ubiquitinated protein forms are difficult to detect by traditional Western blots, it could be 
informative to compare the complement of ubiquitinated proteins in GAN iPS-MN cultures as 
compared with the rescue lines. Ubiquitin conjugates could be determined by IP of endogenous 
or tagged-ubiquitin. A MS approach would also allow for the identification and quantification of 
ubiquitin chain topologies (Xu and Peng, 2006), which would discriminate between mono- and 
polyubiquitinated targets. The MS approach would also be helpful if it turns out that 
polyubiquitinated IFs are found at very low abundance.  
Gigaxonin as an HSP adaptor  
A second possibility is that gigaxonin interacts with HSPs for the regulation of IFs, rather 
than for their direct degradation. In addition to HSP90, both HSPA9 and HSPD1 were identified 
as BTB-interacting partners of gigaxonin. The HSPA9 gene encodes the mitochondrial stress-70 
protein, which belongs to the heat shock protein 70 family (Domanico et al., 1993). HSPD1 
encodes the chaperone protein heat shock 60 kDa protein 1 (Perez et al., 2001). Several 
mutations in HSPs – including those thought to interact with gigaxonin - are associated with 
neuropathies. For example, mutations in HSPD1 are associated with autosomal dominant forms 
of hereditary spastic paraplegia (Hansen et al., 2002). In addition, missense mutations in the 





neuropathy: CMT type 2F and distal hereditary motor neuropathy (distal HMN) (Almeida-Souza 
et al., 2011). In independent IP experiments I was able to detect an interaction between 
gigaxonin and HSP90, as well as between vimentin and HSP90, suggesting that they may form a 
functional complex. The association between HSPs and other hereditary neuropathies makes 
chaperone proteins a possible therapeutic target for GAN. HSPs could be important for refolding 
of damaged IFs, proper integration of IFs into the network, or degradation of IFs by chaperone-
mediated autophagy (CMA). In the absence of an appropriate gigaxonin-HSP-IF complex, IFs 
could accumulate if not properly integrated into the cytoskeleton or sent for degradation by 
HSPs. 
Gigaxonin as a kinase/phosphatase adaptor  
A third possibility is that gigaxonin interacts with a kinase or phosphatase. 
Phosphorylation has been shown to be important for the structure of IFs, and gigaxonin may be 
important for facilitating interaction between IFs and a kinase or phosphatase, either by 
degrading the molecule or by bringing it into proximity with IFs. Loss of control of the 
phosphorylation state of IFs due to gigaxonin loss-of-function could result in loss of IF structure: 
forced phosphorylation of NF-L results in filament disassembly (Hisanaga et al., 1990). Kelch-
interacting phosphatases identified in my MS screen include SSH2 and PTPN9; kinases include 
MAST2, SPEG, MAPK43, PRKD1 and LRRK2. LRRK2 is particularly interesting because 
mutations in this kinase are responsible for a significant proportion of both sporadic and familial 
Parkinson’s disease (Gomez-Suaga et al., 2012). I was unfortunately unable to confirm an 
interaction between LRRK2 and gigaxonin due to lack of a reliable LRRK2 signal on Western 





kinases/phosphatases, and to determine if accumulated IFs in GAN null cells display aberrant 
phosphorylation states.       
Gigaxonin as a translational regulator   
A fourth possibility is that gigaxonin interacts with a regulatory molecule that controls 
the translation of IFs. Translational regulation of IFs is not well understood, but it is interesting 
that peripherin mRNA-containing particles (messenger ribonucleoproteins or mRNPs) move 
mainly along MTs and are translationally silent, initiating translation only when they stop 
moving (Chang et al., 2006). If gigaxonin degraded a regulator of IF translation that could result 
in higher than necessary protein levels in the absence of gigaxonin, without corresponding 
changes in the transcript levels. A major drawback to this scenario is that it would only explain 
different levels of IFs, but not changes in the cellular distribution of IFs. In this case, one 
possibility could be that failure to inhibit translation in ribonucleoproteins would result in the 
failure of IFs to transport along MTs, resulting in accumulation of protein in cell bodies. Possible 
clues could come from looking for similarities between the translational control regions 
peripherin and NF-L as compared with less affected IFs, such as NF-M and NF-H. The theme of 
gigaxonin having a differential effect on different IFs is explored in the next section.  
Not all IFs are created equal  
In addition to understanding the general role of gigaxonin’s interactions with IFs, it will 
be important to determine whether the significance of the interaction varies according to 
different IF types. For example, it is puzzling that gigaxonin could have such different effects on 
two IFs in the same class: vimentin and peripherin. My MS screen revealed interactions of 





V). I was unable to detect an interaction with the class I/II keratins due to an inability to 
distinguish between human keratin from the HEK293 cells and keratin contamination from the 
experimenter. However, these findings suggest that gigaxonin can interact with IFs from nearly 
all classes.  
Levels of vimentin are not elevated in GAN patient fibroblasts (Pena, 1982), and only 
slight elevated in GAN iPS-MNs. By contrast, levels of peripherin are elevated 3-4-fold in GAN 
iPS-MNs. While levels of vimentin do not appear dysregulated in GAN fibroblasts, the cellular 
distribution of the protein is abnormal: 10% of GAN patient fibroblasts contain a collapsed 
vimentin network (this is not observed in control fibroblasts) (Leung et al., 2007). Taken 
together, these observations suggest that gigaxonin is important for the normal regulation of both 
vimentin and peripherin, but perhaps through different mechanisms. Two possibilities exist: that 
gigaxonin has a different mechanism of interaction with the two different filaments, or that the 
two filaments are in different states and are differentially accessible to gigaxonin. The second 
possibility seems the most parsimonious. It is known that peripherin forms heteropolymers with 
the other nIFs (Yuan et al., 2012), whereas vimentin, although it can form heteropolymers, 
generally forms homopolymers (Mendez et al., 2010). It is possible that the pattern in which IFs 
polymerize could expose (or protect) key gigaxonin-interacting sites. The model presented in 
Figure 7.1 does not explain how the distribution of vimentin could change but not the overall 
expression levels. However, it remains possible that gigaxonin has multiple effects on IFs, such 
as the ones presented as hypotheses in the preceding sections.  
Relevant to the pathology of GAN, there is some evidence that rather than total protein 
levels, the stoichiometry of IFs is a more important determinant of neuronal health. Under 





et al., 2011). The precise subunit stoichiometry of the NF proteins is essential for the 
establishment of proper axonal caliber and alteration has been implicated as a possible 
contributing factor in neurodegenerative disease (Perrot et al., 2008). In multiple sclerosis, for 
example, the ratio of NF-L:NF-H is increased to 11.95:1 (Kim et al., 2011). Therefore, another 
therapeutic route could be to express or stimulate the expression of other IFs to balance the 
abnormalities that result from the loss of gigaxonin. Overexpression of NF-M and H could serve 
as a tool for proof of concept studies. Alternatively, this might be possible pharmacologically; 
RA (retinoic acid) results in upregulation of NF-L much more so than M and H in carcinoma 
cells (Chiu et al., 1995), although in the case of GAN a drug to upregulate NF-M and H 
expression would be needed.  
Identifying a candidate binding site between gigaxonin and nIFs 
It would also be helpful to determine if gigaxonin interacts with IFs directly or indirectly. 
Direct binding between gigaxonin and IFs would suggest that gigaxonin is modifying them 
directly, rather than, for example, degrading a secondary regulator of IFs. This could be done by 
IP studies of purified gigaxonin and IFs. Commercial cell-free protein expression systems have 
been used previously to produce the IF lamin A and detect an association with the membrane 
protein emerin (Vaughan et al., 2001). Although technically challenging, such an approach 
should be able to be used to produce purified gigaxonin and IFs and to determine if they are able 
to interact independent of other cellular partners.    
If gigaxonin does appear to interact directly with IFs, several approaches could be taken 
to determine the location of the interaction site. The interaction site between Keap1 and Nrf2 has 
been mapped to just a few key residues (Chen et al., 2011), so mutating these residues or 





another approach could be to block the interaction with specific cell penetrating TAT peptide 
sequences. Successful blockade would identify the key binding sequence.  
IF accumulations: helpful or harmful?  
While high levels of IFs are present in many postmortem samples, it remains to be 
conclusively determined if IF accumulation is universally harmful. Could it have benefits? Or is 
it simply an innocent bystander in another pathological process? The GAN iPS model, as the first 
iPS model in which nIFs accumulate, offers a new tool to address these questions.  
There is considerable evidence that high levels of nIFs are harmful for neurons. Elevated 
levels of NF-L correlates with neuropathy in TRIM2-deficient mice, overexpression of α-
internexin causes motor coordination problems and neuronal death in a dose-dependent manner, 
and overexpression of peripherin in PC12 cells causes mitochondrial and ER dysfunction, 
followed by neuronal death (Balastik et al., 2008; Ching et al., 1999; Lee et al., 2012). In 
addition, GAN iPS-MNs show increased susceptibility to oxidative stress. This suggests that 
these neurons are more vulnerable than control neurons. To conclusively demonstrate that the 
reduced survival results from elevated levels of nIFs, the same experiments should be performed 
with GAN cultures with reduced nIF levels. One strategy could be to infect GAN cultures with 
lentivirus expressing shRNAs to peripherin and NF-L to determine if lowering the nIF load 
results in increased survival in the face of oxidative stress.  
Alternatively, it is possible that accumulation of nIFs is either not damaging to the nerve 
and simply a by-product of another pathological process, or even provides some benefit to the 
nerve cell. As described above, most evidence suggests that IF aggregates are harmful to 





to the cell. For example, conversion of the yeast prion protein Mod5 from a soluble form to an 
aggregated state in the face of stress (selective pressure from an antifungal drug) provides a 
survival advantage (Suzuki et al., 2012). In addition, higher levels of IFs might confer an 
advantage in certain contexts by acting as a sink for excess phosphorylation that would otherwise 
lead to activation of cell death pathways or by binding and inactivating proapoptotic molecules 
(Inada et al., 2001; Kim and Coulombe, 2007). The GAN iPS model provides a unique 
opportunity to determine if reducing nIF levels confers a survival advantage on human MNs.  
Future perspectives for GAN iPS model and development of GAN therapeutics 
Gene therapy 
 For a monogenetic, loss-of-function disease, gene therapy is in many ways the most 
straightforward approach for treatment. It is promising that tests on human iPS-MNs seem to 
suggest that replacement of gigaxonin is able to clear IFs after accumulation. It is also 
encouraging that there is no overt toxicity from even high levels of gigaxonin.  
 While these results are encouraging, further work remains to be done. An important 
complement to any in vitro studies is the testing of gene therapy in animal models for both safety 
and efficacy. Safety is very important given that the injections will be done intraspinally. 
Intraspinal injection is preferable to bypass the requirement for AAV retrograde transport in 
order to maximize gene transfer to motor neurons (Franz et al., 2009). This approach has been 
used safely for lentiviral and AAV gene delivery in animal models (Towne and Aebischer, 
2009), although preclinical safety studies are still lacking. 
  Determining the efficacy of gene therapy in animals would be greatly aided by an 





months of age and beyond, so looking for reduction in their levels could be a straightforward 
readout. If gigaxonin could reduce nIF levels, this would be sufficient evidence to support a 
clinical trial. However, several approaches could be taken to improve on the animal model. First, 
my data suggest that Keap1, as well as gigaxonin, can bind to Cul3. If the key function of 
gigaxonin is as a Cul3 adaptor, this suggests that Keap1 may be compensating for some of 
gigaxonin’s functions in mice. Therefore the Gan-/- mice could be crossed with Keap1-/- mice. 
These experiments are possible if not challenging - Keap1 null mice are viable until ~3 weeks 
after birth (Wakabayashi et al., 2003) – but unfortunately would not make a better model of 
human GAN.  
Screening for regulators of IFs and therapies for GAN 
 Another issue with gene therapy is development of antibodies to gigaxonin. Although the 
CNS is immune-privileged (Carson et al., 2006), it is possible that the immune system of patients 
who have never had gigaxonin might eventually develop an immune reaction to the full-length 
protein. Additionally, intraspinal injection is invasive, and determining the proper dosage of 
gigaxonin could be difficult. Given these challenges, it is prudent to pursue pharmacological 
regulation of IF levels in addition to gene therapy. While research is ongoing to determine the 
mechanism by which gigaxonin regulates IFs, another viable approach is to perform a screen on 
human iPS-neurons with elevated levels of IFs to find compounds that reduce their levels. Such 
as assay could be greatly facilitated by introduction of an IF reporter, such as peripherin or NF-L 
fused to GFP. The screen would have therapeutic benefit for GAN, but also for other diseases in 
which elevated levels of IFs have been implicated in the pathophysiology, such as CMT and 





Figure 7.1C outlines a few approaches that could be used as the foundation for 
identifying compounds that could reduce nIF levels in GAN iPS-MNs. The first possibility is 
upregulation of alternative lysosomal pathways, independent of p62. If p62 is important for 
selective degradation of targets, perhaps increases in non-selective macroautophagy could 
improve the GAN phenotype. Rapamycin, a macrolide antibiotic and widely used inhibitor of 
mTOR (mammalian target of rapamycin) upregulates autophagy in neurons (Boland et al., 2008; 
Rangaraju et al., 2010) and it would be interesting to see if treatment of GAN iPS-MNs with 
rapamycin reduced nIF levels and improved survival. Additionally, antisense oligonucleotides 
could also be used to more directly inhibit the translation of nIF mRNA, thereby reducing nIF 
levels. A second possibility is conversion of K63 ubiquitinated proteins to K48 proteins, which 
can be degraded by the proteasome. I was not able to find published reports of such a drug, but 
one strategy could be to activate specific deubiquitinating enzymes (DUBs) and E3/E4 enzymes. 
Third, HSPs have emerged as potential therapeutics for a number of diseases, and drugs are 
being developed for both their up and downregulation (Soti et al., 2005). Geranyl-gernayl 
acetone, a non-toxic HSP70 inducer, has been shown to protect neurons against cerebral 
ischemia (Yasuda et al., 2005). Upreguation of HSPs that associate with IFs could facilitate their 
turnover by the proteasome or chaperone-mediated autophagy.   
 In addition to screening for compounds and pathways that could reduce IF levels, it could 
also be informative to identify compounds that promote the survival of GAN neurons in the face 
of oxidative stress. This would be particularly important if it turns out that this vulnerability is 
independent of the elevated levels of IFs. The screen would be performed on GAN and rescue 
iPS-MN lines treated with a low dose (25 μM) of hydrogen peroxide for 24 hrs. Readouts could 





or by scoring live MNs/neurons with the appropriate fluorescent reporters. To determine 
protective compounds and pathways, cultures would be treated with individual drugs, and 
successful drugs would be protective for GAN iPS-MNs.    
In summary, there are many promising avenues towards the development of GAN 
therapeutics. In addition to direct replacement of gigaxonin by gene therapy, the iPS model 
provides a screening platform for the identification of drugs that protect neurons from elevated 
levels of IFs and/or from death in the face of oxidative stress, two readouts that have potential 
application to many other neurodegenerative conditions. The data summarized in the working 
model presented in Figure 7.1 points to autophagy as a promising route of investigation in the 
short term. 
In conclusion, I have shown that gigaxonin associates with the very IFs that accumulate 
in GAN, as well as machinery associated with the autophagic degradation of proteins. GAN iPS-
MNs display reduced survival in the presence of oxidative stress. Preliminary experiments 
suggest that in iPS-MNs nIFs are degraded by contributions from both the proteasome and 
lysosome. My experiments also suggest that gigaxonin interacts with the autophagy protein p62 
which has been implicated in the clearance of ubiquitin aggregates by the lysosome, and this 
interaction is greatly enhanced in the presence of oxidative stress. My data provide the first direct 
link between gigaxonin loss and IF aggregation, and suggest that gigaxonin may be a substrate 
adaptor for the degradation of IFs by autophagy, pointing to future approaches for the treatment 






Chapter 8. Experimental Procedures 
Isolation of fibroblasts from patients with GAN. Dermal fibroblasts from five patients with 
GAN were obtained through skin biopsy. All samples were taken previous to the study, and 
written informed consent of the parents of patients was obtained for the identifiable samples 
according to the protocol approved by the Internal Research Board of Columbia University. 
Three other samples were sent to Columbia University as de-identified tissue samples. The only 
demographic data collected was age, date of birth, and the mutation, if known.  
Cell culture. Human GAN and control fibroblasts were maintain in DMEM medium 
supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin at 37°C with 5% 
CO2. All fibroblast samples were tested for mycoplasma, and positive GAN fibroblasts (GAN1 
and 3) were treated with Plasmocin (1:5000, InvivoGen) for two weeks, at which point they were 
re-tested after 1 week in antibiotic-free media and determined to be cleared of the infection. 
GAN and control iPSCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) in 
HuESM (DMEM/F12 supplemented with 20% knockout serum replacement (KSR), non-
essential amino acid (NEAA), L-glutamine, β-mercaptoethanol (BME) and 20 ng/mL of basic 
fibroblast growth factor (bFGF)). Media was changed every 24 hours and lines were passaged 
using dispase (Gibco, 1 mg/mL in HuESM for 30 minutes at 37°C). 
GAN iPSC derivation. 20,000 fibroblasts were infected in 1 mL of HuESM in one well of a 6-
well plate with a combination of OCT4, SOX2, cMYC, and KLF4 containing murine leukemia 
retroviruses as described previously (Dimos et al., 2008). Cells were incubated with virus in 1 
mL of HuESM for 24 h before medium was supplemented with 1 mL of fibroblast medium to 





compounds (Lin et al., 2009) PD0325901 (0.5 μM, Stemgent), SB431542 (2 μM, Stemgent) and 
Thiazovivin (0.5 μM, Stemgent). Approximately one week later, FACS was used to isolate 






 cells. These were sorted as single cells 
onto MEFs in 6-well plates and iPSC colonies were manually picked based on morphology 
within in 2-4 weeks.  
Karyotyping. Karyotype analysis was performed by Cell Line Genetics, LLC. 
qRT-PCR. Total RNA was isolated using Trizol LS (Invitrogen), 1 μg was treated with DNase 
(Invitrogen) and was subsequently used to synthesize cDNA with iScript (Bio-Rad). Quantitative 
RT-PCR was then performed using SYBR green (Bio-Rad) and the iCycler system (Bio-rad). 
Quantitative levels for all genes were normalized to endogenous B2M (for iPSC 
characterization) or GAPDH (for all other experiments). For pluripotency genes levels were 
expressed relative to the levels in human ES line HUES42. For viral genes levels were expressed 
relative to the levels in HEK293 cells infected with the reprogramming viruses for 2-3 days. 
Standard curves were run to ensure equal efficiency of all primers, and RNA from 293 cells 
transfected with the plasmids encoding the transgenes was used as a positive control for viral 
transgene detection. Primer sequences are available upon request. Data were analyzed using the 
comparative quantitation by the 2
-ΔΔC
T equation. ΔΔCT = ΔCT (sample) – ΔCT (control), where 
ΔCT is the threshold cycle (CT) value of the housekeeping gene (B2M or GAPDH) subtracted 
from the Ct value of the target gene. Expression ratios in Figure 3.9 were generated using the 
REST (relative expression software tool) program, which uses a mathematical model based on 





(Pfaffl et al., 2002). Subsequently, the expression ratios of the 8 investigated transcripts were 
tested for significance by a randomization test.  
Immunohistochemistry. Pluripotency marker stains of iPSCs were performed after fixation 
overnight in 4% paraformaldehyde at 4°C as previously described (Dimos et al., 2008). Neuronal 
cultures were fixed in 4% PFA for 30 minutes at 4°C, permeabilized and quenched with 0.1-
0.2% Triton-X in PBS (Wash buffer) and 100mM Glycine (Sigma) for 20 minutes. Cells were 
blocked in Wash with 10% donkey serum for 30 minutes and then incubated in primary antibody 
overnight, secondary antibodies for 1 hour. Primary antibodies used in this study are  TRA1-60 
(1:500, Chemicon, MAB4360), NANOG (1:500, R&D, AF 1997), OCT3/4 (1:500, Santa Cruz, 
sc-9081), ISL1 (1:200, DSHB, 40.2D6), HB9 (1:100, DSHB, MNR2 81.5C10-c), MAP2 
(1:2,000, Neuromics, CH22103), NF-H (1:2000, Neuromics, CH22104), PRPH (1:500, provided 
by Dr. Ron Liem), anti-MYC (1:50, DSHB, 9E10-s), anti-GFP (1:5,000, Invitrogen, A11122). 
Secondary antibodies used were DyLight 488, 549, 647 conjugated (1:500, Jackson 
ImmunoResearch).  
Microscope image acquisition. Images were acquired on a fully automated Ziess Observer Z1 
epi-fluorescence microscope at standard stage positions (12-25 positions per well of a 96-well 
plate). Objectives used included: Plan Apo 20X 0.8 DICII and Plan Apo 10X 0.45 DICII. 
Confocal images were acquired using a Zeiss LSM 510 META with a Plan Apo 100X 1.4 Oil 
objective. Temperature for image acquisition was 22-24° Celsius. All images were acquired in 
Wash buffer or Fluoromount-G (confocal). Camera used was the CoolSNAP HQ
2
. Images were 
acquired using AxioVision 4.8. Where indicated, the Trophos Platerunner was used to acquire 





Quantitative Image Analysis. Quantitative image analysis of differentiated neuronal cultures 
was performed using the Multi-Wavelength Cell Scoring module in MetaMorph (Molecular 
Devices) software. In brief, intensity thresholds were set (blinded to sample identity) to 
selectively identify positive cells which displayed an unambiguous signal intensity above local 
background. These parameters were used on all samples, and only minimally adjusted for 
different staining batches as necessary. Script and Parameter files available upon request. Where 
stated, cells were visually identified and average cell body intensity measured by drawing a 
region of interest that encompassed the cell body. Brightness and contrast of each 
grayscale channel were adjusted to improve clarity.  
Protein isolation and Western Blot Analysis. Cells were isolated, suspended in RIPA lysis 
buffer supplemented with protease and phosphatase inhibitor cocktail (Roche), triturated and 
centrifuged at 10,000 g for 15 minutes at 4°C. 1-10 μg of total protein was separated on 10% 
SDS-polyacrylamide gels, transferred to a nitrocellulose membrane and probed with various 
primary antibodies, followed by horseradish-peroxidase-conjugated secondary antibody 
(1,:5000-10,000, for mouse or rabbit primaries respectively, Invitrogen), and visualized using 
ECL chemiluminescence (Pierce). Primary antibodies used in this study are GIG (1:150, a 
generous gift from Dr. Pascale Bomont), HISH3, (1:500, Millipore, MAB052), PRPH (1:5,000, 
kindly provided by Dr. Ron Liem), NF-L (1:200, Neuromics, MO22104), NF-M (1:200, Sigma, 
G9670), VIM (1:500, Sigma, V2258), TAU (1:150, DSHB, 5a6), MAP1B-LC (1:4,000, Santa 
Cruz, H-130), αTUB (1:10,000, Abcam, AB4074). For quantification, band size and intensities 
were measured using Image J software. Values were normalized first to their respective loading 
control followed by the control line to generate a fold change. Peripherin signal was undetectable 





since nIF levels did not vary significantly for the control line between experiments. For viral 
experiments the membranes were stripped and re-probed for NF-L. Membranes were washed in 
PBS Tween, incubated for 15 min at RT with stripping buffer, followed by 7 minutes at 37 deg. 
They were then washed for 1 hour in PBS Tween, blocked, and probed with appropriate 
secondaries to confirm that the original signal was removed before reprobing.  
Motor neuron differentiation of GAN and control iPSCs. Pluripotent stem cell colonies were 
treated with dispase (1 mg/mL) to separate colonies from feeder cells, washed, then triturated to 
5-10 cell clumps and seeded in low-adherence dishes in HuESM medium with 20 ng/mL of 
bFGF, SB431542 (10 μM , SIGMA), LDN193189 (0.2 μM, Stemgent) and Y-27632 (20 μM 
Ascent) for the first 2 days. At day 3 EBs were switched to a neural induction medium 
(DMEM/F12 with L-glutamine, NEAA, penicillin/streptomycin, Heparin (2 ug/ml), N2 
supplement (Invitrogen), BDNF (10 ng/mL) and Ascorbic acid (0.4 μg/mL).  At day 7, RA (1 
µM, Sigma), SAG (1 μM, Calibiochem smoothened agonist 1.3) and Purmorphamine (1 μM, 
Stemgent) were added. At day 17 the base medium was changed to Neurobasal (Invitrogen), with 
all previous factors and with the addition of 10 ng/mL each of BDNF, GDNF, and CNTF (R&D) 
plus B-27 supplement (1:50, Invitrogen).  At day 28 EBs were then dissociated with 0.05% 
trypsin (Invitrogen), and plated onto poly-lysine laminin-coated 96-well plates or 6-well plates at 
10,000 or 1 million cells/well, respectively.  Plated neuron cultures were cultured in the same 
medium with the addition of 25 μM Betamercaptoethanol (Millipore) and 25 μM glutamic acid 






Statistical analysis. All quantitative data was analyzed using Microsoft Excel or GraphPad. The 
Kolmogorov-Smirnov test was used to compare the probably distribution of the peripherin 
intensities of GAN and control motor neurons using an XLSTAT macro in Excel. Non-Gaussian 
sample groups were compared with a Kruskal-Wallis test using GraphPad Software.  Student’s t 
test was used where indicated.  
Calcium imaging. For epifluoresence microscopy, cells were loaded with 3 μM Fluo-4. Images 
were acquired at approximately 2 Hz. Image analysis was performed using ImageJ software and 
custom macros. Ca
2+
 transients were determined from regions of interest encompassing the soma 
of individual cells, using raw pixel intensities.  
Viral rescue experiments. Myc-tagged human gigaxonin was cloned from a plasmid courtesy of 
Dr. Steven Gray (UNC). NSC34 cells were infected with 10-fold dilutions of viral supernatant. 
4d later cells were fixed and stained for myc of GFP and quantified with MetaMorph and the 
transducing units per μL were determined from the slope of the linear regression. For subsequent 
experiments with motor neurons, virus was added at 0.22-0.27 TU/cell. For Western blot and IF 
data, motor neurons were infected 12 d after plating and were collected/fixed 7-9 d later. 
Affinity purification and mass spectrometry analysis. HEK293 cells were transfected with 
PGK::FLAG-GAN or PGK::FLAG-BTB constructs. 24 hours later, a subset was treated with the 
proteasome inhibitors MG132 (10 μM, Sigma) or Millenium (2 μM, MLN-4924, Active 
Biochem) or vehicle for 4 hours. Cells were lysed and immunoprecipitation was performed as 
previously described (D'Angiolella et al.). For the soluble fraction, cells were lysed using 150 
mM NaCl, 20 mM TRIS (pH 7.5), 0.5% Triton-100, EDTA, NaF, NAVO4, and protease 





transferred to a new tube. For the insoluble fraction, the remaining pellet was lysed in 50 mM 
NaCl, 20 mM TRIS (ph 7.5), 0.5% Triton-100, EDTA, NaF, NAVO4, protease inhibitors and 
benzonase. The pellet was sonicated and incubated on ice for 30 min. The insoluble buffer was 
then added 1:1 (without the addition of benzonase) and the cells spun and the supernatant 
collected. FLAG IP was performed using M2 beads (Sigma) overnight at 4°C. Targets were 
eluted by incubation with 3X FLAG peptide (Sigma). Samples were analyzed by Applied 
Biomics, Inc (Hayward, CA) by NanoLC-MS/MS after tryptic digestion, and only high 
confidence hits (CI > 95%) were considered for analysis. For follow-up immunoprecipitation 
experiments, the same strategy was used to isolate flag-gigaxonin. Endogenous gigaxonin was 
immunoprecipitated using rabbit α gigaxonin (NBP1-49924, Novus Biologicals). Endogenous 
vimentin was immunoprecipitated using mouse α vimentin (BD 550513 or AMF-17b). Ubiquitin 
was immunoprecipitated using Kit 89899 from Pierce. The mouse peripherin construct was a 
generous gift from Jean-Pierre Julienne. The HA-Cul3 construct was a gift from Mark Hannink.   
Silver staining. Compatible with mass spectrometry, excellent signal-to-noise ratio. (Ref: 
http://www.lamondlab.com/pdf/silver_staining.pdf). The gel was fixed for 2 hrs (50% MeOH, 
12% acetic acid, 0.05% Formalin), then washed three times for 20 min each wash (35% EtOH). 
The gel was sensitized using 0.02% Na2S2O3 for 2 min, and then washed three times for 5 min 
each in water. The gel was stained for 20 min using 0.2% AgNO3, 0.076% formalin, and then 
washed two times for 1 min each in water. Developing was done using 6% Na2CO3, 0.05% 
formalin, 0.0004% Na2S2O3 until the desired band intensity was achieved; the staining was then 
stopped using 50% MeOH, 12% acetic acid for 5 min and imaged and stored in 1% acetic acid at 





Nucleofection of iPS lines. For rescue lines the plasmid used was EF1α::FLAG-gigaxonin, 
which contains a puromycin-resistance cassette. iPS lines were dissociated into single cells using 
trypsin and incubated with Y-27632 as single cells for one hour before nucleofection. Cells were 
nucleofected using the Amaxa Nucleofector® II (5 million cells and 5 μg linearized plasmid). 
Cells were then plated on puromycin-resistant MEFs and allowed to form small colonies before 
beginning antibiotic selection. After 10 or more days of selection, large colonies were picked and 
expanded for further characterization.  
HBG1 survival assays. Plating conditions. Conditions for adding conditions. Read-out. Plates 
were coated with 1000 (CONC) polyornithine and 15 μg/mL laminin. Basal media was prepared 
as M199 media with the addition of glutamine (1:100), glutamate (1:1000), pen-strep (1:100) and 
UFdU 5 μM. This media served as the negative control. Frozen MNs were thawed by adding 
warm media (Neurobasal and B-27) to the vial followed by centrifugation with a BSA cushion. 
Cells were seeded at 10,000 cells/well into 96-well plates in 100 μL. NC and PC conditions were 
added in 50 μL at 3X the final concentration. The final concentration of the conditions were 
0.1% BSA carrier for the NC and 10 ng/mL of each: BDNF, CNTF, GDNF, IGF1, NT3 and 
FGF2, as well as 10 μM forskolin. Plates were imaged on the Trophos Platerunner on day 0, 1, 3 
and 5.  
GAN stressor assays. For stressor tests, cells were seeded in 96-well plates in cNB at a density 
of 20,000 cells/well. Eleven days later, the media was removed and replaced with media 
containing the concentrations of hydrogen peroxide or CPA as indicated. A readout was made 24 
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